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The use of protein aptamers for target validation is a relatively new approach whereby 
the activity of the target is inhibited at protein level. The aim of this project was to 
develop bioactive protein aptamers that bind to eIF4E, a rate limiting translation 
initiation factor that is essential for the initiation of cap-dependent translation. eIF4E has 
been implicated as a potential anti-cancer target as upregulation of eIF4E has been 
detected in a variety of cancers and the down-regulation of eIF4E has been shown to 
result in growth and tumour suppression. Validation of the exact functions of eIF4E 
would therefore serve to further elucidate the suitability and potential of using eIF4E as 
target for anti-cancer therapy.  
In this project, the potential of two proteins from different organisms (plant and 
Escherichia coli) as scaffolds for the construction of bioactive eIF4E binding aptamers 
were evaluated. The binding affinities of the aptamers were found to be dependent on 
the type of scaffold used. Rational design of the aptamers was carried out to improve 
binding in vitro, but the enhanced binding detected in vitro did not translate into 
bioactivity in cells.   
A comparison was also made between synthetic protein aptamers constructed using 
scaffold proteins from a foreign origin and protein aptamers that were obtained from the 
modification of a human eIF4E-binding protein (4EBP1). The modified 4EBP1 aptamer 
was found to be more effective and stable in cellular based assays. This comparison 
raises the possibility and highlights the potential of using human proteins as scaffolds for 
the construction of aptamers to circumvent issues with protein stability in vivo and 
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1.1. Target validation and available techniques  
Target validation refers to the process of determining that a target is critically involved 
in a disease process, and that modulating the target will have a therapeutic effect 1. The 
process of target validation involves the selective inhibition or activation of a target gene 
followed by the assessment of the downstream effects of the particular perturbation, in 
order to elucidate target gene function. Several methods can be used to disrupt the 
selected target gene function, the more common ones being the use of small interfering 
RNAs (siRNAs), small binding chemical molecules and transgenic animal models 2.  
mRNA knockdown using siRNAs is currently one of the more popular techniques used 
for target validation in vivo 3. siRNAs are designed to have sequences complementary to 
that of the gene of interest and utilize a natural mechanism within cells to target the 
mRNA of the gene of interest for degradation. Briefly, the double stranded siRNAs that 
are transfected into cells are processed and incorporated into a RNA-induced silencing 
complex (RISC) 4,5. The RISC then binds to mRNAs with sequences complementary to 
that of the processed siRNA and RISC-bound mRNAs are subsequently targeted for 
degradation, leading to a down-regulation of target protein expression 6. 
Small chemical compounds that bind specifically to the target protein can also be used to 
evaluate the effects of disrupting the target protein’s interaction with other proteins or 
inhibiting enzymatic activity 7. These small chemical compounds are usually known as 
small molecule inhibitors. They usually bind to a pocket on the target protein and disrupt 





activities which are dependent on interaction with that particular surface 8,9,10. They are 
ideal for evaluating specific functions of a target protein as they can be used to inhibit a 
particular activity of the protein in a drug-like manner 11,12 
Lastly, transgenic animal models have been the gold standard for validating of the 
physiological role and function of an individual gene in vivo 13. Knockout or knock-in 
animal models have enabled the study of the effects of a target gene in the context of a 
whole organism. Conditional or inducible knockouts, such as the Cre-lox system and 
tamoxifen inducible expression of Cre, have also been developed for the knockout study 
of embryonic lethal genes 14.   
Nonetheless, there are drawbacks associated with each technique. As a result, new 
approaches are constantly being developed and various techniques are often used 
complementarily. In recent years, the aptamer technology has been developed as an 
alternative approach for target validation 15. Aptamers can be either oligonuclei acid or 
peptide molecules that bind a specific target molecule. This thesis will focus on protein 
aptamers, and the design, construction and application of various protein aptamers 
against the target protein, eIF4E. eIF4E is a translation initiation factor that is found to 
be upregulated in cancers and associated with translation of mRNA transcripts that 
encode oncoproteins 16,17. The importance of eIF4E as a target protein for validation will 
be further illustrated in subsequent chapters.  
In the following sections, the aptamer technology and the construction of aptamers will 
be described. Subsequently, the role of eIF4E in translation and the role of translation in 
tumourigenesis will be illustrated, followed by an introduction to the endogenous 





binding partners of eIF4E which the aptamers were designed based on. Lastly, an 
emphasis will be made on the relevance and importance of eIF4E as an anti-cancer 
target for validation. 
1.2. The protein aptamer approach to target validation 
The aptamer approach to target validation involves the development of miniproteins 
called protein aptamers. Protein aptamers are small recognition proteins, which contain 
constrained peptides that can bind to target proteins and inhibit or interfere with the 
activity of the target protein 18,19. The aptamers are made up of binding peptides of 
variable length, usually from 10 to 20 amino acids, inserted into a small, compact and 
soluble protein scaffold 20.  
A protein aptamer is able to bind to and specifically inhibit the protein-protein 
interaction of interest, allowing for characterization of a particular function of the 
protein in vivo under physiological conditions 15. The target protein is not removed in the 
process of target validation using protein aptamers, therefore minimizing disruption of 
the other roles of the protein within the cell. Complete removal of the target protein will 
result in multiple downstream effects and possibly compensatory mechanisms that will 
complicate analysis and obstruct the study of a specific function of the target protein 2,21.  
The aptamer technology resembles that of inhibition with small chemical molecules. 
However, protein aptamers have the advantage that they can be rationally designed 
based on known binding partners and are not dependent on large scale screening nor the 
presence of small binding pockets, which can be uncommon. Furthermore, aptamers can 





be readily modified for regulation of expression such as through an inducible system, as 
well as for enhanced delivery by attaching protein transduction domains for cell 
permeability for example 22. These modifications usually have minimal effects on 
binding affinity 23. In contrast, small molecules are usually not amenable to such 
modifications without affecting binding affinity and specificity. 
As previously stated, the construction of protein aptamers can be based on the known 
binding sequences of the interaction partners of the target protein. Alternatively, binding 
aptamers can also be obtained from screening aptamer libraries that consist of 
randomized peptide sequences using phage display or yeast two hybrid techniques 24. 
Protein aptamers that bind cyclin dependent kinase 2 (Cdk2) were first successfully 
isolated in 1996 by Roger Brent’s group through this approach 25. A random peptide 
library of 20 amino acid residues was inserted in the active site loop of Escherichia coli 
thioredoxin and displayed on the active site loop of the protein. Yeast two hybrid was 
then used to screen for aptamers that bound to Cdk2 26. In this project, aptamers against 
eIF4E were constructed by inserting known eIF4E binding peptide sequences into a 
scaffold protein. 
Besides the binding peptide, the other component of an aptamer is the scaffold protein. 
This is usually a protein that is small, compact and soluble 27. A good scaffold protein 
should be able to tolerate substitutions or insertions of amino acids at the surface of the 
folded protein, so that the peptide can be properly presented, without any major 
disruptions to protein conformation and stability 28. The next chapter will further 





describe the characteristics and advantages of a good scaffold protein, followed by some 
examples.  
1.2.1.  Characteristics of a good scaffold protein  
Scaffold proteins are proteins used for the constraint and presentation of bioactive 
peptides 29. There are several characteristics that make a protein a good scaffold. Firstly, 
the scaffold protein should be small and compact. The chances of non-specific 
interactions for a smaller molecule should theoretically be reduced and compactness of a 
molecule usually translates into better thermal stability 27.  
Secondly, the structure of the scaffold protein should preferably be known. This will 
facilitate decisions on possible insertion sites for the binding peptide so that the peptide 
can be inserted within the solvent accessible surface of the protein 29. Random insertions 
of a binding peptide into protein sequences with unknown structure may result in the 
peptide being buried within the folded protein or even cause the destabilization and 
unraveling of the entire protein.  
Thirdly, the scaffold protein should have enough flexibility to tolerate insertion of 
peptides that vary in length and sequences 30. More often than not, the ability of the 
scaffold to constrain the peptides and remain stably folded is an important factor in 
designing a peptide aptamer that works not only in vitro but also in vivo.  
Fourthly, the scaffold itself should be biologically inert so that aptamers will be selected 
for the desired phenotype due to the peptide presented and not the scaffold 24. Also, the 





scaffold protein should preferably be composed of one polynucleotide chain 27 to 
facilitate genetic engineering or rational design for improvements in peptide presentation.  
Lastly, the scaffold protein should be able to fold similarly in prokaryotic and eukaryotic 
systems to ensure that the in vitro binding obtained would be reproducible in cellular 
based assays 31. Therefore, even if the binding in cellular based assays did not concur 
with the in vitro data, non-binding due to dissimilar folding of the protein in vivo could 
be ruled out. It is noteworthy however, that this aspect of the scaffold is hard to achieve 
due to differences in intracellular environment and post-translational modifications.        
1.2.2.  Advantages of constraining peptides in a scaffold protein 
Constraining peptides in a scaffold can confer higher binding affinity to the peptide 
compared to its unstructured linear counterpart 32. The restriction of a peptide within a 
scaffold reduces the diversity of conformations that the peptide can undertake and 
allows the presentation of the peptide in a conformation that may not be favoured if the 
peptide was unconstrained 33,34. Hydrophobic residues would tend to be buried if they 
were not prevented by the scaffold from doing so. Most importantly, the scaffold plays 
an important role in maintaining the peptide stability within intracellular environments. 
Constraining an unstable peptide within a stable scaffold improves the likelihood that 
the aptamer will remain stable and that the binding properties observed in in vitro assays 
will be unchanged in in vivo assays. 





A more stable aptamer will also allow for further structural studies and faciliatate 
insights into the structural requirements for binding to a specific target protein, thus 
enabling the design of better aptamers or small molecule inhibitors 32,35. 
1.2.3.  Examples of scaffold proteins used for construction of protein aptamers 
Some examples of scaffolds used for development of binding aptamers include: green 
fluorescent protein (GFP), Staphylococcal protein A (Z domain), enzymes, and protease 
inhibitors 30,31.  
GFP is a 27kDa protein isolated from Aequorea victoria (jellyfish). GFP fluoresces 
green when exposed to blue light and has been shown to be well expressed in both 
prokaryotic and eukaryotic systems 32,36. The use of GFP as a scaffold allows for visual 
detection of the protein aptamer. Loop insertions and C-terminal fusions of peptide to 
enhanced GFP (EGFP) have been shown to have no effect on the folding or fluorescence 
of the protein 20. Protein aptamers exhibiting anti-proliferative effects have been 
successfully isolated in a screen using a random library of peptides fused to the C-
terminal of GFP 37, demonstrating the feasibility of using GFP as a scaffold protein.  
The Z domain of staphylococcal protein A is derived from a membrane protein of the 
bacterium Staphylococcus aureus. The class of engineered binding proteins based on 
this domain, known as affibodies, is highly soluble, extremely stable and expresses well 
in bacteria 38,39. The use of this scaffold has been demonstrated in the construction of a 
randomized library of binding proteins against Taq polymerase, human insulin and 
apolipoprotein 40. More recently, affibodies targeting the extracellular domain of the 





human epidermal growth factor receptor 2 (HER2) receptor which is over expressed in 
some breast cancers were isolated by phage selections 41.   
Enzymes are generally protein molecules that contain naturally occurring active sites, in 
which specific substrates dock, in order for catalysis to occur. These accessible active 
sites are therefore excellent sites for peptides to be inserted and presented. In theory, the 
biological activity of the enzyme would be disrupted by the insertion of a binding 
peptide at the active site and should not interfere with the phenotype observed 42,43.   
Nonetheless this should be noted when choosing an enzyme as a scaffold for aptamer 
construction, so as to avoid potential unwanted interactions with proteins that regulate 
enzymatic activity. Site directed mutagenesis could be performed to remove these 
interaction sites if necessary. In addition, some enzymes are synthesized as zymogens or 
inactive pre-cursor forms, which may have their inactive sites sequestered 44. A specific 
example (thioredoxin A) will be further described in subsequent paragraphs.   
Lastly, protease inhibitors, which are usually small and extremely stable, are potentially 
good candidates for scaffold proteins as well. Being inhibitors of enzymes, these 
proteins are intrinsically less prone to enzymatic degradation. In general, their protease 
binding site consists of a stretch of amino acids extending from the main body of the 
protein to form an extended loop that is accessible for binding to proteases 29. This 
exposed loop is a choice location for insertion and replacement of a peptide: the peptide 
inserted would be accessible to the environment and the insertion would also result in 
the inactivation of the biological activity of the inhibitor. The slow hydrolysis rate of 
protease inhibitors and their ability to bind to their target enzymes tightly 45 makes these 





proteins a potential model scaffold. An example of a protease inhibitor used as a scaffold 
would be Chymotrypsin inhibitor 2 (CI2). 
Chymotrypsin inhibitor 2 and thioredoxin A were chosen to be used for the construction 
of aptamers in this project. A brief introduction of the chosen scaffolds will be described 
in the following section.  
1.2.4.  Scaffold proteins used for the construction of aptamers  
1.2.4.1.  Chymotrypsin inhibitor 2 
Chymotrypsin inhibitor 2 (CI2) is a serine protease inhibitor isolated from the soluble 
albumin fraction of barley seeds 46. CI2 is a small protein consisting of 83 amino acids 
and no cysteine residues. The first 19 amino acid residues were found to be structureless 
and were subsequently removed for crystallization studies. The crystal structure of CI2 
was obtained in 1987 by McPhalen and coworkers 47. Briefly, the structure of CI2 
consists of 4 mixed parallel and anti-parallel beta strands and an alpha-helix on one side 
of the beta strands 48. The peptide loop containing the reactive site of the protein spans 
the other side of the beta strands, opposite that of the alpha helix (Diagram 1). The 
structure of CI2 does not vary greatly between the free inhibitor form or when 
complexed to its target subtilisin 47. This indicates rigidity in the structure of CI2, which 
is one of the ideal features for a scaffold protein. The lack of cysteine residues which 
translates into the absence of disulphide bonds adds to the suitability of CI2 as a scaffold, 
as proper folding of the protein can take place in the reducing intracellular environments. 





Two arginine molecules located at positions 65 and 67 of CI2 amino acid sequence were 
found to extend into the space between the reactive site loop and beta sheet of the 
protein as shown in Diagram 2. These two amino acids were found to provide most of 
the electrostatic and hydrogen bond interactions that stabilizes the conformation of the 
reactive site loop 47. It was hypothesized that the interactions provided by these two 
arginines might compensate for the absence of cysteine residues in CI2 to hold the 
protein together after hydrolysis at the reactive site loop.  
CI2 has been shown to tolerate peptide insertions (up to 13 amino acids) in its reactive 
site loop without affecting its ability to fold properly. The stability of the protein on the 
other hand was affected. As the length of the inserts increased, the stability of CI2 
decreased. Nevertheless, the decrease in stability was not proportional to the increase in 
insert length. The decrease in stability was greater for the first few residues inserted and 
was reduced subsequently for additional residue insertions 49. Removal of the 
unstructured 19 amino acids from the N-terminal was found to have no effects on CI2 
stability 50. 
Nevertheless, CI2 has been shown to tolerate a peptide insertion of 37 amino acids and 
still exhibit binding abilities and biological activities in cellular based assays 51.  
Karlsson and coworkers demonstrated the feasibility of using CI2 as a scaffold to 
present Mdm2 binding peptides and successfully activated p53 activity by inhibiting the 
Mdm2 activity with the Mdm2 binding CI2 aptamers. Co-localization of the aptamers 
with Mdm2 was demonstrated by immunofluorescence studies and the interaction 
between the aptamers and Mdm2 were confirmed by co-precipitation experiments. The 





study also established that the activities of the Mdm2 binding peptides were enhanced by 
constraining them on CI2 as compared to free unconstrained peptides which did not 
exhibit any activity beyond background levels. 
Therefore, based on the successful results obtained by Karlsson in using CI2 as the 
scaffold for an aptamer and in addition to the intrinsic properties of the protein itself, the 
small, stable, cysteine-free CI2 with the ability to tolerate peptide insertions, seemed to 
be an ideal scaffold despite it being less commonly used.  
 
 
Diagram 1. Three dimensional molecular structure of CI2. (Picture provided by Dr 
Chandra Verma, BII, A*STAR.) 
Reactive site loop 
α –helix  











Diagram 2. Stabalization of the reactive site loop by arginine residues extending towards 
the loop. (Picture provided by Dr Chandra Verma, BII, A*STAR.) 
Arg 65 
Arg 67 





1.2.4.2.  Thioredoxin A  
Thioredoxin A (TrxA) is a small cytosolic protein (108 amino acids) found in 
Escherichia coli. TrxA together with gluthathione is responsible for maintaining an 
intracellular reducing environment, essential for regulating metabolic processes 52. The 
protein is easily expressed in both bacteria and yeast. TrxA is highly soluble and has a 
rigid structure made up of 4 alpha-helices and 5 beta-sheets 53,54 as shown in Diagram 3. 
This redox enzyme has an active site loop constrained by disulphide bonds. This active 
site loop is highly accessible to the environment and is amendable for the insertion of 
peptides 53. The insertion of peptides inactivates the redox activity of TrxA.  
TrxA is the one of the better characterized scaffold used for construction of aptamers. 
Table 1 shows the successful examples of using TrxA as the aptamer scaffold. In 
addition, TrxA aptamers have been shown to be expressed and properly folded in 
reducing intracellular environments 55. The insertion of peptides did not affect the 
expression levels of TrxA and therefore a high yield of recombinant protein can be 
obtained for in vitro assays 42.  
Brent and coworkers have successfully used TrxA as a scaffold for construction of 
aptamers against human cyclin dependent kinase (cdk2). The isolated aptamers 
demonstrated cell cycle inhibitory effects (G1 arrest) in cellular based assays. 26 Studies 
using TrxA as the scaffold for E2F binding peptides have also yielded protein aptamers 
that bind to and inhibit E2F activity in mammalian cells, resulting in G1 cell cycle arrest  
56. These aptamers may be potentially useful for development as antiproliferative drugs 
that may be useful for medical applications.  





Aptamers that bind the core protein of hepatitis B virus (HBV) 57 and E6 protein of 
human papillomavirus (HPV) 58 have been isolated and shown to inhibit the replication 
of HBV and induce apoptosis of tumour cells expressing HPV E6 protein respectively. 
These aptamers using TrxA as the scaffold may form the basis of new therapeutic 
strategies against these long known cancer causing agents.  
TrxA has been used to present peptides that bind to Mdm2 and an aptamer that inhibited 
Mdm2 was successfully isolated and characterized (SuperTIP). The aptamer was found 
to bind to the p53 binding site on Mdm2 and prevent the interaction between p53 and 
Mdm2. By inhibiting interaction between Mdm2 and p53, degradation of p53 is 
inhibited. Expression of the SuperTIP in cells resulted in the accumulation of p53 and 
activation of p53 dependent transcriptional activity. The activation of p53 activity by 
SuperTIP also led to cell cycle arrest in the cells expressing the aptamer 59.  
More recently, aptamers that bind mutant p53 were isolated 60. These aptamers were 
similarly constructed by presenting peptides on TrxA scaffold. Mutant p53 interferes 
with the normal activity of wild type p53 by sequestering the functional p53 in defunct 
complexes, thus preventing wild type p53 from carrying out its normal function. These 
aptamers bind to mutant p53 and prevent them from binding to wild type p53, thereby 
allowing normal p53 to perform its functions. The aptamers were shown to selectively 
bind mutant p53 and induce apoptosis in mutant p53 containing cells. The induction of 
apoptosis in cells containing mutant p53 cells was significantly reduced when the 
expression of mutant p53 was knocked down using siRNA.  





The multiple successes obtained for using TrxA for the construction of aptamers makes 
thioredoxin A an ideal candidate scaffold for this project.  
 














Organism  Target protein 
Hepatitis B virus Core protein 
Human papillomavirus E6, E7 
Escherichia coli Thymidylate synthase 
Drosophila Cyclin dependent kinase 2 
Human  Cyclin dependent kinase 2 
Human E2F 
Human Mdm2, Mdm4, mutant p53 
Human  EGF receptor 
Human Stat3 
Table 1. Examples of successful applications of using Thioredoxin A as the scaffold for 
construction of binding aptamers. (Modified from Woodman R et al, 2005 61) 
Having discussed the scaffolds that will be used for construction of aptamers to eIF4E, 
this next chapter will proceed to illustrate the implications of translation and eIF4E in 
tumourigenesis.  
 





1.3. Gene regulation by translation  
Proteins are essential and important for the survival and function of living cells. Genes 
are expressed in the form of proteins to perform their roles both intracellularly and 
extracellularly. Briefly, gene expression involves transcribing the genetic information 
encoded within DNA onto an RNA template, followed by processing and translation of 
the RNA into proteins, which execute the functions of a particular gene 62.  
Regulation of gene expression is extremely important for coordinated, controlled and 
normal proliferation of cells. This regulation occurs at both transcription and translation 
levels through differential splicing of pre-mRNAs, nuclear export of mRNAs, post-
translational modifications of proteins, and many other processes 63,64. Therefore, 
approaches to interfere with gene expression can be carried out at the level of 
transcription or translation. In the context of my introduction, regulation of the 
expression of a gene at the translational level is defined to begin from the binding of the 
ribosomal complex to the mRNA. Regulatory processes prior to the binding of 
ribosomal proteins to mRNA are categorized as regulation at the transcriptional level. 
Approaches to regulate gene expression at the transcriptional level involve changing the 
transcription efficiencies and mRNA stability 65,66, which affects translation and 
therefore leads to a change in protein expression levels. Regulating gene expression at 
the translational level however requires only modifications to translation efficiencies or 
preferences. Therefore, controlling the gene expression at the translational level allows 
for rapid responses to environmental stimuli and hormonal changes 67, while keeping the 
mRNA levels unchanged. In contrast to gene regulation at transcriptional level, gene 





regulation at the translational level allows for an acute response to changes in the 
environment 68.   
Translational gene regulation occurs both globally and at the level of individual mRNAs 
69. Global translation regulation occurs via modulating the levels of translation 
machinery proteins 70, resulting in a change in the protein levels of most mRNAs. 
However, what we are interested in and will be focusing on is mRNA specific 
translation regulation. mRNA specific translation regulation is the modulation of the 
expression levels of a particular subset of mRNAs without affecting protein synthesis in 
general. This particular mode of regulation is governed by the sequence and structure of 
the mRNA (Diagram 6) 69.  
1.4. Types of translation involved in protein synthesis 
Basically, protein translation can be divided into two types: cap-dependent and cap-
independent translation. The translation of proteins comprises of basically 3 steps: 
initiation, elongation and termination 71. The processes of elongation and termination 
remain largely similar for both cap-dependent and cap-independent translation, the main 
difference between these two modes of translation lies at the initiation step 72. For 
prokaryotes and viruses, protein translation occurs primarily via a cap-independent mode. 
In eukaryotes however, translation occurs mainly via the cap-dependent mechanism 73. 
The type of translation that occurs depends on the structure of the mRNA 74,75. Cap-
independent translation is facilitated by the absence of complex secondary structure in 
the 5’ untranslated region (UTR) of the mRNA and the presence of internal ribosomal 





entry sites (IRES) in the 5’ UTR of an mRNA also favours cap-independent translation 
by allowing for direct recruitment of ribosomes. On the other hand, cap dependent 
translation occurs for mRNAs that exhibit complex secondary structures in their 5’ 
UTRs 76. In these instances, the formation of a translation initiation complex is required 
for translation to proceed. Besides affecting the mode of translation, the structures of 
mRNAs also play a role in regulating the amount of proteins synthesized (i.e.: rate or 
frequency of protein translation) 71,74.   
1.4.1.  Cap dependent translation 
Cap-dependent translation is the principle mode of translation that occurs within 
eukaryotic cells under normal conditions. Cap-dependent translation initiation requires 
the formation of the translation initiation complex eIF4F, which involves translation 
initiation factors such as eIF4E, eIF4G and eIF4A. eIF4F together with eIF4B and eIF3 
brings the initiation complex and mRNA close to the 40S ribosomal protein for binding 
to occur 77,78.  
eIF4E binds to the 5’ 7-methylguanosine cap 79 found on the mRNAs of most eukaryotic 
mRNAs and in the presence of growth factor signaling, binds to eIF4G, which acts as a 
scaffold protein for the recruitment of additional initiation factors and links the mRNA 
to the translation machinery 80. eIF4G binds to eIF4A, an ATP dependent RNA helicase, 
and eIF3 of the 40S ribosomal subunit 81. eIF4A on its own has weak RNA helicase 
activity and requires binding to eIF4G and cofactor eIF4B for activation 82. eIF4B is an 
initiation factor that stimulates eIF4A’s helicase activity and promotes the recruitment of 
the 40S ribosomes to mRNA 83,84. Through the complex interactions of the initiation 





factors, the mRNA is brought into contact (via eIF4E) with the 40S ribosomal subunit 
(via eIF4G and eIF3). The 40S ribosomal subunit is recruited together with eIF2-
GTP/Met-tRNA, eIF1A and eIF3, forming the 43S pre-initiation complex that unwinds 
(with help from eIF4A) and scans the mRNA for a translation start codon 85,86. The 
interaction of the various initiation factors are illustrated in Diagram 4.  
 
Diagram 4. Simplified illustration of the translation initiation complex binding to other 
initiation factors to form the translation machinery required for unwinding and scanning 
of the mRNA for a start codon. (Some of the initiation factors involved are not shown.)  
1.4.2.  Cap independent translation 
Cap-independent translation occurs mainly for uncapped viral mRNAs and some 
eukaryotic cellular mRNAs that code for housekeeping genes such as ß-actin. The 
occurrence of this mode of translation depends on the presence of an internal ribosomal 
entry site (IRES) for internal translation initiation 87,88 as opposed to initiation at the 5’ 
end of mRNAs for cap-dependent translation. IRESs are not defined by mRNA 






















be predicted by looking at mRNA sequences yet; actual testing for IRES activity has to 
be performed to verify if the sequence actually constitutes an IRES 91.  
The presence of an IRES precludes the requirement for cap-binding factor eIF4E and the 
formation of translation initiation complex eIF4F for translation to take place. Initiation 
at the IRES of encephalomyocarditis virus (EMCV) takes place by the binding of eIF4G 
together with eIF4A to the IRES structure directly 92,93. The 43S pre-initiation complex 
is then recruited accordingly to complete the translation machinery. The IRESs of 
hepatitis C virus (HCV) and cricket paralysis virus (CrPV) are even able to bind directly 
and specifically the 40S ribosome subunit without requiring other translation initiation 
factors such as eIF4G and eIF4A, in addition to eIF4E (Diagram 5) 94-97. This is not 
unexplainable as initiating translation in the middle of the RNA at an IRES close to the 
translation start site would circumvent the need for unwinding and scanning of the 
mRNA untranslated regions to look for the start codon, thus eliminating the need for a 
RNA helicase and its corresponding partners.  
 
Diagram 5. Simplified diagram of cap-independent translation initiation at an IRES. The 
40S ribosomal subunit binds directly to the IRES (e.g. IRES of HCV), requiring only 
some of the canonical translation initiation factors. (Some of the initiation factors 




















1.5.  Effects of mRNA structure on protein translation  
The type of translation an mRNA undergoes under normal conditions depends largely on 
their structure. A eukaryotic mRNA is basically made up of the 5’ 7-methylguanosine 
cap, the 5’ untranslated region (UTR), the coding region, followed by the 3’ UTR and 
poly-A tail as illustrated in Diagram 6 98. Numerous regulatory elements within an 
mRNA, such as the cap, the UTRs, IRESs, the presence of upstream open reading 
frames and the poly-A tail, affect the ability of the transcript to be translated 71. It is of 
interest in this project to target the translation regulatory mechanisms that are specific 
for different 5’ UTRs.   
 
Diagram 6. Simplified illustration of the structure of an mRNA. 
The translational efficiency of an mRNA depends on both the stability of the mRNA and 
its intrinsic secondary structure. The capping of the mRNA at the 5’ end increases the 
stability of the transcript by preventing 5’ to 3’ exonuclease degradation 99, whereas the 
5’ UTR of the mRNA regulates translation efficiency by modifying the structure of the 
transcript. The presence of a long, GC rich 5’ UTR with highly complex secondary 
structure greatly reduces translation efficiency, whereas a short and unstructured 5’ 
UTR enables translation 17.  
5’ UTR 3’ UTR Coding region Poly A tail 
Start codon Stop codon 
5’ cap 





A high degree of secondary structure in the 5’ UTR of an mRNA reduces translation 
efficiency by hindering the recognition of the cap molecule by the initiation complex 
and obstructs the process of scanning for a start codon 17,100. The translation of such 
mRNA transcripts is highly dependent on and very sensitive to the helicase activity of 
the translation initiation complex 101,102. In contrast, a shorter and less complex 5’ UTR 
is easier to unwind and therefore facilitates the scanning for a start codon by the 
initiation complex 17. Therefore, mRNAs of proteins whose expression needs to be 
highly regulated usually contain complex 5’ UTRs with a high degree of secondary 
structure. Non-coincidentally, mRNAs which encode proteins that are involved in 
growth regulation and cell survival have highly structured 5’ UTRs. Examples of these 
mRNAs include mRNAs that code for proteins such as ornithine decarboxylase (ODC), 
which is the first and rate-limiting enzyme in the synthesis of polyamines essential for 
cell division; vascular endothelial growth factor (VEGF), a growth factor involved in 
angiogenesis, c-myc, which causes uncontrolled proliferation when over expressed; and 
matrix metalloproteinases (MMP), which play essential roles in metastasis 16,17,103,104. In 
contrast, proteins such as ß-actin, which are required by all cells for general cellular 
structures, have short and unstructured 5’ UTRs (Diagram 7).  
Nevertheless, IRESs have been found in the mRNA transcripts of several oncogenes 
(e.g.: c-myc), growth factors (e.g.: FGF2, VEGF) and proteins involved in the regulation 
of programmed cell death (e.g.: Bcl-2, Bcl-XL), cell cycle progression and stress 
response, previously thought to be cap-dependent 105-108. The type of translation these 
transcripts undergo is dependent on the environmental conditions of the cell. It is 
hypothesized that IRES-mediated translation of these transcripts may be important for 





the maintenance of cellular processes or to carryout cellular repair or apoptosis in times 
of cellular stress or even mitosis, when cap-dependent translation is inhibited 108,109. It is 
therefore important to keep in mind that the translation processes that mRNAs undergo 
are not fixed, but are subjected to the environmental conditions that are present at the 
time of translation.  
 
Diagram 7.  5’ UTR structures modeled for mRNA transcripts encoding proteins 
involved in proliferation and cell survival (Ornithine decarboxylase /ODC; vascular 
endothelial growth factor /VEGF) and regular cellular proteins (ß-actin).  ODC is a rate-
limiting enzyme essential for polyamine synthesis, while VEGF plays an important role 
in angiogenesis. (Diagram obtained from Graff J.R and Zimmer S.G, 2003)17 
The importance of the role of eIF4E in selectively translating the mRNAs, possibly 
leading to tumourigenesis, will be further discussed in the next section.  





1.6. The function and importance of eIF4E 
1.6.1. Role of eIF4E in protein translation 
Eukaryotic translation initiation factor E (eIF4E) is a 25 kDa protein that plays an 
essential role in cap-dependent translation which is the main mode of translation for key 
proteins involved in proliferation and cell survival 110. eIF4E is required for the 
recruitment of ribosomal proteins to mRNAs: eIF4E binds to the 7-methylguanosine cap 
found on the 5’ end of mRNAs and interacts with initiation factors that bind the 40S 
ribosomal subunit. eIF4E levels were found to be the rate-limiting factor for cap-
dependent translation 111,112, and therefore plays an important role in regulating the rate 
and efficiency of cap-dependent translation. eIF4E is also implicated in embryonic 
development 113, 114, cell survival 115, apoptosis 116,117 and cancer.  
The activity of eIF4E is regulated mainly by the binding of 4EBP1, which inhibits its 
activity, and eIF4G, which promotes the formation of the initiation complex 110,118. 
mRNA translation initiation is stimulated by hormones, growth factors and mitogen that 
activate phosphatidylinositol 3 kinase (PI3K), leading to a signaling cascade that 
activates mammalian target of rapamycin (mTOR). mTOR, also known as FKBP12-
rapamycin associated protein (FRAP), rapamycin and FKBP12 target (RAFT), 
rapamycin target (RAPT) or sirolimus effector protein (SEP), binds to raptor and GßL 
(interacting proteins) upon activation 119. The activated mTOR complex phosphorylates 
4EBP1, causing dissociation of 4EBP1 from eIF4E 120, enabling eIF4G to bind to eIF4E 
for formation of the translation initiation complex. The mTOR complex also 





phosphorylates and activates ribosomal protein S6 kinase (S6K) which in turn activates 
eIF4B by phosphorylation 121. Activated eIF4B plays an important role in the stimulation 
of the helicase activity of eIF4A, and therefore affects the formation of the translation 
initiation complex. In essence, the activity of eIF4E, and indirectly the eIF4F complex, 
is regulated by the binding of either 4EBBP1 or eIF4G, determined by extracellular 
signals via a PI3K/mTOR signaling cascade 122.  
Activation of Ras signaling pathway by growth factors or stress leads to the 
phosphorylation of eIF4E via MAP kinase pathway by Mnk 123. Phosphorylation of 
eIF4E on Ser209 has been said to be important for its mRNA cap binding and translation 
initiation activity but there are also reports that indicate otherwise 124-127. Nevertheless, it 
has been shown that the tumourigenic activity of eIF4E is dependent on Ras signaling 128. 
The regulation of eIF4E is briefly summarized in Diagram 8; the illustration is not 
comprehensive but describes the main signaling processes currently known to regulate 
the activity of eIF4E in translation initiation.  






Diagram 8. The regulation of eIF4E translation initiation activity by signaling cascades 
activated by growth factors and mitogens.  
Upregulation of eIF4E activity has been shown to result in increase in the translation of 
a specific subset of proteins: proteins involved in growth, cell survival, angiogenesis, 
and metastasis, while the expression of normal housekeeping proteins such as beta-actin, 
remained largely unaffected 129. The mRNAs that are preferentially translated when 
eIF4E levels are high include ornithine decarboxylase (ODC), cyclin D1, c-myc, VEGF 
and FGF-2 120.  
ODC is the rate limiting enzyme in the synthesis of polyamines: molecular compounds 
that are essential for proliferation, survival and cell differentiation. Biosynthesis of 
polyamines has been implicated in tumourigenesis 130. Cyclin D1 regulates the 
progression of mammalian cell cycle and is required for entry into S phase. The 





























breast and pancreatic cancers 131,132.  Overexpression of c-myc has also been known to 
lead to cancer 133, whereas upregulation of VEGF and FGF-2 leads to angiogenesis 
which is important for tumour growth and metastasis. In summary, upregulation of 
eIF4E leads to enhanced translation of mRNA transcripts that encode proteins that 
promote proliferation, tumourigenesis and metastasis 104.  
The differential effect of increased eIF4E activity on the mRNAs is related to the 
structure of the mRNA as mentioned previously. The presence of complex secondary 
structure in the 5’ UTR of mRNAs render the transcript more sensitive to the levels of 
eIF4E available. These highly structured 5’ UTRs rich in GC content hinder efficient 
scanning of the mRNA for a start codon and are therefore ineffectively translated 
especially when the levels of eIF4E, and therefore the translation initiation complex 
eIF4F, are limiting. In contrast, the 5’ UTRs of cellular mRNAs are comparatively 
shorter and less structured: the scanning of these mRNAs for their start codons occurs 
readily and efficiently, thus these mRNAs are preferentially translated when the levels of 
eIF4E are limiting. The translation of the different mRNA transcripts in relation to their 
secondary structure and cellular eIF4E levels is illustrated below in Diagram 9 as 
described by Benedetti and Graff (2004) 16.  
eIF4E has also been shown to be involved in the transport of cyclin D1 mRNA 134 from 
the nucleus to the cytoplasm. The upregulation of eIF4E has been shown to result in an 
increase in nuclear export of cyclin D1 mRNA, thereby increasing the amount of mRNA 
available for translation which eventually led to an increase in cyclin D1 protein; in 
contrast, no increase in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or beta-





actin mRNA was observed 134,135. The role of eIF4E in the nuclear export of mRNAs 
with an “eIF4E sensitivity element (4E-SE)” in their 3’ UTRs has been shown to be an 
additional mechanism through which eIF4E mediates its tumourigenic activity 134. 
Nonetheless, this project aims to specifically disrupt the translation initiation function of 
eIF4E, which has been implicated in tumourigenesis.  
 
 
Diagram 9. Differential translation preferences of mRNAs with increasing levels of 
eIF4E and therefore eIF4F activity. Strong mRNAs refer to mRNAs with short, 
unstructured 5’ UTRs that facilitate translation; translation of these mRNAs is less 
dependent on the levels of eIF4E as they are preferentially translated when eIF4E is 
limiting due the lower energy requirement for scanning of a start codon. Weak mRNAs 
refer to transcripts with highly structured 5’ UTRs that require more energy to be 
expended for scanning of a start codon. The translation of these transcripts is therefore 
more dependent on the levels of the translation initiation complex. (Model obtained from 
Benedetti A.D et al, 2004 16) 





1.6.2. Outcomes of eIF4E over expression 
Overexpression of eIF4E has been commonly found to occur in many human cancers, 
such as breast, head and neck, colorectal, bladder, prostate, lung, cervical cancers and 
lymphomas 136-142. The elevated levels of eIF4E in these cancers have been generally 
found to correlate with disease progression and poorer patient prognosis. Increased 
levels of eIF4E was also detected in a variety of transformed cell lines 143. 
Overexpression of eIF4E has been shown to transform NIH3T3 and CREF fibroblast 
cells, resulting in anchorage independent growth and tumour formation in nude mice   
144,145.  
eIF4E levels in breast cancer has been found to be elevated 3 to 30 fold above the levels 
in normal breast tissue 16. Li and coworkers have shown using 112 breast specimens, 
that overexpression of eIF4E was detected in malignant breast cancer tissues and not 
normal or benign specimens. It was also determined that the greater the elevation of 
eIF4E levels in the breast tissue, the higher the chances of cancer recurrence and death 
146.  
Amplification of eIF4E gene and overexpression of eIF4E protein were detected in 
clinical specimens of head and neck squamous cell cancers (HNSCC) 147. HNSCC have 
been known to have a high reoccurrence rate due to the difficulty in removing the 
tumour completely and some studies have shown that the cellular levels of eIF4E in the 
margin of the excised tumours are sufficient to predict the recurrence of HNSCC within 
2 years 148,149. 





Upregulation of eIF4E found to play an important role in the early stages of colorectal 
cancer development 137. The eIF4E levels in bladder cancer tissues and lung carcinomas 
were also found to be elevated significantly compared to normal cells. The levels of 
eIF4E were associated with invasiveness of the tumour and poor disease prognosis 141,150. 
Similar upregulation and correlation of eIF4E to disease progression and tumour 
invasiveness was also established in non-Hodgkin’s lymphoma 142.  
eIF4E has also been implicated in evading apoptosis, inducing drug resistance and 
metastasis of cancer cells. Overexpression of eIF4E has been found to block apoptosis 
117,151 and promote drug resistance 152,153. eIF4E upregulation facilitates metastasis by 
enhancing the expression of growth factors (eg: VEGF, FGF-2) and proteins involved in 
proliferation (e.g: cyclin D1, ODC) and suppressing apoptosis. These are some of the 
essential requirements for survival of cancer cells that break away from the primary 
tumour 154.  
1.6.3. Outcomes of eIF4E inhibition 
The upregulation of eIF4E has been shown to result in tumourigenesis and drive 
metastasis via selective upregulation of the translation of proteins that are involved in 
these processes. Therefore, blocking the activity of eIF4E and removing the selective 
advantage for these oncogenic mRNA transcripts is a plausible and attractive targeted 
approach to cancer therapy. The inhibition of eIF4E translational activity could be 
mediated through a several manners: by interfering with the interaction between eIF4E 
and the mRNAs, by disrupting the formation of the translation initiation complex or by 
reducing the expression levels of eIF4E.  





The binding of eIF4E to mRNAs can be disrupted by designing small molecules that 
bind prevent binding of eIF4E to the 7-methylguanosine cap on the 5’ end of mRNAs. 
There had been reports previously of a small molecule ribavirin that might interfere with 
the interaction between eIF4E and mRNAs. Ribavirin successfully suppressed eIF4E-
mediated transformation of cells in vitro and tumour growth in vivo 155. The direct 
binding of the molecule to the 7-methylguanosine cap however has been disputed 156-158. 
The development of small molecule inhibitors to eIF4E and 7-methylguanosine cap 
would require a more directed approach that remains to be designed.  
Alternatively, disrupting the formation of the translation initiation complex will result in 
a similar targeted disruption of cap-dependent translation. The assembly of eIF4F 
initiation complex can be disrupted in 3 ways: inhibiting eIF4E activity by preventing 
the dissociation of 4EBP1, disrupting the interaction of eIF4E and eIF4G, and by 
inhibiting the function of eIF4A. The overexpression of 4EBP1 in cells transformed with 
eIF4E resulted in a reversion of the tumourigenic phenotype 159. Cell permeable peptides 
that bind to eIF4E had been shown to induce apoptosis with a dose dependent effect 160. 
More recently, Wagner and coworkers identified a small molecule 4EGI-1 that 
effectively displaces eIF4G from eIF4E, while enhancing the binding of 4EBP1 at the 
same time. 4EGI-1 reduced the expression levels of c-myc and Bcl-xL in mammalian 
cells without affecting the protein levels of beta-actin. The compound was also found to 
preferentially induce apoptosis in cancer cells 161. Lastly, the formation of functional 
eIF4F can also be disrupted by preventing eIF4A binding. A natural marine product 
pateamine A was found to bind to eIF4A and prevent its incorporation into the 
translation initiation complex 162,163.   





The inhibition of eIF4E with antisense RNA that physically blocks the translation of 
eIF4E resulted in suppression of the malignancy of fibroblast cells transformed with Ras. 
The expression of proliferation and malignancy promoting proteins: VEGF, ODC, FGF-
2 and matrix metalloprotease (MMP) were found to be decreased 164-166. The 
transformed cells with decreased eIF4E also exhibited reduced invasive and metastatic 
abilities. The expression of antisense RNA against eIF4E in a HNSCC cell line has been 
shown to reduce the tumourigenic and angiogenic properties of the cells: the cells no 
longer grew in soft agar, expressed lower levels of VEGF and FGF-2, and failed to cause 
tumours in nude mice 167. The knockdown of eIF4E expression with siRNA also resulted 
in growth inhibition of different types of breast cancer cells with a reduction in cyclin 
D1, Bcl-2 and Bcl-xL expression levels 168.  
Recently, tremendous success has been obtained using antisense oligonucleotides (ASO) 
as therapeutic agents to specifically reduce eIF4E levels. Improved ASOs with increased 
stability and half-life in plasma have been engineered by Eli Lily and are currently in 
clinical trials. ASOs work by base pairing with the target mRNA and induces 
degradation of the bound mRNA. The eIF4E targeting ASOs specifically reduced eIF4E 
expression and the proteins levels of mRNA dependent on eIF4E for translation as 
previously described, without greatly affecting global protein synthesis in cellular based 
assays. Apoptosis was also induced in cells treated with the ASOs. In animal models, 
these eIF4E-specific ASOs have been shown to effectively and significantly reduce 
eIF4E levels in human tumor xenografts and suppress tumour growth and angiogenesis. 
The mice bearing the xenografts did not exhibit any distress nor had any significant 
changes in weight. The effects of the ASOs were also assessed in normal mice: the 





eIF4E levels in normal cells were reduced without any detectable side effects to the 
health of the mice. The ASOs demonstrate the specificity of targeting eIF4E in the 
elimination of cancer cells without harming normal cells, thus further establishing the 
potential of eIF4E as a specific anticancer target 169,170.  
1.7. Endogenous binding proteins of eIF4E 
eIF4E plays a central role in the initiation of translation. The binding partners of the cap-
binding protein are therefore of interest and relevant to our understanding of the 
requirements of inhibiting eIF4E. The well characterized proteins that interact with 
eIF4E would be eIF4G: resulting in the formation of eIF4F, and 4EBP1: resulting in the 
sequestering of eIF4E in an inactive form. These proteins share a conserved homology 
in their eIF4E binding sequence: YXXXXL∅ (where x is any residue and ∅ is a 
hydrophobic residue) as shown in Diagram 10. The function of eIF4G has been 
previously described in the section summarizing protein translation. Briefly, eIF4G acts 
as a scaffold protein to link eIF4E to other translation initiation factors and ribosomal 
proteins, resulting in the formation of a translation initiation complex 80. eIF4G was later 
renamed as eIF4GI upon discovery of another homolog eIF4G II; both homologues are 
thought to be involved in translation initiation 171.  






Diagram 10. Alignment of eIF4E binding sequences: YXXXXL∅ (where x is any 
residue and ∅ is a hydrophobic residue) is conserved for eIF4E binding proteins from 
mammalian to yeast and plants.  
eIF4E binding proteins (4EBPs) are the best characterized eIF4E inhibitory proteins. 
The family of 4EBPs, also known as phosphorylated heat and acid soluble protein 
stimulated by insulin (PHAS-I) is currently known to consist of 3 members: 4EBP1, 
4EBP2 and 4EBP3. The mRNA of 4EBP1 is ubiquitously expressed in most tissues, 
with the highest expression in skeletal muscles, adipose tissues, pancreas, liver and 
kidney; while 4EBP2 mRNA is ubiquitously expressed, but more abundant in liver and 
kidney 172. The expression of 4EBP3 mRNA resembles that of 4EBP1 but is poorly 
expressed in the liver. The reasons behind the different tissue distribution of the 4EBP 
isoforms have yet been determined. All 3 isoforms of 4EBP bind eIF4E, but 4EBP1 is 
the main 4EBP isoform whose activity has been associated with tumourigenesis 173,174.  
                    
     Mammalian 
       -R- I -I -Y-D-R-K-F-L-M-E-C-R-N-  4E-BP1  
    -R- I -I -Y-D-R-K-F-L-L-D-C-R-N-  4E-BP2 
    -R- I -I -Y-D-R-K-F-L-L-E-C-K-N-  4E-BP3 
    -K-K-R-Y-D-R-E-F-L-L-G-F-Q-F-  eIF4GI 
    -K-K-Q-Y-D-R-E-F-L-L-D-F-Q-F-  eIF4GII 
   
Yeast 
    -K-Y-T-Y-G-P-T-F-L-L-Q-F-K-D-  p150 
    -K-Y-T-Y-G-P-T-F-L-L-Q-F-K-D-  p130 
    -M-I -K-Y-T-I-D-E-L-F-Q-L-K-P-  p20 
 
Wheat Germ 
    -R-V-R-Y-S-R-D-Q-L-L-D-L-R-K-  p82 
 





The activity of 4EBP1 is regulated by phosphorylation by mTOR, as illustrated in 
Diagram 1, and protein phosphatase 2A (PP2A) 175 (not shown in diagram). To date, 6 
phosphorylation sites in 4EBP1 have been described to be sensitive to mitogens 176,177. 
Phosphorylation of 4EBP1 upon growth factor stimulation, leading to the dissociation of 
the protein from eIF4E is thought to occur sequentially. The phosphorylation of 4EBP1 
at threonine 37 and 46 is thought to prime the protein for subsequent phosphorylation at 
threonine 70 and serine 65 178,179. The exact mechanism and kinases involved in the 
phosphorylation of 4EBP1 has not been established yet. Nevertheless, 
hyperphosphorylated 4EBP1 which does not bind eIF4E has been found to be expressed 
in breast, ovary and prostate tumours and is associated with malignancy and adverse 
patient prognosis 173,174.    
Other eIF4E binding proteins that regulate eIF4E activity have been found in Drosophila 
and frog oocytes: Cup, Bicoid and Maskin, which interact weakly with eIF4E and bind 
to proteins that interact with the 3’ UTRs of mRNAs 180. eIF4E is also found to bind a 
mammalian protein 4E-T (eIF4E-Transporter), a protein which mediates the nuclear 
transport of eIF4E 181. This protein may not play a direct role in the formation of 
translation initiation complexes, but by sequestering eIF4E in the nucleus, away from 
the cytoplasm where translation takes place, the activity of 4E-T may have an important 
consequence and repressive effect on translation initiation. Nevertheless, the effect of 
4E-T on translation initiation inhibition has yet to be established. Lately, a new 
mammalian eIF4E inhibitory protein has been identified: DDX3, a RNA helicase, was 
found to contain an eIF4E binding consensus sequence (YIPPHLR) and appeared to 
bind eIF4E at a site similar to eIF4G 182. DDX3 was found to be able to suppress 





tumourigenesis and the removal of critical binding residues to eIF4E in DDX3 abrogated 
its tumour suppressive ability.  
The peptide sequences for 4EBP1 and eIF4GI were selected for evaluation of binding 
affinity to eIF4E for subsequent considerations of aptamer construction.  





1.8. Role of deregulated translation in carcinogenesis: eIF4E as an anti-cancer 
target 
Protein biosynthesis is essential for the maintenance of basic activities such as growth, 
proliferation, repair and apoptosis in a cell, and properly regulated protein synthesis is 
crucial to ensure that the cell grows and dies when it should. When deregulated 
translation of mRNA occurs, uncontrollable proliferation or cell death can occur. In the 
event whereby deregulated translation leads to increased biosynthesis of oncogenic 
proteins that promote cell growth or inhibit cell death, uncontrollable cell growth results. 
Similarly, deregulated translation can lead to decreased biosynthesis of proteins with 
tumour suppressive properties, thus leading to a less robust apoptotic response. Either 
one of these events or a combination of both can lead to unregulated cell growth and 
drive tumourigenesis.  
The aim of this project is to specifically target the role of eIF4E in the preferential 
translation of oncogenic proteins that promote cell growth and survival during 
tumourigenesis. As described previously, the mRNAs that encode these oncogenic 
proteins generally have highly complex secondary structures in their 5’ UTRs. The 
synthesis of these oncogenic proteins is therefore highly dependent on cap-dependent 
translation and the presence of a translation initiation complex which binds to the 5’ cap 
of the complex mRNA transcript 183. The level of translation initiation complexes 
available in cells is dependent on the availability and activity of eIF4E. As the 
upregulation of eIF4E occurs in several types of cancers, targeting eIF4E for cancer 
therapy would hopefully result in selective cytotoxic effects in tumourigenic cells with 





minimal toxic side effects on normal cells. The selective activity of the recently 
discovered small molecule inhibitor 4EG-I and the ASOs further illustrates the 
possibility of a targeted approach to cancer therapy by inhibiting the function of eIF4E  
161,170,184. 
Therefore this project aims to develop a protein aptamer that specifically disrupts the 
formation of the translation initiation complex, by interfering with the binding of eIF4G 
to eIF4E. This should result in a decrease in the tumourigenic phenotype observed for 
upregulation of eIF4E activity.  




2. Material and methods 
2.1. General  
2.1.1. Materials 
Equipment:  
 Eppendorf 5417R tabletop centrifuge 
 Eppendorf 5810R centrifuge 
 Sigma Laboratory Centrifuges 3K30, Sartorius 
 Beckman Coulter J6-MI centrifuge 
 Sorvall RC 5C Plus 
 XCell II Blot Module (Invitrogen) 
 Trans-Blot Semi-Dry transfer cell (Biorad)  
Loading dyes:  
 NuPAGE LDS sample buffer (4X): Invitrogen;106 mM Tris HCl, 141 mM 
Tris base, 2% LDS, 10% Glycerol, 0.51 mM EDTA, 0.22 mM SERVA® Blue 
G250, 0.175 mM Phenol Red, pH 8.5. 
 6X TriTrack Loading Dye: Fermentas; 10 mM Tris-HCl (pH 7.6), 0.03% 
bromophenol blue, 0.03% xylene cyanol FF, 0.15% orange G, 60% glycerol, 
60 mM EDTA. 
Ladders:  
 1kb Plus DNA ladder: Invitrogen; diluted to 0.1ug/ul with TriTrack loading 
dye and water (use 6ul for loading).   
 1kb DNA ladder: New England Biolabs (NEB); working concentration of 
0.1ug/ul.  
 SeeBlue Plus2 Pre-Stained Standard: Invitrogen. 
 BenchMark Pre-Stained Protein Ladder: Invitrogen 
 Precision Plus Protein Prestained Standards: Biorad. 
Buffers:  
 NuPAGE MOPS SDS Running Buffer (20X): Invitrogen; 50 mM MOPS, 50 
mM Tris base, 0.1% SDS, 1 mM EDTA, pH 7. 
 NuPAGE® Transfer Buffer (20X): Invitrogen; 25 mM Bicine, 25 mM Bis-
Tris (free base), 1 mM EDTA, pH 7.2 




 Tris-Acetate-EDTA (TAE) Buffer: 2 M Tris-Acetate, 0.05 M EDTA, pH 8.3 
in water.   
 Mini/maxi preps: 
 P1 (resuspension buffer): 50mM Tris-HCI pH8.0, 10mM EDTA, 100ug/ml 
RNase A. 
 P2 (lysis buffer): 200mM NaOH, 1% SDS (w/v). 
 P3 (neutralization buffer): 30M potassium acetate pH5.5. 
 QBT (equilibration buffer): 750mM NaCl, 50mM MOPS pH7.0, 15% 
isopropanol (v/v), 0.15% Triton X-100 (v/v). 
 QC (wash buffer): 1.0M NaCI, 50mM MOPS pH7.0, 15% isopropanol (v/v). 
 QF (elution buffer): 1.25M NaCl, 50mM Tris-HCI pH8.5, 15% isopropanol 
(v/v). 
Lysis buffers: 
 Nonidet P-40 (NP40) lysis buffer: 150mM NaCI, 1% NP40, 50mM Tris-HCI 
pH8.0.  
Vectors: 
 pET19b: Novagen  
 pET32a: Novagen 
 pcDNA3: Invitrogen  
Drugs /Chemicals: 
 Rapamycin: Calbiochem 553210, C51H79NO13 (Figure 2A), dissolved in 
DMSO. 
 Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal Z-LLL-CHO (MG132): 
Calbiochem 474790, C26H41N3O5 (Figure 2B), dissolved in DMSO; used at 
a working concentration of 20uM. 
 Complete, Mini, EDTA-free protease inhibitor: Roche. 
 GelStar:  
Beads:  
 Protein G Sepharose 4 Fast Flow: Amersham Biosciences 
 Streptavidin agarose beads: Invitrogen 
 Ni-NTA agarose beads: Qiagen 
 7-methyl GTP sepharose (m7GTP) beads: Amersham Biosciences 
 Avidin agarose resins: Pierce 
 Dynabeads M-280 Streptavidin: Invitrogen, Dynal 





 NuPAGE Novex Bis-Tris Gels: Invitrogen; 4-12% gradient, 12 % gels.  
 Nitrocellulose membrane 0.2uM: Biorad. 
 Immun-Star HRP Chemiluminescent  Kit: Biorad. 
 SuperSignal West Dura Extended Duration Substrate: Pierce. 
 Ponceau S Solution: Biochemika. 
 Western blot wash buffer (PBST): PBS with 0.1% Tween 20. 
 Blocking Solution: 5% non-fat milk dissolved in PBST. 





Name Species Type  Company Working dilution 
eIF4E (P-2) Mouse, monoclonal Primary, IgG1 Santa Cruz 1:1000 




monoclonal Primary, IgG1 Sigma  1: 2500 
Anti-FLAG M2 Mouse, monoclonal Primary, IgG1  Sigma - 





HRP conjugated,  Sigma 1:1000 
Anti-GFP  Mouse, monoclonal Primary, IgG1 Roche 1:2000 
Anti-Thio Mouse, monoclonal Primary, IgG1 Invitrogen 1:5000 









Ras  Rabbit, polyclonal Primary 
Cell 
signalling 1:1000 











Peroxidase Polymer N.A HRP conjugate Sigma 1:2000 
Table 2. List of antibodies used.  




Cell culture reagents: 
 Dulbecco’s Modified Eagle’s Medium (DMEM)/ High Glucose: Hyclone; 
4.00mM L-Glutamate, 4500mg/ml L-Glucose. 
 Fetal Bovine Serum (FBS): Hyclone; 40nM filtered. 
 Bovine Calf Serum (CS): Hyclone. 
 Penicillin and Streptomycin (100X): Gibco. 
 Geneticin (50mg/ml): Gibco. 
 Hygromycin B (100mg/ml): Invitrogen 
 Poly-L-Lysine (): Sigma. 
 1mM Hepes, pH7.3. 
 0.125% Trypsin/ Versene, pH7.0. 
 Cell line Nucleofector Kit V: Amaxa. 
 Lipofectamine 2000: Invitrogen. 
PCR reagents: 
 PfuTurbo DNA Polymerase: Stratagene. 
 PfuUltra High-Fidelity DNA Polymerase: Stratagene. 
 Herculase II Fusion DNA Polymerase: Stratagene. 
 PfuUltra II Fusion HS DNA Polymerase: Stratagene. 
Competent cells: 
 MAX Efficiency DH5α competent cells: Invitrogen 
 BL21 Gold (DE3): Stratagene 
 XL10-Gold Ultracompetent cells: Stratagene 
Kits: 
 Miniprep: Qiagen 
 Maxiprep: Qiagen 
 PCR cleanup: Qiagen  
 Gel extraction: Qiagen 
 DNeasy Blood and Tissue Kit: Qiagen 
 QuikChange XL Site-Directed Mutagenesis Kit: Stratagene 






Name Buffers  BSA Company 
BamHI 100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, 1mM DTT, pH7.9  Y NEB 
XhoI  
50mM potassium acetate, 20mM 
Tris-acetate, 10mM Magnesium 
Acetate, 1mM DTT, pH7.9  
Y NEB 
RsrII  100mM Tris-HCl, 100mM MgCl2, 10mM DTE, pH7.5 N Roche 
T4 DNA ligase 50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 10mM DTT, pH7.5 N  NEB 
T4 DNA Quick 
ligase 
132mM Tris-HCl, 20mM MgCl2, 
2mM DTT, 2mM ATP, 15% 






0.5M Tris-HCl, 50mM MgCl2, 
pH8.5  N Roche 
T4 polynucletide 
kinase  
70mM Tris-HCl, 10mM MgCl2, 
5mM DTT, pH7.6 N NEB 
Table 3. List of enzymes used.  





Plasmid /DNA purification:  
Purifications of the plasmids were carried out accordingly to manufacturer’s 
recommendations and are briefly described as follows. The recipes of the buffers used 
are listed in general materials. (Compositions of buffers for PCR cleanup and gel 
extraction are proprietary.) 
 Small scale (miniprep): 
5ml of overnight bacterial culture was spun down and resuspended in 250 µl of Buffer 
P1. 250 µl of buffer was then added and the tube was inverted 4-6 times to lyse the 
bacteria. 350 µl of Buffer N3 was then added and the tube was inverted immediately 4-6 
times to neutralize the lysis buffer. The suspension was spun down at 13, 000 rpm for 10 
mins (5417R) and the supernatant was applied to the QIAprep spin column. Subsequent 
centrifugation steps were carried out at 13,000 rpm for 1 min. The column was spun 
down and washed once with 750 µl of PE buffer. An additional spin was included to 
remove all traces of ethanol. The column was then placed in a clean 1.5ml tube and 50 
µl of molecular grade water was added to the membrane. The column was spun after 5 
mins to obtain the plasmid DNA. The concentration of the plasmid prep was then 
measured.  
 Large scale (maxiprep):  
450 ml of overnight bacterial culture was spun down at 6,000 rpm for 15 mins in a 
Sorvall RC 5C Plus centrifuge. The bacteria pellet obtained was resuspended in 15 ml of 
P1 buffer and transferred to a 50ml tube. 15ml of Buffer P2 was added and mixed 
thoroughly to lyse the cells. 15 ml of chilled Buffer P3 was then added and mixed well 
to neutralize the acidity. The suspension was spun down at 12,000 rpm for 15 mins 
(3K30). Prior to application of the lysate supernatant, the maxiprep column was 
equilibrated with 10 ml of QBT buffer. The sample was applied to the column and the 
column was washed twice with 30 ml of QC buffer, followed by elution with 15 ml of 
QF buffer. 10.5 ml of isopropanol was added to the elutant and mixed well. The mixture 




was spun down at 12,000 rpm for 20 mins. The DNA pellet obtained was transferred to a 
1.5ml tube and washed 3 times with 70% ethanol. The pellet was air-dried before the 
addition of 100 µl of molecular grade water. The pellet was incubated in water at 4 °C 
overnight before resuspension for better dissolution. The concentration of the plasmid 
prep was then measured.        
PCR cleanup: 
5 volumes of Buffer PB were added to 1 volume of the PCR sample and mixed well. 
The sample was then applied to the QIAquick column. The flow-through was discarded 
and the column was washed with 0.75 ml Buffer PE. The column was centrifuged for an 
additional 1 min to remove all traces of ethanol the PCR products were eluted with 50 µl 
of sterile water. All centrifugation steps were carried out at 13,000 rpm for 1 min. 
 Gel extraction:  
The DNA fragment from the agarose was excised and weighed. 3 volumes of Buffer QG 
to 1 volume of gel (100 mg ~ 100 μl) were added to dissolve the gel. The gel was 
incubated at 50°C for 10 min and vortexed every 2–3 min to aid in dissolution. 1 gel 
volume of isopropanol was added to increase the yield of DNA fragments between 500 
bp and 4 kb in size. The sample was then applied to a QIAquick column and washed 
with 0.75 ml of Buffer PE. The column was centrifuged for an additional 1 min to 
remove all traces of ethanol the DNA fragment was eluted with 50 µl of sterile water. 
All centrifugation steps were carried out at 13,000 rpm for 1 min. 
DNA Ligation: 
Digested insert and vector were mixed in a 3:1 molar ratio together with the ligation 
buffer and ligase according to manufacturer’s recommendations. The mixture was either 
incubated at room temperature for 10mins if quick ligase was used or at 16 °C for 
30mins if normal T4 ligase was added. All ligations were carried out with normal T4 
ligase unless otherwise stated.  





Chemical competent cells and the plasmid DNA to be transformed were incubated on ice 
for 30mins followed by heat shock at 37 °C for 2 mins (for ligation with quick ligase) or 
42 °C for 60 secs (normal T4 ligase). 250 µl  of pre-warmed LB was then added and the 
bacteria were incubated with shaking at 37 °C for 1 hr. The bacteria were plated onto LB 
agar plates with antibiotic for selection.  
DNA gel: 
To cast a 1% gel, 1g ultrapure agarose was dissolved in 100ml of 1X TAE buffer and 1X 
GelStar was added. TriTrack loading dye was added to the DNA samples, which were 
then loaded onto the gel. The gel was then run in 1X TAE buffer at 100V for 30 mins. 
1kb Plus DNA ladder was used as a marker unless otherwise stated. The gel was 
visualized under UV for bands.     
Protein gel: 
 Gel running:  
Proteins samples to be analyzed were heated for 95 °C for 5 mins (unless otherwise 
stated), spun down at 14,000 rpm for 5 mins and loaded onto NuPAGE gels (4-12% or 
12%).All gels were ran at 200V for 1 hour in MOPS running buffer and SeeBlue Plus2 
Pre-Stained Standard was used as the marker unless otherwise stated. 
 Western gel transfer:  
The protein gel was equilibrated in ice cold NuPAGE transfer buffer (1X) with 10% 
methanol for 10 mins and transferred to a nitrocellulose membrane (0.2um) using Biorad 
Trans-Blot Semi-Dry transfer cell for 1 hour 30 mins at 20V.  
 Western blot:  
The membrane was stained with Ponceau S to check for proper transfer of proteins and 
cut into strips for probing with different antibodies if applicable. Ponceau S was 




removed by washing in deionized water and the membrane was blocked overnight or for 
at least 1 hour in blocking solution. The membrane was washed once and then incubated 
with primary antibody, diluted in either blocking buffer or 5% BSA in PBST, for 1 hour 
or overnight, according to manufacturer’s specifications. The membrane was washed 3 
times and incubated with secondary antibody for 1 hour at room temperature. The 
membrane was then washed 3 times and developed. All washes were performed with 
wash buffer and on a shaker for 10 mins.  
Sequencing setup:  
 Reagents Volume /µl 
Miniprep DNA (150ng-300ng) x 
Forward/ reverse sequencing 
primer (3.2uM) 1 
Big Dye 8 
Sterile water 6 - x 
Total volume 20 
Table 4. Reagents for setting up a sequencing reaction. 
Sequencing cycle conditions:  
Step Temperature /°C Time Comments 
1) Initial denaturation 96 1 min  
2) denaturation 96 10 secs  
3) annealing 50 5secs  
4) extension 60 4 mins Go back to step 2 (25 cycles) 
5) Hold 4 -  
Table 5. Cycle conditions for sequencing reaction. 




2.2. Cloning and characterization of eIF4E  
cDNA of Hela cells: generously donated by Dr Amanda Goh, IMCB DPL.  
Primers for cloning eIF4E into pET19b:  
- XhoI, Forward (5' CTC GAG ATG GCG ACT GTC GAA CCG GAA ACC A 3’);  
- BamHI, Reverse (5’ GGA TCC TTA AAC AAC AAA CCT ATT TTT AGT G 3’)  
Primers for cloning eIF4E into pcDNA3:  
- BamHI, Forward (5’ ATG GCG GGA TCC ATG GCG ACT GTC GAA CCG GAA 
3’); 
- XhoI, Reverse (5’ CGC TAA CTC GAG CTA AAC AAC AAA CCT ATT TTT 3’) 
Amplification of eIF4E gene by polymerase chain reaction (PCR) and cloning:   
Reagents eIF4E amplification Negative control 
10X Pfu buffer 10 µl 10 µl 
dNTP mix (10uM each) 2 µl 2 µl 
Forward primer (10uM) 2 µl 2 µl 
Reverse primer (10uM) 2 µl 2 µl 
DNA template 4 µl - 
PfuTurbo DNA polymerase 
(3U/ul) 1 µl 1 µl 
Sterile water 79 µl 83 µl 
Total volume 100 µl 100 µl 
Table 6. Reagents added to PCR mixture. 




The PCR reaction mixtures were assembled as shown in the table 5 above and amplified 
according to the cycling conditions shown in the table below.  
Steps Temperature /°C Time Comments 
1) Initial denaturation 95 5 mins  
2) Denaturation 92 40 secs  
3) Annealing 50 30 secs  
4) Extension 72 1 min Go back to step 2 (40cycles) 
5) Final extension 72 10 mins  
6) Hold 4 -  
Table 7. PCR conditions for amplification of eIF4E from a pool of cDNA. 
The PCR product was cleaned up using the PCR cleanup kit from Qiagen. Restriction 
digestion was subsequently carried out according to the table as follows and incubated 
for 2 hours at 37 °C.   
Reagents Volume / µl 
Purified PCR product 66 
10X BamHI buffer 9 
10X BSA 9 
BamHI (20U/ul) 3 
XhoI (20U/ul) 3 
Total volume  90 
Table 8. Reaction mixture for double digestion of eIF4E PCR product.   




Gel extraction of the digested PCR products was carried out and the purified PCR insert 
was ligated into pET19b as shown in Diagram 11. The ligation mixture was set up 
(Table 9) and incubated at room temperature for 10 mins.  
 
Diagram 11. Picture of pET19b plasmid with eIF4E gene insertion between XhoI and 
BamHI at the multiple cloning site (MCS). The insertion was in frame with the start 
codon of an N-terminal His-tag.   
eIF4E




Reagents Volume / µl 
Digested pET19b 
(165.5ng/ul) 1 
Insert eIF4E (37.11ng/ul) 1.5 
2X quick ligase buffer 10 
Quick T4 DNA ligase 1 
Sterile water 6.5 
Total volume 20 
Table 9. Reagents required for ligation of eIF4E into pET19b vector.  
2 µl of the ligation mixture was then transformed into 50 µl of DH5alpha competent 
cells. All of the bacteria were plated onto LB plates with ampicillin. The plates were 
then incubated at 37 °C overnight. 
10 bacteria clones were picked and 5 ml cultures were grown for miniprep. Screenings 
of the 10 clones were then carried out using restriction enzyme analysis with XhoI and 
BamHI.  
Reagents Volume /µl 
Miniprep DNA 5 
10X BamHI buffer 0.3 
10X BSA 0.3 
BamHI (20U/µl) 1 
XhoI (20U/µl) 1 
Total volume 2.4 
Table 10. Restriction enzyme screening reaction mixture for pET19b with eIF4E insert.   




The digestion was carried out at 37 °C for 3 hours and ran on a 1% gel. Clones with the 
correct size for the excised insert were picked for sequencing with T7 forward and 
reverse primers as described previously in Table 4 and Table 5.  
The cloning of eIF4E into pcDNA3 vector (as illustrated in Diagram 12) was carried out 
in a similar manner.  
 
Diagram 12. Picture of pcDNA3 plasmid with eIF4E gene insertion between BamHI and 
XhoI at the multiple cloning site (MCS).  
eIF4E




Induction of protein expression: 
A starter culture of BL21 bacteria was grown overnight with shaking at 37 °C and 
diluted 1 in 1000 times into fresh LB with ampicillin the next day. The fresh culture was 
then grown at 37 °C with shaking until the optical density (OD) of the culture at 600nm 
reached 0.6-0.8. IPTG was then added to 1mM working concentration to the culture to 
induce protein expression. The induced culture was incubated at 37 °C for 3 hours for 
protein expression. The optimal induction time was determined by collecting aliquots of 
BL21 at 1 hour intervals for 5 hours after IPTG induction. The aliquots together with an 
aliquot of uninduced BL21 were lysed with 2X LDS loading dye and ran on a 4-12% gel 
to check for maximal protein expression.  
Separation of BL21 into different fractions for analysis: 
Buffers:   
- Resuspension buffer: 50 mM Tris pH 8.0, 10 % sucrose. 
- Tris/ Triton wash buffer: 50 mM Tris pH 8.0, 2 mM EDTA, 100 mM NaCL, 0.5 % 
Triton X-100. 
BL21 cells were harvested by centrifugation. A sample of the supernatant (LB) was 
collected for analysis: media fraction. The cell pellets were resuspended in resuspension 
buffer and sonicated on ice: 6 times for 20 secs with 20 secs rest intervals. The 
suspension was spun down at 10,000 rpm for 10 mins at 4 °C. The supernatant was 
collected for analysis: soluble fraction. The cell pellet obtained (inclusion bodies) was 
resuspended in Tris/Triton wash buffer and spun down at 12,000 rpm for 15 mins at 4 
°C. This step was repeated once more. The pellet obtained at the end was saved and a 
sample lyzed in 2X LDS loading buffer for analysis: insoluble fraction. Samples of the 
individual fractions were ran on a gel and analyzed for eIF4E expression by coomassie 
staining and western blot.  




His-tagged eIF4E protein purification by batch method: 
Buffers for protein purification: 
- Denaturation buffer: 6M urea, 0.5M NaCl, 20mM Tris-HCI, 5mM imidazole, pH7.9 
- Binding buffer: 6M urea, 0.5M NaCl, 20mM Tris-HCI, 5mM imidazole, pH7.9 
- Wash buffer: 6M urea, 0.5M NaCl, 20mM Tris-HCI, 60mM imidazole, pH7.9 
- Elution buffer: 6M urea, 0.25M NaCl, 10mM Tris-HCI, 500mM imidazole, pH7.9  
- Refolding buffer: 0.25M NaCl, 10mM Tris-HCI, 500mM imidazole, pH7.9  
The inclusion bodies were solubilized in denaturation buffer and added to Ni-NTA 
beads washed twice with denaturation buffer. The protein solution was incubated with 
Ni-NTA beads for 1 hour with rotation at 4 °C. The beads were then spun down at 4,000 
rpm for 5 mins and the supernatant was removed. The beads were washed 4 times with 
wash buffer and eluted by incubating the beads with elution buffer for 15 mins with 
rotation at 4 °C. The eluted protein was dialyzed using SnakeSkin Pleated Dialysis 
Tubing (10,000 MWCO) with the refolding buffer. The refolding buffer was changed 
every 4 hours for 3 times for complete removal of the denaturing urea.  
His-tagged eIF4E protein purification by Fast Performance Liquid Chromatography 
(FPLC): 
Buffers for protein purification: 
- Buffer A: 6M Guanidinium Hydrochloride (GnHCl), 50mM Hepes-KOH pH 7.6, 5mM 
DTT. 
- Buffer B: 50mM Hepes-KOH pH7.6, 5mM DTT. 
- Buffer C: 500mM Imidazole, 50mM Hepes-KOH pH7.6, 5mM DTT.  




The inclusion bodies obtained as described earlier on, were solubilized in Buffer A and 
the protein concentration of the solution was measured using Bradford assay and 
adjusted to approximately 1mg/ml. The protein solution was then filtered with a 0.2um 
filter to remove protein aggregates and loaded onto a 1ml HisTrapFF column 
(Amersham) on an ÄKTA FPLC machine. The machine was run according to a program 
previously set up by Dr Chris Brown, IMCB DPL. Briefly, the denatured protein was 
loaded onto the column and washed with large volumes of Buffer A until a stable UV 
reading at 280nm was obtained. Mixtures of Buffers A and B were then applied to the 
column in increasing proportions of Buffer B and decreasing proportions of Buffer A, to 
remove the denaturing GnHCI for refolding of eIF4E. The refolded protein was then 
eluted in fractions with increasing proportions of Buffer C and decreasing proportions of 
Buffer B. The fraction whereby a spike in UV absorbance at 280nm was observed was 
when the bound eIF4E was eluted.  
FPLC purification of untagged eIF4E protein: 
Rossetta pLysS competent bacteria were transformed with the pET11d expression 
plasmid containing the full-length eIF4E clone. Both materials were provided by 
Cyclacel Ltd., Dundee. 
The inclusion bodies were solubilized in Buffer A and the protein concentration of the 
solution was similarly adjusted to approximately 1mg/ml. The denatured protein was 
refolded via a 1/10 dilution into refolding buffer consisting of 20 mM Hepes-KOH, 100 
mM KCl and 1 mM DTT. The refolded protein was concentrated and desalted using a 
Amersham PD10 column into refolding buffer. The eIF4E protein sample was run over a 
monoQ column and eluted with a 1 M KCl gradient. eIF4E eluted as a sharp peak at a ~ 
0.3M KCl. 
The purification was carried out according to the protocol obtained from Brown C.J et al 
(2007) 185. 





1ug of eIF4E antibody was coupled to 15 µl of NP40 lysis buffer (NP40) washed Protein 
G beads. Excess antibodies were removed by washing twice with NP40. The beads were 
then incubated with purified protein or cell lysates (250ug) for 1hour with rotation at 4 
°C. The beads were washed 3 times with 1 ml of NP40 and the bound proteins were 
eluted with 30ul of 2X LDS loading buffer and heating at 70 °C for 10 mins. The eluted 
proteins were run on 4-12% gels and analyzed by coomassie staining and western blot. 
The proteins eluted were not detected by coomassie staining. All centrifugation steps 
were carried out at 10,000 rpm for 1 min at 4 °C.   
m7GTP binding of eIF4E:  
Buffers:  
- m7GTP buffer: 20mM Tris-HCI pH8.0, 80mM potassium acetate, 2.5mM magnesium 
acetate, 1mM DTT, 5% glycerol. 
- Hepes buffer: 20mM Hepes-KOH pH7.6, 100mM potassium chloride, 1mM DTT. 
Purified eIF4E was incubated with 15 µl of washed m7GTP beads in either m7GTP or 
Hepes buffer on a rotator for 1 hour at 4 °C. The beads were washed 5 times with their 
respective buffers and the bound proteins were eluted with 25 µl of 1mM of m7GTP 
diluted in their respective buffers. The bound proteins were analyzed on a 4-12% gel by 
coomassie staining and western blot.   




2.3. Affinity-based precipitation of proteins using peptides (peptides pulldowns) 
Biotinylated peptides: synthesized by Mimotopes Pty Ltd, Australia; dissolved in DMSO 
to a final concentration of 1ug/µl. 
Streptavidin agarose beads: Invitrogen, Cat no. SA100-04 
NP40 lysis buffer: 150mM NaCl, 1% NP40, 50mM Tris, pH8.0  
eIF4E (P-2) antibody: Santa Cruz (sc-9976), mouse monoclonal 
 
The qualitity of the peptides were verified by mass spectrometry (MS) (sample of 
analysis shown in Figure 1) and the purity of the peptides was found to range from 60-
80%.  
 
Figure 1. Sample diagram of MS analysis of peptides synthesized (Data supplied by 
peptide manufacturer: Mimotopes). 




Coupling of the peptides to beads: 
10ug of biotinylated peptides were coupled to 40 µl of streptavidin agarose beads 
(washed 4 times with ice-cold PBS) by incubating the beads with the peptides in 500 µl 
of PBS for 1 hour at 4 °C on a rotator. Unbound excess peptides were removed by 
washing with PBS for 4 times. The peptide-coupled beads were stored in PBS at 4 °C 
(not more than a day) and washed 3 times with NP40 lysis buffer prior to use. All 
centrifugation steps were carried out at 2,500 rpm for 3 mins at 4 °C, unless otherwise 
stated, using an Eppendorf 5417R centrifuge. A 15 cm dish of U2OS cells was used for 
pulldown with each peptide.  
Standard protocol for preparation of cell lysates for pulldown assays:  
The dishes of cells were washed once with cold PBS and scraped in 2 ml of cold PBS. 
The scraped cells were then spun down at 3,000 rpm at 4 °C, using an Eppendorf 5810R 
centrifuge. The cell pellet was then resuspended with 200ul/ 10cm dish (~ 1  X 106 cells) 
of NP40 lysis buffer. The lysate was passed through a 23G syringe approximately 10 
times and incubated on ice for 10 mins. The lysate was then spun down at 14, 000 rpm 
for 10 mins at 4 °C (5417R) and the supernatant was collected. The supernatant 
collected was incubated with the NP40-washed beads for 1 hour at 4 °C on the rotator. 
The beads were then washed 3 times with 1 ml of NP40 lysis buffer (5417R). The final 
wash was aspirated as clean as possible and 40 µl of 2X NuPAGE LDS sample buffer 
was added. The beads were incubated for 20 mins on a shaker. 100mM of DTT was 
added and the beads were incubated at 70 °C for 10 mins. The beads were then spun 
down and 20 µl of the supernatant was loaded onto a SDS-PAGE gel for western blot 
analysis using eIF4E (P-2) antibody.   




2.4. Aptamer Construction: CI2 
Chymotrypsin inhibitor 2 scaffold with eIF4G peptide insertion: synthesized by Midland, 
Molecular Biology Group, Texas. 
Primers for cloning into pET19b:  
- XhoI, Forward (5’ ATG GCG CTC GAG AAC TTG AAA ACG GAG TGG CCA 3’);  
- BamHI, Reverse (5’ CGC TAA GGA TCC TTA CTA GCC GAC ACG AGG GAC 3’)  
Primers for site-directed mutagenesis of the critical binding residues: 
- Forward (5’ GGC ACT AAA AAA CGC GCG GAT CGC GAA TTT GCG GCG 
GGC TTC CGG ATT GAC  3’);  
- Reverse(5’ GTC AAT CCG GAA GCC CGC CGC AAA TTC GCG ATC CGC GCG 
TTT TTT AGT GCC  3') 
Primers for removing extra N-terminal residues, shifting the FLAG tag from the C-
terminal to the N-terminal and cloning into pET19b: 
- Forward (5’ ATG GCG CTC GAG GAC TAC AAA GAT GAT GAT GAC AAA 
AAC TTG AAA ACG GAG TGG CCA GAA 3’) 
- Reverse (5’ CGC TAA GGA TCC TTA CTA GCC GAC ACG AGG GAC TTG GGC 
GAT  3’) 
Primers for site-directed mutagenesis of 2 arginines on CI2 scaffold:  
- Forward (5’ G GAA TAT CGG ATT GAC GCT GTA GCT CTG TTT GTA GAT 
AAA C 3’) 
- Reverse (5’ G TTT ATC TAC AAA CAG AGC TAC AGC GTC AAT CCG ATA 
TTC C 3’) 




Primers for site-directed mutagenesis of lysine in eIF4G insert sequence: 
- Forward (5’ TT CTG CCG GTG GGC ACT AAA GCA CGC TAT GAT CGC GAA 
TTT CT 3’)  
- Reverse (5’ AG AAA TTC GCG ATC ATA GCG TGC TTT AGT GCC CAC CGG 
CAG AA 3’)      
Primers for removal of eIF4G insert sequence: 
- Forward (5’ TCG TTC TGC CGG TGG GCA CTC GGA TTG ACC GTG TAC GTC 
T 3’) 
- Reverse (5’ AGA CGT ACA CGG TCA ATC CGA GTG CCC ACC GGC AGA ACG 
A 3’) 
Primers for reconstruction of the original WT CI2:   
- Forward (5’ CAG ATT ATC GTT CTG CCG GTG GGC ACT  ATT GTG ACC ATG 
GAA TAT CGG ATT GAC CGT GTA CGT CTG TTT GTA 3’) 
- Reverse (5’ TAC AAA CAG ACG TAC ACG GTC AAT CCG  ATA TTC CAT GGT 
CAC AAT  AGT GCC CAC CGG CAG AAC GAT AAT CTG 3’) 
Primers for cloning CI2 aptamers into pcDNA3: 
- BamHI, Forward (5’ ATG GCG GGA TCC GAC TAC AAA GAT GAT GAT GAC 
AAA AAC TTG 3’) 
- XhoI, Reverse (5’ CGC TAA CTC GAG TTA CTA GCC GAC ACG AGG GAC TTG 
GGC GAT 3’) 




Cloning of CI2 aptamer into pET19b and pcDNA3 vectors: 
PCR amplification of the CI2 gene using primers (stated above) with restriction sites 
specific for insertion into the vectors were carried out as previously described in section 
2.2. Similarly, restriction digestion and ligation were carried out as described. The 
clones obtained were screened (by both RE digest and PCR) and sequenced in the same 
manner. 
CI2 protein expression and purification: 
Buffers:  
- Resuspension buffer: 50 mM Tris pH 8.0, 10 % sucrose. 
- Binding buffer: 20mM Tris-HCI pH8.0, 500mM NaCl 
- Wash buffer: 20mM Tris-HCI pH8.0, 500mM NaCl, 10mM imidazole 
- Elution buffer 1: 20mM Tris-HCI pH8.0, 500mM NaCl, 100mM imidazole 
- Elution buffer 2: 20mM Tris-HCI pH8.0, 500mM NaCl, 500mM imidazole 
Protein expression trials were conducted as previously described for eIF4E.  
The CI2 aptamers were purified using Ni-NTA beads from the media and soluble 
fraction of the induced bacteria, obtained as described previously for eIF4E. The buffers 
used for the purification of CI2 aptamers do not contain urea as the aptamers were 
already in soluble form. Similarly, the LB media or soluble fraction was incubated with 
Ni-NTA beads for an hour in binding buffer at 4 °C and washed 4 times with the wash 
buffer. The bound proteins were then eluted first with elution buffer 1 (3 X 1ml fractions) 
to elute non-specific binding proteins that were not removed by washing. 5 X 1ml 
fractions of elution buffer 2 were then used to elute His-tagged CI2 aptamers. The 
elution fractions were then run on a gel and coomassie stained to locate where the 
purified proteins were. The fractions with the purified aptamer were then dialyzed using 




Slide-A-Lyzer Dialysis Cassettes (MWCO 3500; Pierce) and concentrated before being 
used for experiments.  
Cross-linking experiment: 
Chemicals:  
- Crosslinker - 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride (EDC): 
Thermo Scientific 
- Reaction stabilizer - N-hydroxysulfosuccinimide (Sulfo-NHS): Thermo Scientific 
- ß-mercaptoethanol (ß-mercap): Sigma 
Buffer:  
- Phosphate buffer: 20mM Na2HPO4, 100mM KCI, 0.2mM DTT 
eIF4E and CI2 aptamer (FL-CI2-eIF4G) were first dialyzed into the phosphate buffer 
that was to be used subsequently. 3 reaction tubes were set up for the cross-linking 
experiment using the above chemicals which have been validated by Dr Robert 
Robinson‘s lab, IMCB. The protocol was devised by Dr Xue Bo from his lab. Briefly, 
4mM of EDC and Sulfo-NHS were added to 10uM of eIF4E alone, CI2 alone or a 
mixture of equimolar of eIF4E and CI2 in phosphate buffer. The tubes were incubated at 
room temperature for 1 hour and the reaction was halted with 10mM of ß-mercap. The 
samples were run on a 12 % gel for greater separation of the proteins according to 
molecular weight and stained with coomassie blue.  




Gel filtration experiment: 
Purified eIF4E and CI2 aptamer (FL-CI2-eIF4G) were also dialyzed into the phosphate 
buffer that was used for the subsequent size exclusion experiment. The column used was 
a 16/60 column packed with Superdex 75 prep grade resin (GE healthcare) and the 
machine used was AKTA prime. Both the equipment and protocol were generously 
provided by Dr Robert Robinson, IMCB with assistance from Dr Xue Bo.  
eIF4E and CI2 protein preps were first separately run on the column with extensive 
washings in between, using the phosphate buffer previously described. The UV readings 
at 280nm of the elution profiles of eIF4E and CI2 proteins separately were recorded. 
eIF4E and CI2 were then mixed and applied together to the washed column and the 
elution profile was recorded. The elution fractions were collected and fractions from the 
UV peaks that were unique to the elution profile for eIF4E and CI2 mixture were 
analyzed by western blot.     
m7GTP pulldown: 
m7GTP pulldown was performed as previously described for binding to eIF4E, but 
crude bacterial lysate was used in addition to purified eIF4E. m7GTP beads were first 
incubated with bacterial lysate containing eIF4E and washed several time to remove 
unbound proteins. CI2 aptamers were then added. The beads were then incubated at 4 °C 
for 1 hour with rotation and followed by 4 washes with m7GTP buffer to remove 
unbound aptamers. The bound proteins were eluted with 2X LDS loading buffer and ran 
on a 12% gel for analysis by western blot. 




Site-directed mutagenesis:  
Polyacrylamide gel electrophoresis (PAGE) purified primers were diluted to a working 
concentration of 100 ng/µl and the DNA template to be mutated was diluted to 10 ng/µl. 
The PCR mutagenesis reaction was set up as follows: 
Reagents Volume /µl 
10X reaction buffer 5 
DNA template (10 ng/µl) 1 
Forward primer (100 ng/µl) 1.25 
Reverse primer (100 ng/µl) 1.25 
dNTP mix (10uM each) 1 
QuikSolution 3 
Sterile water 37.5 
PfuTurbo DNA polymerase 1 
Total volume 51 
Table 11. PCR mutagenesis reaction mixture.  
PCR mutagenesis was carried out according to the cycle conditions as shown in Table 
12. After the PCR, 1 µl of the restriction enzyme Dpn1 (10 U/µl) was added to removal 
the parental template by incubating at 37 °C for at least 4hours.  




Steps Temperature /°C  Time  comments 
1) Initial Denaturation 95 1 min  
2) Denaturation 95 50 secs  
3) Annealing 60 50 secs  
4) Extension 68 6 mins 
1 min per kb 
Go back to step 2 (18 cycles) 
5) Final extension 68 7 mins  
6) Hold 4 -  
Table 12. Cycling conditions for PCR mutagenesis.  
2 µl of the Dpn1 treated DNA was then added to 45 µl of XL-Gold competent cells and 
transformation of the bacteria was carried out. The entire transformation reaction 
mixture was plated on LB plates with ampicillin selection.   
Mammalian cell transfection using electroporation: 
Electroporation was carried out according to Amaxa’s manufacturing recommendations. 
Briefly, the procedure was carried out as described. Cells were harvested by 
trypsinization and counted. 2 x 106 cells were used per sample of DNA to be transfected. 
The cells were resuspended carefully in 100 μl room temperature Nucleofector® 
Solution and mixed with 2ug of plasmid DNA. The cell suspension was then transferred 
to the cuvettes provided and electroporated using the program P-020 for high 
transfection efficiencies. The electroporated cells were transferred into warm media in a 
6 well plate and incubated for either 24 or 48 hours before harvesting.   




2.5. Alternative aptamer: Thioredoxin  
Insertion of eIF4G peptide into Thioredoxin scaffold: 
1) Restriction Digestion of pET32a vector: 
The thioredoxin gene within pET32a vector was digested with restriction enzyme RsrII 
for 4 hours at 37 °C. The digestion reaction was set up as shown in Table 13. The 
enzyme was then inactivated by incubating at 65 °C for 20mins. The digested vector was 
also treated with shrimp alkaline phosphatase (AP) to remove the phosphate on the 5’ 
end of the digested vector to prevent the vector from re-ligating to itself in a reaction 
mixture set up as shown in Table 14. The reaction mixture was incubated at 37 °C for 
1hr. The cleaved and AP-treated vector was then checked on a 1% agarose gel. The band 
of the right size corresponding to cut pET32a vector (~5900bp) was excised and 
extracted from the agarose using the gel extraction kit as previously described.    
 Reagents Volume /µl 
pET32a (1ug) 16.5 
10X SuRE/Cut  
buffer L  2 
Rsr II  (10 U/µl) 1.5  
Total volume 20 
Table 13. Restriction enzyme digestion of thioredoxin with Rsr II.   




Reagents Volume /µl 
Heat inactivated RE mixture 20 
AP (1 U/µl; 20U for 1ug of 
DNA)  20  
10X buffer   4.5 
Total volume 44.5 
Table 14. Alkaline phosphatase treatment of digested pET32a vetor to remove the 
5’phosphate. 
2) Annealing and phosphorylation of oligonucleotides: 
Primers for –eIF4G insert: 
- Forward (5’ GTC CGC CTA AAA AAC GCT ATG ATC GCG AAT TTC TGC TGG 
GCT TTC AGT TTG AAA ACG 3’);  
- Reverse (5’ GAC CGT TTT CAA ACT GAA AGC CCA GCA GAA ATT CGC GAT 
CAT AGC GTT TTT TAG GCG 3’) 
Primers for -eIF4G-ala insert: 
- Forward (5’ GT CCG CCT AAA AAA CGC GCG GAT CGC GAA TTT GCG GCG 
GGC TTT CAG TTT GAA AAC G 3’); 
- Reverse (5’ G ACC GTT TTC AAA CTG  AAA GCC CGC CGC AAA TTC GCG 
ATC CGC GCG TTT TTT AGG CG 3’) 
Primers for -SG-eIF4G insert:  
- Forward (5’ GTC CGC CTA GCG GCA AAA AAC GCT ATG ATC GCG AAT TTC 
TGC TGG GCT TTC AGT TTG AAA ACG 3’); 




- Reverse (5’ GAC CGT TTT CAA ACT GAA AGC CCA GCA GAA ATT CGC GAT 
CAT AGC GTT TTT TGC CGC TAG GCG 3’) 
Primers for –SG-eIF4G-ala insert:  
- Forward (5’ GT CCG  CCT AGC GGC AAA  AAA  CGC GCG GAT CGC GAA TTT 
GCG GCG GGC TTT CAG TTT GAA AAC G 3’); 
- Reverse (5’ G ACC GTT TTC AAA CTG AAA GCC CGC CGC AAA TTC GCG 
ATC CGC GCG TTT TTT GCC GCT  AGG CG  3’)    
Annealing buffer: 100mM NaCl in TE buffer (10 mM Tris-HCl pH8.0, 1 mM EDTA) 
Phosphorylation buffer: 500 mM Tris-HCl, 100 mM MgCl2, 10 mM ATP, 100 mM 
DTT, pH7.5 
The oligonucleotides were diluted to 1uM and 2.5 µl of each oligo was added to an 
eppendorf tube containing 45 µl of annealing buffer. The tube was then heated at 95 °C 
for 5 mins and allowed to cool slowly back to room temperature. 1 µl of the annealed 
oligos were used for phosphorylation. 1 µl of the phosphorylation buffer (as described 
above), together with 7 µl of sterile water and 1 µl of T4 polynucleotide kinase were 
added to the oligos. The oligos were then incubated at 37 °C for 30mins.  
3) Ligation of annealed oligos into pET32a: 
2 µl of the phosphorylated oligos and 2.5 µl of digested vector (20 ng/µl) were used for 
ligation using T4 DNA ligase. The oligos were inserted into thioredoxin, upstream of a 
Hia-tag, as shown in Diagram 13. The ligation was carried out as described in the 
general methods section. 10 µl of the ligation reaction was used for transformation of 
DH5α competent cells. The bacteria were plated onto LB plates with ampicillin selection. 
The bacteria clones were picked and screened by sequencing using T7 forward primer. 





Diagram 13. Insertion of annealed oligos into the RsrII cleaved pET32a vector. The 
thioredoxin aptamers were constructed in frame with the C-terminal His tag available in 
the vector.  
eIF4G / SG-eIF4G 
C-terminal His-Tag 




Protein expression and purification:  
The thioredoxin aptamers verified to be of the right sequence were transformed into 
BL21 bacteria and protein induction trials were carried out. The protocol for the trial 
induction was as previously described for eIF4E. The expression of thioredoxin was 
carried out for different durations (1 to 5 hours) at both room temperature and 37 
degrees, to check for the optimal protein expression conditions. The affect of 
temperature on the expression of the thioredoxin aptamer proteins was compared after 
five hours of incubation of the bacteria at either 37 °C or room temperature. 
The purification of thioredoxin aptamers was similar to the protocol used for purification 
of CI2 aptamers. A slight modification was made in the resuspension buffer used. 
Binding buffer with 0.5% of Trition X was used to resuspend the pellet instead of the 
previous resuspension buffer described. The addition of Triton X for resuspension of the 
bacteria pellet helps to improve the release of soluble proteins by permeabilizing the cell 
membranes. 
The purified protein fractions were run on a gel and the elution fractions containing the 
aptamers were pooled for 100nm imidazole elution and for 500nm imidazole elution, 
and dialyzed into PBS using the Slide-A-Lyzer cassettes previously described for CI2. 
The dialyzed protein was checked for precipitation, spun down and concentrated. The 
concentrated protein preparation was then stored in aliquots in -80 °C.   
Ni-NTA beads pulldown: 
20 µl of Ni-NTA beads were washed with PBS and incubated with 5ug of His-tag Trx 
aptamers for an hour at 4 °C on a rotator. The beads were washed 3 times with PBS 
containing 0.05% Tween 20. The beads bound Trx aptamers were then incubated with 
250 µl of the soluble fraction of bacteria lysate induced to express eIF4E that was 
untagged. The beads were incubated at 4 °C for 1 hour on a rotator and washed 5X with 
PBS containing 0.05% Tween 20. The bound proteins were then eluted with 50 µl of 
loading dye and run on a gel for analysis by western blot.   





- C-terminal fluorescein-labeled peptide: KYTYDELFQLK-(FITC); synthesized by Dr 
Brian Chia, ETC. 
- Unlabeled peptides: eIF4G (KKRYDREFLLGFQF) and p53 (QETFSDLWKLLP); 
synthesized and HPLC purified by 1st Base, Singapore (> 90% purity) 
- Dilution buffer: PBS with 0.05% Tween 20 
Purified non-tag eIF4E and 4EBP1 were generously provided by Dr Chris Brown, DPL 
IMCB. The experiment was done in a black 96 well plate and the readings were taken 
using a Safire II 96 well plate reader (Tecan). 
The anisotropy data were plotted against concentration of ligand (labeled peptide or 
aptamers) and the curve fitting for estimation of binding constants was carried out based 
on equations derived by Roehrl and coworkers (2004). The respective dissociation 
constants (KD) were calculated using the Prism 4.0, Graphpad program. 
Validation of fluorescein-labeled peptide: 
The labeled peptide was kept at a constant concentration of 60nM and eIF4E was added 
in increasing concentrations. The experiment was conducted in duplicates and included 
controls such as dilution buffer only, peptide only, and eIF4E only. The polarization 
values or anisotrophy was recorded after an incubation at room temperature for 30mins, 
and plotted against the concentration of eIF4E added, using Prism 4.0, Graphpad.  
The specificity of the labeled peptide for eIF4E was verified by keeping the 
concentrations of both eIF4E and labeled peptide constant (6.5uM and 60nM 
respectively), while titrating the amount of 4EBP1 added. Titrations of DMSO and 
FAM-labeled p53 peptide were also carried out.  




Aptamer competition assays: 
Competition assays were conducted as described briefly for validation of the labeled 
peptide. The concentrations of eIF4E and FITC-labeled peptide were kept constant while 
the amount of competing aptamer or unlabeled peptide was added in increasing amounts.  
Thermal shift assay: 
- SYPRO® Red protein gel stain (5000X in DMSO): Invitrogen 
- iCycler Real Time Detection System: Bio-Rad, Hercules, CA 
100uM of aptamer protein in 25 µl of PBS was used each time for the thermal shift 
assay which was carried out in a black 96 well plate. Sypro red, a dye which emits 
fluorescence when bound, was added to the protein solution at a working concentration 
of 3.125X. The assay was performed using an iCycler Real Time Detection System 
which has a heating and cooling system that allows accurate manipulation of 
temperature, and a charge-coupled device (CCD) that captures and converts fluorescence 
light into digital signals. The plate was heated from 20 °C to 90 °C with by a 1 °C 
increment per min. The changes in fluorescence intensity were measured using an 
excitation wavelength of 575nm and an emission wavelength of 635nm. The 
fluorescence data obtained were fitted to a curve based on the equation derived by 
Pantoliano M.W et al (2001)186 and the melting temperature of the aptamers were 
calculated using the program Prism 4.0, Graphpad. 
The experiment was also conducted in the presence of 1mM DTT to measure the effects 
of the disulphide bond on the thermal stability of thioredoxin.  




Mammalian cells transfection: 
- Lipofectamine 2000: Invitrogen. 
- Opti-MEM® I Reduced Serum Media: modified Eagle's Minimum Essential Media, 
containing HEPES buffer, 2,400 mg/L sodium bicarbonate, hypoxanthine, thymidine, 
sodium pyruvate, L-glutamine, trace elements, growth factors, and phenol red reduced to 
1.1 mg/L; Invitrogen 
Transfection of MCF7 cells were carried out using lipofectamine 2000 according to 
manufacturer’s instructions. Briefly, 0.4 million of MCF7 cells were seeded into 6 well 
plates in 2ml of antibiotic-free media. 4ug of plasmid DNA and 10 µl of lipofectamine 
2000 were diluted in 250 µl of Opti-MEM separately and incubated at room temperature 
for 5 minutes. The diluted DNA was then mixed with diluted lipofectamine 2000 and 
further incubated for 20 minutes at room temperature. The mixture was then added to the 
cells and mixed well by rocking the plate. The cells were then incubated for 4-6 hours at 
37 °C. The media was changed and the cells were grown for either 24 or 48 hours before 
harvesting.  
Conditions such as DNA concentration, DNA to Lipofectamine ratio and cell density 
were optimized for maximum transfection efficiency. The conditions at which 
expression of the thioredoxin aptamers were found to be most satisfactory were used for 
subsequent transfections and assays.  




Soft agar assay: 
- BD DIFCO Agar, Noble: BD Diagnostics 
- Crystal violet: Sigma 
- MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide): Sigma 
The assay involves seeding single cells (ideally) into 0.35% agar and allowing the cells 
to grow for 2 to 3 weeks depending on the cell line. The layer of cells is overlaid on top 
of a base layer of 0.5 % agar to ensure that the cells are not attached to the plastic 
surface of the wells. 
1) Casting of the base agar: 
1% agarose in PBS was prepared using a microwave and cooled to 40 °C in a water bath. 
The agar was then mixed with equal volume of DMEM containing 20% of FBS to give a 
0.5% agarose in DMEM with 10% FBS. 1.5ml of the 0.5% agar was added to each well 
of a 6 well plate and allowed to solidify for at least 15mins. Plates were kept at 4 °C and 
used within a week. The plates were removed from the fridge at 30mins before plating 
of the top agar to allow the base agar to be at room temperature.  
2) Seeding cells into top agar: 
0.7% of agarose in PBS was prepared and cooled to 40 °C. DMEM containing 20% of 
FBS was warmed to 40 °C as well. The transfected cells were trypsinized carefully and 
counted. Equal volumes of the 0.7% agar and DMEM was mixed to give 0.35% agarose 
in DMEM with 10% FBS. The transfected cells were seeded at densities of 5000, 25000 
and 100000 cells per well. The cells were resuspended in 1.5ml of the 0.35% agar in 
DMEM and plated on to the wells. Each transfected sample was seeded in triplicates. 
The top agar was allowed to solidify in the hood for 15mins before transferring to the 
incubator. 1ml of media with 20% FBS was added after 3 hours and replenished every 3 
to 5 days. The cells were allowed to grow for 14 days before they were harvested. 




3) Colony staining and counting:  
The colonies were stained using 0.5ml of 0.005% crystal violet for 1 hour and counted 
under a microscope at 4X magnification. The number of colonies in 3 different 
microscope views were tabulated and averaged to minimize differences due to uneven 
seeding of cells. 
Subsequently, colonies were counted using a colony counter (GelCountTM from Oxford 
Optronix) and stained with MTT, a metabolic substrate which is reduced by living cells 
to form an insoluble purple product, to reduce background. 
Transformation of NIH3T3 cells: 
Bovine Calf Serum (CS): Hyclone 
NIH3T3 cells were grown and maintained in DMEM with 10% CS instead of the normal 
FBS for transformation assays. Only NIH3T3 cells with low passage numbers (less than 
15) were used for the transformation assays to minimize spontaneous transformations.  
0.25 million cells were seeded for transfections using lipofectamine 2000. The cells 
were transfected with 1 to 4ug of plasmid DNA encoding either Ras or eIF4E. The 
selection for transformed cells was carried out in two ways: natural selection and 
antibiotic selection. The transformed cells were allowed to grow naturally until the cells 
start stacking and growing on top of one another, forming foci of transformed cells. 
Alternatively, selection of cells that carried the transfected gene with 0.5mg/ml of 
geneticin was carried out until visible colonies were obtained. 
Genomic DNA isolation: 
Genomic DNA isolation was carried out using Qiagen’s DNeasy blood and tissue kit. 
The isolation was carried out according to the manufacturer’s protocol. Briefly, 5 
million cells were spun down at 5 min at 300 x g and resuspended in 200ul PBS. 20 µl 
of proteinase K was added, followed by 200 µl of Buffer AL. The tube was mixed 




thoroughly by vortexing, and incubated at 56°C for 10 min. 200 µl of 100% ethanol was 
added to the sample, mixed thoroughly and appled to the DNeasy Mini spin column. The 
column was spun at 6000 x g for 1 min and the flow-through and collection tube were 
discarded. The DNeasy Mini spin column was transferred to a new 2 ml collection tube 
and 500 µl of Buffer AW1 was added. The flow-through and collection tube were 
discarded. 500 µl of Buffer AW2 was added to the column which was then spun for 3 
min at 20,000 x g to remove all traces of ethanol. The column was transferred to a clean 
1.5ml tube and the genomic DNA isolated was eluted with 100 µl of Buffer AE after 5 
mins of incubation. (The buffers compositions are proprietary information.) 
PCR screening for gene integration: 
Primers specific for pcDNA3 promoter and BGH poly-A tail: 
Forward (5’ AGG CGT GTA CGG TGG GAG GTC TA 3’) 
Reverse (5’ CAC GGG GGA GGG GCA AAC AAC 3’) 
PCR using primers specific for DNA sequences found only in the pcDNA3 vector 
carrying the transfected gene, were carried out. The isolated genomic DNA was used as 
the template and the PCR mixture was set up as shown in Table 15 and run according to 
conditions specified in Table 16. The PCR products were run on a gel and selected based 
on the detection of a single band corresponding approximately to the length of the eIF4E 
gene transfected (654bp). The selected PCR products were then purified and subjected to 
another round of PCR using eIF4E-specific primers. The protocol was as described 
previously for eIF4E amplification. The products from the second PCR were verified on 
a gel and then sent for sequencing.  
 




Reagents eIF4E amplification Negative control 
5X Hercules II buffer 10 µl 10 µl  
dNTP mix (25mM each) 0.5 µl 0.5 µl 
pcDNA3 promoter primer 
(10uM) 1.25 µl 1.25 µl  
BGH poly-A tail primer (10uM) 1.25 µl 1.25 µl 
Genomic DNA template (100ng) x µl  - 
Hercules II DNA polymerase  0.5 µl 0.5 µl 
Sterile water (36.5 – x) µl 36.5 µl 
Total volume 50 µl 50 µl 
Table 15. PCR reaction mixture to screen for integrated eIF4E gene in the genomic 
DNA of isolated stable clones. 
 
Steps Temperature /°C Time Comments 
1) Initial denaturation 95 1 min  
2) Denaturation 95 5 secs  
3) Annealing 55 30 secs  
4) Extension 72 30 secs Go back to step 2 (30cycles) 
5) Final extension 72 10 mins  
6) Hold 4 -  
Table 16. PCR conditions for screening genomic DNA for integrated eIF4E in pcDNA3 
vector.    





Cells were fixed with 3% Paraformaldehyde (PFA) and 0.1% Triton X in PBS for 
20mins at room temperature. The cells were then washed with PBS for 3 times and 
blocked in DMEM media with 10% FBS for 1 hour. eIF4E (P-2) antibody was diluted to 
1ug/ml in DMEM (with 10% FBS) and added to the cells. The cells were incubated 
overnight at 4 °C with the antibody. After incubation, the cells were washed 3 times with 
PBS and the mouse HRP polymer secondary antibody was added for 1 hour at room 
temperature. The cells were then washed 3 times with PBS and the chromogen substrate 
(3’-diaminobenzidine or DAB+) was added. The cells were incubated with the substrate 
for 5 to 10mins until a brown precipitate was observed and the reaction was stopped by 
adding distilled water. A well omitting only the addition of anti-eIF4E was included as a 
control for background staining. The plates were then washed with 100% ethanol, rinsed 
with distilled water and dried for long term storage.  
Note: The antibody eIF4E (P-2) did not work well when methanol/acetone fixation was 
used to fix the cells.  
Foci formation assay: 
NIH3T3 cells were transfected concurrently with 0.5ug of Ras encoding plasmid DNA 
and 5ug of Trx-eIF4G or Trx-eIF4G-ala encoding plasmid DNA and allowed to grow for 
2 to 3 weeks in 10cm2 dishes. The petri dishes of cells with foci were then fixed with 3% 
PFA, permeabilized with 0.1% Tween20 and stained with Hoechst stain. Pictures of the 
plates were taken using Biorad Gel Doc machine.  
Gateway (GW) cloning:  
Adaptor primers for incorporating attB sites:  
attB1 forward (5’ G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC GAA 
GGA GAT AGA ACC ATG 3’); 




attB2 reverse (5’ GGG GAC CAC TTT GTA CAA GAA AGC TGG GTG TTA 3’) 
Gene-specific primers:  
Thioredoxin forward (5’ GAA GGA GAT AGA ACC ATG AGC GAT AAA ATT ATT 
CAC CTG 3’); 
Thioredoxin reverse (5’ GTA CAA GAA AGC TGG GTT TTA GGC CAG GTT AGC 
GTC GAG 3’) 
M13 sequencing primers: 
Forward (5’ GTA AAA CGA CGG CCA G 3’);  
Reverse (5’ CAG GAA ACA GCT ATG AC 3’) 
Vectors:  
- pDONR221: Invitrogen  
- pCMV-HBGI-N-FLAG-FRT GW Destination vector: provided generously by Dr Petr 
Muller. 
- pcDNA6.2-N-SBP GW Destination vector: provided generously by Dr Petr Muller. 
Enzymes: 
- BP clonase II enzyme mix: Invitrogen; contains integrase (Int), and integration host 
factor (IHF). 
- LR clonase II enzyme mix: Invitrogen; contains Int, excisionase (Xis), and IHF. 
Gateway Technology uses lambda phage-based site-specific recombination instead of 
restriction endonuclease and ligase to insert a gene of interest into an expression vector. 
The recombination sites used in Gateway Cloning are not wild-type sites: several point 
mutations were engineered into the wild type att sites to generate novel specific sites that 




will not recombine with wild type sites. (Refer to Gateway Cloning Technology manual 
for more details.)  
1) Introduction of GW recombination sites: 
PCR was first performed using thioredoxin specific primers which contained 
complementary sequences to the attB primers and plasmids encoding the thioredoxin 
aptamers as template. The reaction mixture was set up as shown in Table 17 and the 
PCR conditions were as stated in Table 18. An initial amplification was carried out at 
lower annealing temperature as nearly half of the sequence of the primers used contained 
dissimilar nucleotides. The subsequent amplifications were carried out at higher 
annealing temperature to ensure that specific amplification of the template containing 
the GW sequences (amplified in the step 3, Table 18) was carried out. The PCR products 
were treated with Dpn1 digestion for 1 hour at 37 °C to remove parental template 
without the GW sequences and purified.  
The purified PCR products were then used as templates for the second round of PCR 
using the same setup and conditions, but using the attB adaptor primers to extend the 
GW recombination sequences required for cloning. The PCR products were run on a gel 
and verified that they were of the correct size before gel extraction was carried out.  




Reagents GW amplification Negative control 
10X PfuUltra II buffer 5 µl 5 µl 
dNTP mix (25mM each) 0.5 µl 0.5 µl 
Forward primer (10uM) 1.5 µl 1.5 µl 
Reverse primer (10uM) 1.5 µl 1.5 µl 
DNA template (20ng/ul) 1.0 µl - 
PfuUltra II DNA polymerase  1.0 µl 1.0 µl 
Sterile water 39.5 µl 40.5 µl 
Total volume 50 µl 50 µl  
   Table 17. PCR reaction mixture for Gateway cloning amplification.  
 
Steps Temperature /°C Time Comments 
1) Initial denaturation 95 30 secs  
2) 1st annealing 45 30 secs  
3) 1st extension 70 30 secs  
4) Denaturation 95 5 secs  
5) Annealing 55 20 secs  
6) Extension 72 30 secs Go back to step 2 (10cycles) 
7) Final extension 72 10 mins  
8) Hold 4 -  
Table 18. PCR conditions for amplifying thioredoxin with GW specific primers and for 
introducing the GW recombination sites using adaptor primers. 




2) BP recombination reaction: 
BP reaction is carried out with pDONR221 and PCR inserts containing the attB sites to 
generate pENTR plasmids according to manufacturer’s recommendations. Briefly, 50 
fmol of the insert (~13.5ng) and vector (~150ng) were mixed in TE buffer to a final 
volume of 8 µl. 2 µl of BP clonase II were added and the reaction was incubated at 25 
°C for 1 hour. 1 µl of proteinase K was added followed by incubation for 10mins at 37 
°C. 1 µl of the reaction mixture was then transformed into 50 µl of TOP10 competent 
cells. The cells were plated on LB agar plates with kanamycin antibiotic selection. 
Bacteria colonies were picked and cultures were grown for miniprep. The purified 
plasmid DNA was then sequenced using M13 forward and reverse primers.   
3) LR recombination reaction: 
50-150ng of the entry clone (pENTR) was mixed with 150ng of the destination vector in 
TE buffer to a final volume of 8 µl. 2 µl of LR clonase II was added and the reaction 
was incubated at 25 °C for 1 hour. 1 µl of proteinase K was added followed by 
incubation for 10mins at 37 °C. 1 µl of the reaction mixture was then transformed into 
50 µl of TOP10 competent cells. The cells were plated on LB agar plates with 
spectinomycin for pcDNA6.2-N-SBP destination vectors and ampicillin for pCMV-
HBGI-N-FLAG-FRT destination vectors.  
4) Screening for the recombined destination vector:  
Clones were picked and screened for successful recombination by restriction enzyme 
digestion and gene-specific PCR. Enzymes that will generate different restriction 
digestion profiles for vector containing insert and empty vector were chosen to perform 
the restriction enzyme digest screen. The enzymes chosen to digest pcDNA6.2-N-SBP 
and pCMV-HBGI-N-FLAG-FRT were NcoI and RsrII respectively.      




Antibiotic selection for integration of aptamers: 
H1299 cells containing 1 FRT site (H1299 LZ4): generated by Dr Petr Muller, DPL 
IMCB. 
H1299 LZ4 was transfected with 0.4ug of aptamer encoding plasmid DNA and 3.6ug of 
DNA encoding the recombinase (POG44 70F) required for flipping in the aptamer into 
the FRT site. After transfection, the cells were incubated at 32 °C for 2 days to allow for 
recombination of the aptamer DNA into the FRT site of the genomic DNA. The cells 
were then transferred back to 37 °C and antibiotic selection was carried out with 
250ug/ml of hygromycin . The selection procedure was deemed complete when all the 
cells in the untransfected well were killed. The remaining colonies of cells were fixed 
and stained with Hoechst stain for picture taking. 
 Streptavidin binding peptide (SBP) tag pulldowns: 
293FT cells were transfected for 48 hours in 6 well plates with Trx aptamers and 
harvested by scraping. The cells were lyzed in 200 µl of NP40 lysis buffer with protease 
inhibitors and incubated on ice for 15mins. The cell lysates were spun down at 14,000 
rpm (Eppendorf 5417R tabletop centrifuge) for 10mins and the supernatant was 
transferred to new 1.5ml tubes. 15 µl of washed avidin agarose beads was added to the 
supernatant and incubated for 1 hour at 4 °C on a rotator. The beads were spun down 
and the supernatant was transferred to a new 1.5ml tube. 100 µl of washed streptavidin 
beads were added to the supernatant and incubated for 1 hour at 4 °C on a rotator. The 
beads were then washed 4X with 1ml of NP40 lysis buffer and the bound proteins were 
eluted with 1mM biotin in NP40 lysis buffer. The eluted proteins were run on a gel and 
analyzed by western blot.  




2.6. Validation of nature’s own aptamer: 4EBP1 as an aptamer 
Cloning of 4EBP1 and the modified 4EBP1 aptamers: 
Primers for mutating the phosphorylation sites threonine 46 to alanine:  
Forward (5’ ACG CTC TTC AGC ACC GCC CCG GGA GGT ACC AGG 3’); Reverse 
(5’ CCT GGT ACC TCC CGG GGC GGT GCT GAA GAG CGT 3’) 
Primers for mutating the phosphorylation sites serine 65 to alanine: 
Forward (5’ ATG GAG TGT CGG AAC GCA CCT GTG ACC AAA ACA 3’); Reverse 
(5’ TGT TTT GGT CAC AGG TGC GTT CCG ACA CTC CAT 3’) 
Primers for mutating the phosphorylation sites threonine 37 to alanine:  
Forward (5’ GAC TAC AGC ACG GCC CCC GGC GGC ACG 3’); Reverse: (5’ CGT 
GCC GCC GGG GGC CGT GCT GTA GTC 3’)  
Primers for mutating the phosphorylation sites threonine 70 to alanine:  
Forward (5’ CCT GTG ACC AAA GCA CCC CCA AGG GAT 3’); Reverse (5’ ATC 
CCT TGG GGG TGC TTT GGT CAC AGG 3’) 
Primers for mutating the critical eIF4E binding residues to alanine: 
Forward (5’ GGT ACC AGG ATC ATC GCA GAC CGG AAA GCA GCA ATG GAG  
TGT CGG AAC 3’)  
Reverse (5’ GTT CCG ACA CTC CAT TGC TGC TTT CCG GTC TGC  GAT GAT 
CCT GGT ACC 3’) 




Primers for removing binding residues (YDRKFLMEC): 
Forward (5’ GCC CCG GGA GGT ACC AGG ATC ATC CGG AAC GCA CCT GTG 
ACC AAA ACA 3’) 
Reverse (5’ TGT TTT GGT CAC AGG TGC GTT CCG GAT GAT CCT GGT ACC 
TCC CGG GGC 3’) 
WT 4EBP1 gene template was provided by Dr Chris Brown, DPL IMCB. Site directed 
mutagenesis was carried out as previously described to obtain the various 4EBP1 
aptamers.  
Fluorescence activated cell sorting (FACS) 
MCF7 cells were transfected using Amaxa electroporation as previously described and 
harvested 48 hours after transfection by trypsinization. The trypsinized cells were spun 
down at 3000 rpm for 3mins and resuspended in 50 µl of PBS. 750 µl of 70% ethanol 
was added to the cell suspension while vortexing. The cells were then fixed at -20 °C 
overnight. The fixed cells were washed twice with 500 µl of PBS and incubated with 
50ug of RNase A in 50 µl of PBS at 37 °C for 30mins. 300 µl of propidium iodide (PI; 
0.025ug/µl) was added directly to the cells and the cells were incubated in the dark for 
15mins. The stained cells were run on a FACS analyzer using excitation /emission 
wavelengths of 535 /615nm respectively. The results obtained were analyzed using 
MofFIT.     
Foci formation assay: 
NIH3T3 cells were transfected concurrently with 0.5ug of Ras and 5ug of WT 4EBP1 or 
non-phosphorylable 4EBP1 and allowed to grow for 2 to 3 weeks in 10cm2 dishes. The 
petri dishes of cells with foci were then fixed with 3% PFA, permeabilized with 0.1% 
Tween20 and stained with Hoechst stain. Pictures of the plates were taken using Biorad 
Gel Doc machine. The foci assay was also performed by transforming NIH3T3 cells 




with 1ug of E1A and 2ug of eIF4E. 1ug of the either WT 4EBP1 or non-phosphorylable 
4EBP1 was cotransfected at the same time to validate their intracellular effects.  
Gateway (GW) cloning:  
Gene specific primers:  
Forward (5’ GAA GGA GAT AGA ACC ATG TCC GGG GGC AGC AGC TGC AGC 
3’); Reverse (5’ GTA CAA GAA AGC TGG GTT TCA AAT GTC CAT CTC AAA 
CTG 3’) 
Vectors:  
- pDONR221, pCMV-HBGI-N-FLAG-FRT and pcDNA6.2-N-SBP GW destination 
vectors as previously described.  
- GAL4-HBGI-N-FLAG-FRT GW destination vector: generously provided by Dr Petr 
Muller. 
Cloning of 4EBP1 into gateway vectors were carried out as previously described.  
Construction of inducible cell lines 
The inducible system was set up with help from Dr Petr Muller. Briefly, H1299 LZ4 
cells were transfected with DNA encoding the transcription receptor (an insect ecdysone 
receptor (EcR) receptor fused to the yeast GAL4 DNA binding domain) and activator (a 
mammalian retinoid-X-receptor (RXR) fused to the viral activation domain VP16). The 
cells were selected for stable integration of these genes using antibiotics (H1299 LZ4 
NEBR). 
H1299 LZ4 NEBR cells were transfected in a 6 well plate with 0.4ug of the aptamer 
genes in GAL4-HBGI-N-FLAG-FRT destination vectors and 3.6ug of recombinase 
plasmid, using lipofectamine 2000 as the transfection reagent. The cells were incubated 
at 32 °C after transfection, for 2 days to allow for recombination of the aptamer DNA 




into the FRT site of the genomic DNA. The cells were then transferred back to 37 °C 
and antibiotic selection was carried out with 250ug/ml of hygromycin. Individual clones 
for each 4EBP1 stably transfected aptamer were isolated. 
Plotting the growth curve:  
50, 000 cells for each stable cell line were plated in each well of a 24 well plate. 
Duplicates were plated for both cells that were induced with 5uM of tebufenozide and 
uninduced control (Diagram 14). Twelve 24 well plates were seeded and the appropriate 
wells were treated with tebufenozide. Individual plates were harvested at different time 
points over a period of 72 hours. The cells were harvested by fixing with 3% PFA and 
0.1% Triton X in PBS for 20mins. The fixed cells were washed twice with PBS and 
stored in PBS at 4 °C until the end of the 72 hours. When all the cells for the various 
time points have been harvested, the fixed cells were lyzed in 100 µl of 0.1% SDS with 
25mM EDTA and proteinase k in water. The cells were incubated at 50 °C for 30mins 
and 900 µl of PBS was added. The lyzed cells were then sonicated to obtain a “uniform 
mixture” of DNA that was not in clumps. The sonicated cell lysate was mixed well with 
Quant-iT PicoGreen reagent (Invitrogen) according to manuafacturer’s instructions. The 
fluorescence was measured with excitation at 480nm and emission at 520nm. Quant-iT 
PicoGreen reagent is highly selective for double stranded DNA, with negligible binding 
to single stranded DNA and RNA.  
The doubling time for the stable cell lines (induced and uninduced) were calculated 
based on the equation obtained from the growth curves plotted, using the formula 
ln2/growth constant. The growth rate constant is equivalent to the gradient of the growth 
curves.  





Diagram 14. Layout of the cells plated for the measurement and construction of the 
growth curve for 4EBP1 aptamers stably transfected inducible cell lines. (1) WT 4EBP1 
stably transfected cells (2) Non-phosphorylable 4EBP1 stably transfected cells (3) Non-
phosphorylable 4EBP1 alanine control stably transfected cells (4) Non-phosphorylable 
4EBP1 deletion control stably transfected cells.  









3. Characterization of starting reagents and verification of eIF4E binding sequence 
3.1.  Introduction and aims 
The over expression of eIF4E protein has been shown to enhance the translation of 
complex mRNA transcripts which encode oncoproteins. Non-coincidentally, eIF4E has 
been found to be selectively upregulated in a number of cancers, ranging from head and 
neck, lung, breast, colon, bladder, cervix to prostate. 
The injection of cells over-expressing eIF4E into nude mice caused tumorigenesis 145 
whereas the inhibition of eIF4E activity by overexpression of 4EBP1 or siRNA 
knockdown of eIF4E was shown to inhibit cell growth and tumorigenesis. Remarkable 
success has been obtained using antisense oligonucleotides (ASOs) as therapeutic agents 
to specifically reduce eIF4E levels: tumour growth and angiogenesis was significantly 
reduced in human tumour xenografts without any detectable side effects on the health of 
the mice 170,187.    
The various observations made and studies conducted implicate that eIF4E plays an 
active role in the genesis and progression of many cancer cell lineages, and hence is a 
potential target for selective inhibition of these cancer cells.  
There are various known binding partners of eIF4E (4E-BPs, eIF4G, etc) and their 
binding motifs have been well characterized 188,189. A study conducted by Herbert T.P et 
al (2000) 160 demonstrated that peptides with sequences corresponding to the eIF4E-
binding sequences of 4E-BP1 and eIF4G were able to bind to eIF4E and induce 
apoptosis in mammalian cells. To enable further investigations of the effects of eIF4E 




inhibition in vivo, the decision to construct an eIF4E binding aptamer was made. An 
eIF4E binding sequence was selected and inserted it into a scaffold protein, for further 
use in studies exploring the physiological effects of inhibiting eIF4E.  
3.2.  Characterization of eIF4E in cells 
In an attempt to identify an appropriate cell line suitable for the purposes of the project 
and to validate the sensitivity and specificity of commercial antibodies purchased, the 
cell lysates of several cell lines were prepared for western blotting to determine the 
eIF4E levels of the cells. The protein concentrations of the cell lysates were quantified 
as accurately as possible and equal amounts of lysate were loaded onto a 4-12% gradient 
gel for western blot analysis. The immunoblots were analyzed separately using either 
mouse monoclonal eIF4E (P-2) or rabbit polyclonal eIF4E (#9742) antibodies. The 
membrane was also probed with an anti-actin (AC-15) antibody as a loading control.  
From Figure 2, it can be concluded that the both the monoclonal and polyclonal 
antibodies for eIF4E performed reasonably well in western blots as both antibodies were 
able to detect intracellular levels of the eIF4E protein without any non-specific 
background staining. The monoclonal antibody was selected for use in subsequent 
western blots as it worked well and should not vary from batch to batch.   
The antibodies were also able to detect the protein in a range of different cell lines. 
eIF4E was found to be present in all the cell lines that were screened (Figure 2) although 
differences in the levels of protein were observed. This information proved useful in 




subsequent experiments. It should be noted that the different cell lines were extracted 
under different lysis conditions.  
 
Figure 2. Western blot analysis of the eIF4E levels in different cell lines. 3ug of protein 
from the different cell lysates were run on 4-12% gradient gels and transferred to 
nitrocellulose membranes for western blotting. The membranes were cut for probing 
with anti-eIF4E and anti-actin antibodies. Blots I and II were probed with mouse 
monoclonal eIF4E (P-2) and rabbit polyclonal eIF4E (#9742) antibodies respectively, 
whereas blots II and IV were probed with antibodies against actin (AC-15) to check for 
equal loading. The lanes were loaded with cell lysates corresponding to different cell 
lines as numbered: 1) H1299, 2) U20S, 3) MCF7, 4) MCF7dd9, 5) HCT116+/+, 6) 
HCT116 -/-, 7) MDCK II, 8) A549, 9) ARN8, 10) HEK293.  
3.3.  Cloning of eIF4E into bacterial and mammalian expression vectors.  
Pure eIF4E was required for various in vitro experiments. To this end, the gene was 
cloned into an N-terminal His-tag fusion in the pET19b bacterial expression vector, 
eIF4E 
(P-2) 

















using XhoI and BamHI restriction enzyme sites. To obtain the gene for eIF4E, primers 
specific for eIF4E were ordered and used to amplify the gene from a pool of cDNA from 
Hela cells. The PCR product was run on a 1% gel and verified that it was of the right 
size (Figure 3).  
 
Figure 3. PCR amplification of eIF4E gene (645bp), using cDNA from Hela cells as 
template..The PCR product was run on a 1% agarose gel stained with ethidium bromide. 
Lane 1 contains the PCR products from Hela cells cDNA whereas lane 2 contains the 
negative control.  
The amplified eIF4E gene was digested and inserted into pET19b between restriction 
enzyme sites XhoI and BamHI of the multiple cloning site as described in material and 
methods. Similarly, the eIF4E gene was also cloned into a mammalian expression vector: 
pcDNA3, between restriction sites BamHI and XhoI. The eIF4E gene insert in both 
vectors were verified to be correct by sequencing and aligning the sequence with the 
sequence available in NCBI, Nucleotide (Accession code: NM_001968.3).  
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3.4.  eIF4E protein expression and purification 
BL21 was transformed with pET19b DNA encoding His-tagged eIF4E. A trial induction 
of eIF4E protein expression was conducted at 37 °C. Samples of the induced bacteria 
were collected and analyzed on a gel by coomassie staining. As shown in Figure 4, the 
expression of eIF4E protein increases as the induction time increases. Nevertheless, 
there seemed to be some leaky expression of eIF4E even when the BL21 bacteria were 
not induced with IPTG as seen in Figure 4, lane 1. Induction with IPTG beyond 3 hours 
did not increase the expression of eIF4E significantly (data not shown). Therefore, an 
induction period of 3 hours was used for subsequent experiments that required the 
expression and purification of eIF4E protein. The band (indicated by an arrow) that was 
suspected to be eIF4E was cut out and sent for mass spectrometry analysis (MS). The 
MS successfully confirmed the protein to be eIF4E (refer to Appendix 2).  





Figure 4. Trial induction of eIF4E protein expression with 1mM of IPTG over a time 
course of 3 hours at 37 °C. The cell lysates of the induced bacteria were ran on a protein 
gel and stained with coomassie blue. Arrow indicates the band that was cut out and sent 
for mass spectrometry analysis which confirmed the identity of the protein to be eIF4E. 
The numbered lanes represent: 1) uninduced BL21, 2) 1 hr induction with IPTG, 3) 2 hrs 
induction with IPTG, 4) 3 hrs induction with IPTG. 
Having determined the optimal induction time for expression of eIF4E protein, the 
fraction in which the protein was expressed was verified next. The methods employed 
for protein purification differs for each fraction and therefore, it was important to 
determine the location of the eIF4E protein expressed. The protein contents of the 
induced bacteria were separated into various fractions: media, soluble fraction and 
insoluble fraction, and tested for eIF4E expression. Proteins in the media and soluble 
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fractions are the easiest to purify as no denaturation is required and the purified proteins 
are almost always correctly folded. Proteins that are sequestered in the insoluble fraction 
are proteins that are incorrectly folded and therefore accumulated in the inclusion bodies. 
To purify proteins from the insoluble fraction, the inclusion bodies must first be 
solublized with chaotrophic agents such as urea or guanidium chloride. The proteins are 
then purified in their denatured forms and refolded subsequently by removing the 
denaturing reagents. The majority of eIF4E expressed was found to be located in the 
insoluble fraction of the bacterial lysate (Figure 5). The observation was confirmed by 
western blot.  
 
Figure 5. Coomassie gel comparing the different fractions of the bacterial pellet for 
eIF4E protein expression. eIF4E expression was detected mainly in the soluble faction 
as denoted by the arrow. The numbered lanes represent: 1) insoluble fraction, 2) soluble 
fraction 3) media. (BenchMark pre-stained marker was used.) 
eIF4E was batch purified as described in material and methods and checked on a gel by 
coomassie staining to ascertain the purity of the purified protein. As shown in Figure 6 
lane 1, the purified eIF4E obtained was relatively clean and sufficiently pure for use in 








the interaction assays. However, the denatured eIF4E had to be refolded after 
purification from the insoluble fraction to regain its function. Attempts were made to 
refold the protein by both gradual dialysis of the denatured eIF4E and rapid dilution of 
the protein into large amounts of buffer without the denaturing reagents, followed by 
protein concentration. In the process of refolding, the majority of the eIF4E precipitated 
out of solution and could no longer be used. Multiple attempts to produce eIF4E protein 
in significant amounts in the soluble fraction: induction of the bacteria at room 
temperature for different durations, induction with different concentrations of IPTG and 
commercial expression medium (Overnight Express Instant TB Medium, Novagen) for 
auto-induction of protein expression, to bypass the refolding step failed. The subsequent 
binding studies were carried out with what was recovered from the refolding and dialysis 
step.  
 
Figure 6. Batch purification of eIF4E using Ni-NTA beads. The purification fractions 
were run on a gel and analyzed by coomassie staining. The numbered lanes contained: 1) 
eIF4E purified from the insoluble fraction. 2) eIF4E purified from the soluble fraction. 3) 
Flow through from soluble fraction after binding with Ni-NTA beads. 
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The difficulties in purifying E.coli expressed functional human eIF4E has been 
previously reported 190. Stern B.D and coworkers encountered similar issues such as 
protein aggregation and low yield of functional protein in the purification of eIF4E. The 
incorrect reformation of disulphide bonds in eIF4E was hypothesized to be the cause. 
According to a study by Slepenkov S.V and coworkers, overnight induction of eIF4E at 
15 °C increases the yield of soluble eIF4E 191. Expression of eIF4E at lower temperature 
may be a feasible method to increase the yield of soluble protein but attempts to induce 
eIF4E at ambient temperature previously did not result in a significant increase of eIF4E 
expression in the soluble fraction.  
Fast protein liquid chromatography (FPLC) purification of eIF4E using an AKTA 
machine was subsequently performed in an attempt to increase the yield of functional 
His-tagged eIF4E. Attempts were made to refold eIF4E while the protein was still bound 
on the column to reduce protein aggregation as described in materials and methods. 
Subsequently, for fluorescent polarization assays, an expression vector encoding the 
untagged eIF4E gene was obtained from Dr Chris Brown and the protein was purified 
using FPLC according to a protocol previously described in Brown CJ et al (2007) 185.  
3.5.  Characterization of eIF4E commercial antibodies 
The aim of this study was to design a synthetic protein aptamer that could bind to and 
inhibit eIF4E activity. It was therefore of utmost importance to have reagents for binding 
assays to be performed. The binding affinities of two commercial eIF4E antibodies were 
examined.  




Immunoprecipitation (IP) assays were carried out using sepharose protein G beads. In a 
pilot experiment, the antibodies were used to isolate eIF4E from cell lysates. The IP 
asssys were consistently unsuccessful for both monoclonal and polyclonal antibodies: 
there was either non-specific binding to the protein G beads or no binding at all (specific 
and non-specific) with more stringent lysis or washing conditions.  
 The IP assay was subsequently repeated with purified eIF4E protein instead. The IP was 
conducted similarly, using rabbit polyclonal anti-eIF4E (#9742). As shown in Figure 7, 
the polyclonal antibody did not IP any protein at concentrations of eIF4E lower than 
0.1ug (lane 4). There was some eIF4E IP by the antibody in lane 5, but the amount of 
protein precipitated was considerably less compared to what was added to the IP 
reaction. The binding in lane 5 was specific and not due to the high amount of purified 
protein added as without eIF4E antibody, no precipitation of eIF4E occurred (lane 1-3). 
Similarly, an unrelated antibody failed to precipitate eIF4E, further emphasizing the 
specificity of the reaction.  





Figure 7. Immunprecipitation of purified eIF4E with rabbit polyclonal anti-eIF4E 
(#9742). The eluted proteins were run on a gel and analysed by western blot using 
mouse monoclonal eIF4E antibodies (P-2). Dimers and trimers of eIF4E were observed 
for the loading controls in lane 9 to 12. 
Lanes:  
(1) protein G beads + 0.1ug of eIF4E.  
(2) protein G beads + 0.5ug of eIF4E.  
(3) protein G beads + 1.0ug of eIF4E.  
(4) protein G beads + 1ug anti-eIF4E + 0.05ug of eIF4E.  
(5) protein G beads + 1ug anti-eIF4E + 0.1ug of eIF4E.  
(6) protein G beads + 1ug DO12 + 0.05ug of eIF4E.  
(7) protein G beads + 1ug DO12 + 0.1ug of eIF4E.  
(8) protein G beads + 1ug of anti-eIF4E.  
 
Lanes 9 to 12 contained loading controls of 0.05ug, 0.1ug, 0.5ug and 1ug of eIF4E 
protein respectively.  
 
The IP was repeated with the second mouse monoclonal antibody (eIF4E P-2). Similarly, 
the monoclonal antibody was able to precipitate eIF4E as shown in Figure 8, lane 7. The 
binding of eIF4E to the antibody was once again specific as there was no non-specific 
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sticking of eIF4E to protein G without anti-eIF4E conjugated (lane 12) and an irrelevant 
anti-FLAG antibody did not precipitate eIF4E (lane 3).     
 
Figure 8.  Western blots of immunoprecipitation experiments with protein G sepharose 
beads and monoclonal antibodies to check for interaction between CI2 and eIF4E. (A) 
Membrane stained with anti-eIF4E antibody to detect eIF4E. (B) Membrane stained with 
secondary anti-mouse antibody to check for monoclonal antibody bound to beads.  
Lane:  
1) Protein G  + 1ug anti-FLAG antibody + 1ug FL-CI2-eIF4G 
2) Protein G  + 1ug anti-FLAG antibody + 1ug FL-CI2-eIF4G (denatured) 
3) Protein G  + 1ug anti-FLAG antibody + 1ug eIF4E 
4) Protein G  + 1ug anti-FLAG + 1ug FL-CI2-eIF4G + 1ug eIF4E 
5) Protein G + 1ug anti-eIF4E + 1ug FL-CI2-eIF4G 
6) Protein G + - + 1ug FL-CI2-eIF4G (denatured) 
7) Protein G + 1ug anti-eIF4E + 1ug eIF4E  
8) Protein G + 1ug anti-eIF4E + 1ug FL-CI2-eIF4G + 1ug eIF4E 
9) Protein G + 1ug anti-FLAG + - 
10) Protein G + - + 1ug FL-CI2-eIF4G 
11) Protein G + - + 1ug FL-CI2-eIF4G (denatured) 




Both commercial antibodies seem to bind eIF4E weakly as they failed to IP eIF4E in the 
presence of other non-specific proteins (i.e.: cell lysates) and the amount of eIF4E 
precipitated from purified protein was incomparable to the amount added into the IP 
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mixtures. Although the apparent weak IP abilities of the antibodies may be due to low 
binding affinity or a hidden epitope, which also explains why no eIF4E could be 
precipitated from cell lysates, it is noteworthy that the low amounts of eIF4E 
precipitated from purified protein IP may also be due to the purified eIF4E not being 
properly refolded, a problem encountered and previously described in section 3.4. 
Nevertheless, it was clear that these two antibodies while adequate in western blot 
analysis were definitely unsuitable for our purposes of carrying out IP experiments to 
validate the binding of our aptamers to eIF4E.  
Fortunately, a valuable reagent: cap analogue 7-methylguanosine 5'-triphosphate 
(m7GTP) coupled sepharose beads was sourced. m7GTP beads have also been used for 
the isolation of functional recombinant eIF4E by various groups 192-194. The m7GTP 
beads enabled interaction assays to be performed without the need for a good antibody 
to recognize and IP eIF4E in its native conformation. As eIF4E is a cap-binding protein, 
it binds to m7GTP beads which resemble the 7-methylguanosine found on the 5’ cap of 
mRNAs111. In addition to its use in performing binding assays, these beads ensure that 
only correctly folded native eIF4E is used to check for interaction with the protein 
aptamers as only correctly folded eIF4E is able to bind to the 5’ cap of mRNAs193.  
The ability of m7GTP beads to precipitate eIF4E was investigated using both purified 
eIF4E and mammalian cell lysates. The m7GTP beads successfully pulled down eIF4E 
in reasonable amounts from cell lysates and purified eIF4E protein. The beads had 
proven to be very useful subsequently in later studies.   





Figure 9. Western blot analysis of m7GTP beads pulldown of eIF4E. Membrane was 
probed with anti-eIF4E to check for interaction of eIF4E with the m7GTP beads.  
Lane:  
1) beads + 1uM purified eIF4E (~5ug) 
2) beads + 1uM purified CI2 (~5ug) 
3) beads + cell lysate (0.5 X 175cm2 flask) 
4) beads only.  
 
3.6.  Affinity-based precipitation of proteins using peptides (peptide pulldown assay) 
To verify and decide on the correct amino acid sequence to use for the construction of 
the inhibitor protein, biotinylated peptides of the same sequences used by Herbert T.P et 
al (2000) in their study, were ordered (Diagram 15) from Mimotopes Pty Ltd, Australia. 
The critical residue responsible for the interaction 160 was mutated for use as the 
negative control for binding assays. Mutation of the critical binding residue tyrosine to 
alanine, removed most, if not all, of the binding to eIF4E, although residual binding was 
observed occasionally (Figure 10Figure 11). In vitro pulldown experiments were 
conducted to confirm the ability of the sequences to bind eIF4E.  











Diagram 15. Sequences of peptides designed and attached to biotin at the N–terminus 
via a hydrophilic linker (-SGSG-). These peptides have been shown to induce apoptosis 
via binding to eIF4E and mutations to alanine at key contact residues abrogate the 
apoptosis inducing effect 160. 
 To investigate the ability of these peptides to bind to eIF4E, equal amounts of 
biotinylated peptides were bound to strepavidin beads and incubated with mammalian 
cell lysate to pull down any interacting proteins. U20S cells which had reasonable 
amounts of eIF4E detectable on western blot, was used for the pulldown. The bound 
proteins were eluted with SDS loading buffer, ran on a 4-12% SDS-PAGE gel and 
analyzed by western blot (Figure 10).   
   Peptides synthesized: 
eIF4G:             KKRYDREFLLGF 
eIF4G-ala:       KKRADREFLLGF 
 
4E-BP1:          RIIYDRKFLMEC 
4E-BP1-ala:    RIIADRKFLMEC 
 





Figure 10. Peptide pulldown of eIF4E from U2OS cell lysates using streptavidin beads 
and biotinylated peptides. 10ug of peptide was used for the pulldown and one-tenth of 
the amount of cell lysate used for the pulldown was loaded in lane 6. Results of the 
pulldown were analyzed via western blot and detected with monoclonal anti-eIF4E 
antibody.  
Lane:  
1) Beads + eIF4G peptide + cell extract 
2) Beads + eIF4G-ala peptide + cell extract  
3) Beads + 4E-BP1 peptide + cell extract  
4) Beads + 4E-BP1-ala peptide + cell extract  
5) Beads + --- + cell extract 
6) Cell extract 
 
The peptides with eIF4E binding sequences corresponding to that of eIF4G and 4E-BP1 
pulled down eIF4E from mammalian cell lysates as shown in Lane 1 and 3 respectively 
(Figure 10). Their respective alanine control peptides with the critical contact residue 
mutated showed negligible binding (Lane 2 and 4). The results demonstrated that the 
interaction between eIF4E and the peptide is dependent on the presence of the tyrosine 
residue. In addition, no eIF4E was pulled down by the beads if no peptide had been 
bound as shown in lane 5. This further demonstrated the specificity of the binding. The 
band in Lane 3 can be seen to be considerably thicker than that in Lane 1, indicating that 
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as compared to the eIF4G peptide (sequence obtained from eIF4G). This may be 
because that the eIF4E binding sequence from 4E-BP1 has greater binding affinity to 
eIF4E as compared to that of eIF4G. Alternatively, the difference in the amount of 
eIF4E pulled down from the cell lysates despite equal amount of peptide used for 
coupling to the beads, could be due to the variations in the purity of the peptide 
synthesized or accidental loss of beads during the pulldown process.  
Subsequently, the same peptide pulldown assay was performed using the biotinylated 
peptides and purified eIF4E. Similarly, both eIF4G and 4EBP1 peptides were able to 
bind to eIF4E (Figure 11). The amounts of eIF4E bound to the peptides in this 
experiment were more or less equivalent and some binding of eIF4E to the alanine 
control peptide for eIF4E was observed. In addition, it was also noted that residual 
binding activity of the alanine peptide could still be present due to the removal of only 
one critical residue out of the three.  
 
Figure 11. Peptide pulldown of purified eIF4E using streptavidin beads and biotinylated 
peptides. Results of the pulldown were analyzed via western blot and detected with 
monoclonal anti-eIF4E antibody.  
Lane: 1) Beads + eIF4G peptide + eIF4E 
          2) Beads + eIF4G-ala peptide + eIF4E  
          3) Beads + 4E-BP1 peptide + eIF4E  
          4) Beads + 4E-BP1-ala peptide + eIF4E 
          5) Beads + --- + eIF4E 
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As shown in Figure 10, it seems as if 4EBP1 peptide was able to bind more strongly to 
eIF4E. However, in Figure 11, the amount of eIF4E bound by both peptides appeared to 
be similar. It could be said that the presence of non-specific proteins in the cell lysate 
interfered with the binding of eIF4G peptide to eIF4E, implying lower binding affinities. 
However, it is important to keep in mind that the peptide pulldowns performed were in 
no means a quantitative assay due to many variables such as different peptide purities, 
amount of bead loss during washing, etc. In addition, the amount of cell lysates used for 
each peptide was not quantified by protein concentration assays; an approximate number 
of cells were used by harvesting from a 15cm plate. On hind sight, the cell lysates 
should have been pooled and aliquoted for each pulldown to ensure that equal amounts 
of lysate was used. Nevertheless, it was not of utmost importance at this point to 
evaluate the binding affinities of the two peptides as the affinities might change upon 
constraining the peptides on a scaffold. The point of the pulldown was to evaluate 
qualitatively, that the peptides were able to bind to eIF4E. Therefore, based on 
observations from peptide pulldowns assays that the eIF4G peptide bound eIF4E well, 
the sequence of the eIF4G peptide was selected for the construction of the synthetic 
inhibitory aptamer.  
 




4. Protein aptamer construction using Chymotrypsin inhibitor 2 as the scaffold 
4.1. Introduction and aims 
Short peptides and siRNAs are prone to degradation and are usually short lived in 
intracellular environments. As a result, long term effects of targeted eIF4E inhibition are 
hard to study. Therefore, we propose to construct a small synthetic protein which binds 
specifically to eIF4E for use as a tool to examine the physiological effects of inhibiting 
eIF4E in vivo as a putative tumour suppressor protein.    
Chymotrypsin inhibitor 2 (CI2) was one of the potential scaffolds for construction of the 
synthetic aptamer due to its small, compact size and lack of cysteines, which enables it 
to fold correctly in both reducing and non-reducing environments. The active site of CI2, 
which is inactivated by the insertion of peptides, forms a peptide presentation loop and 
can tolerate insertions of up to 37 amino acids 51.  
Based on a successful study by Karlsson G.B et al (2004) 51 of the activation of p53 
using Mdm2-binding peptides constrained by CI2, CI2 was chosen as the scaffold 
protein for the construction of an eIF4E interfering aptamer. 
Experiments were conducted to verify and ascertain that the eIF4E binding ability of the 
peptide was retained even though it was constrained within a scaffold. Transient 
transfections of mammalian cells were subsequently performed to check the effects on 
the aptamer in vivo. Efforts were made to improve expression in vivo.  




4.2. Construction of aptamer protein for interaction studies 
4.2.1. Cloning of CI2 aptamers 
Based on the Mdm-2 aptamer designed by Karlsson et al (2004), the selected eIF4G 
peptide of 12 residues was similarly inserted into full length CI2 at its active site loop, 
replacing amino acids 55 to 61 (IVTMEY) to create an eIF4E binding aptamer to be 
used for further interaction studies. 6 amino acids of CI2 were removed in the process. 
Prior studies have shown that the insertion of peptides at the active site loop does not 
affect the stability of the protein in terms of its ability to fold correctly and present the 
peptide inserted 49. For the control aptamer, in addition to the key tyrosine contact 
residue as described earlier in Diagram 15, additional mutations of 2 conserved leucine 
residues to alanine were included in the negative control peptide sequence (Diagram 16). 
This was done, based on knowledge of the crystal structure assignment of eIF4G peptide 
docking on eIF4E, to abrogate any residual binding to ensure a cleaner background.  
The DNA encoding the binding aptamer was ordered to be synthesized from Midland, 
Molecular Biology Group, Texas, and codon optimized for expression in both bacterial 
and mammalian systems (refer to Appendix 1). The plasmid was sequenced upon receipt 
to ensure that the right amino acid sequence was coded for. The DNA encoding control 
aptamer was then obtained by site-directed mutagenesis of the 3 critical binding residues 
to alanine. The aptamers constructs were subsequently cloned into pET19b, between 
restriction enzyme sites XhoI and BamHI with an N-terminal His-tag and a C-terminal 
FLAG tag.   





Diagram 16. Construction of Chymotrypsin inhibitor 2 (CI2) aptamers. (I) Insertion of 
eIF4G binding peptide into full length CI2 (FL-CI2-eIF4G). (II) Insertion of negative 
control peptide (3 contact residues mutated to alanines) into full length CI2 (FL-CI2-
eIF4G-ala). The aptamers were cloned into pET19b with N-terminal His-tags and C-
terminal FLAG-tags. 
 
4.2.2. Protein expression of CI2 aptamers 
The plasmids encoding the aptamers were transformed into BL21 (DE3) bacteria for 
induction of protein expression. The transformed BL21 were induced with IPTG at 37 
°C for 1 to 4 hrs and samples of the induced bacteria were analyzed on a gel by 
coomassie staining. The protein expression was found to be optimal at 3 hours of 
induction (Figure 12, lane 4), with no further significant increase in protein expression 
with increase in induction time (lane 5). Figure 13 shows clearly the induction of CI2 
expression (lane 1) as compared to the uninduced BL21 (lane 2). 
The different fractions of the bacteria were analyzed on a gel by coomassie staining and 
western blot to check for the localization of the induced CI2 aptamer. The expressed 
aptamers were found to be present in all 3 fractions of the bacterial lysate. There is also 
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some expression of the aptamer in the uninduced bacteria, implying leakiness in the 
induction system. Aptamer was also detected in the LB media: it may be due to potential 
secretion of the small protein (~14kDa) or simply bacteria lysis.  
 
Figure 12. Coomassie staining of gel showing the trial induction of FL-CI2-eIF4G 
protein expression with 1mM of IPTG over a time course of 4 hours. The expression of 
FL-CI2-eIF4G was found to increase with time and there was no significant increase in 
target protein expression beyond 3 hours. The position of FL-CI2-eIF4G is indicated by 
the arrow as shown.  
Lane:  
1) Uninduced 
2) 1 hr induction 
3) 2 hrs induction 
4) 3 hrs induction 
5) 4 hrs induction 
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Figure 13. Coomassie stained gel of the expression of FL-CI2-eIF4G aptamer after a 3hr 
induction with 1mM IPTG, in comparison to uninduced bacteria. Subsequent induction 
of CI2 aptamer expression was carried out for 3hours, as further induction did not lead 
to any substantial increase in expression as shown in Figure 12. Arrow indicates the 
position of induced CI2.  
Lanes: 
1) IPTG induced BL21 carrying pET19b with FL-CI2-eIF4G 2 insert. 












Figure 14. Analysis of the presence of FL-CI2-eIF4G in different bacterial fractions. (I) 
Coomassie gel comparing the different fractions of the bacterial pellet for bacteria 
induced to express FL-CI2-eIF4G and uninduced bacteria. Benchmark ladder was used. 
(II) Western blot to detect the expression of the FLAG tagged CI2 aptamer in the 
different fractions of bacterial pellet, using anti-M2 FLAG antibody. The western blot 
was not quantitative as different proportions of each fraction were loaded (i.e.: more 
media was loaded compared to the soluble fraction). The position of FL-CI2-eIF4G is 
indicated by the arrow and the band located at approximately 17kDa is due to non-
specific binding as it is detected in the soluble fraction of uninduced bacteria as well.  
Lane:   
1) Insoluble fraction 
2) Soluble fraction 
3) Media 
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4.2.3. Purification of CI2 aptamers 
Even though there was CI2 protein detected in all three fractions of the bacteria lysate, 
we decided to purify the soluble form (which is usually the correctly folded form) 
aptamer only. A trial, small scale purification was conducted to determine the best 
fraction to use for purification. Both the LB media and soluble fraction of the bacteria 
lysate were used as the starting material for protein purification and the His-tagged CI2 
aptamers were purified using Ni-NTA beads. By purifying the soluble form of the 
aptamer, the need for refolding the protein will be circumvented. If the aptamer could be 
purified from the media, it will save even more time as the bacteria pellet will not have 
to be processed.  
Nevertheless, despite the detection of the aptamer in the media by western blot, the 
protein failed to purify from the fraction as shown in Figure 15, lane 2, even though 1 
litre of the media after induction was used (approximately 500, 000 times the amount 
loaded on the gel). It may be because the protein was present in this fraction at a much 
reduced concentration compared to the other fraction. Fortunately, sufficient amounts of 
aptamer protein could be purified from the soluble fraction of the bacteria lysate (lane 1) 
and was adequate for our use.  





Figure 15. Trial purification of FL-CI2-eIF4G aptamer using Ni-NTA beads and batch 
purification method. (I)The elution and flow-through fractions were run on a gel and 
stained with coomassie blue. (II) The identity of the purified protein was confirmed by 
western blot using anti-FLAG antibody to detect for FLAG-tagged CI2 aptamer. 
Precision Plus ladder was used.  
Lane:  
1) CI2 purified from the soluble fraction of bacteria induced to express protein. 
2) CI2 purified from the media of induced bacteria. 
3) Flow-through from soluble fraction after binding with Ni-NTA beads. 
4) Flow-through from media after binding with Ni-NTA beads. 
 
Having identified the fraction to purify CI2 from, larger culture volumes were induced 
for purification of the aptamers. This time however, the beads were eluted in fractions 
after washing. The eluted fractions were run on a gel and stained using coomassie blue 
to assess which fraction contained the protein and at what purity. As evident from Figure 
16, elution buffer with lower concentrations of imidazole removed most of the non-
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specific proteins (lane 2 and 3), leaving behind mainly pure CI2 aptamer which was 
eluted at higher concentrations of imidazole (lane 4, 5 and 6).  
 
Figure 16. Batch purification of His-tagged CI2 aptamer was carried out as described in 
materials and methods. The bound proteins were eluted in 1ml fractions of wash buffer 
(containing 10mM imidazole) with either 100mM or 500mM imidazole. All eluted 
fractions were run on a gel and stained with coomassie blue.   
 











4.3. Validation of the interaction of CI2 aptamers with eIF4E  
4.3.1. Immunoprecipitation studies  
Immunoprecipitation (IP) experiments to validate interation between eIF4E and CI2 
were carried out. Monoclonal anti-FLAG and anti-eIF4E antibodies were used for 
immunoprecipitation of the CI2 aptamer and eIF4E respectively. Denatured CI2 aptamer 
was used as a negative control in this preliminary binding study.  
The anti-FLAG antibody surprisingly failed to bind FLAG-tagged CI2 in the IP as 
evident in Figure 17(I), even though the commercial antibody was selected based on its 
ability to immunoprecipitate FLAG-tagged proteins and detect proteins on western blots. 
Preliminary examinations of the crystal structure of CI2 showed the C terminus of the 
protein to be situated behind its active site loop (Diagram 17). This suggested the 
possibility of the FLAG tag at the C terminus of the aptamer being blocked by the 
peptide presentation loop, making it an inaccessible epitope for antibody binding in an 
IP experiment, while remaining totally recognizable in a western blot where the protein 
is present in a comparatively denatured form.  
The IP with anti-eIF4E antibody bound to its target protein eIF4E as shown in Lane 7 of 
Figure 17 (II). This binding was however abrogated upon addition of the aptamer 
(Figure 17, lane 8). Figure 17 (III) shows the presence of the mouse primary antibodies 
used for IP on the membrane, eliminating the possibility of the lack of eIF4E in lane 8 
being due to an absence of antibody coupling to the protein G beads. An alternative 
explanation for this surprising observation could be that the binding of the aptamer to 




eIF4E may be altering the structure of eIF4E in such a way that the epitope previously 
present for antibody binding is now sequestered or less accessible. 
Similarly, the anti-FLAG primary antibody used for IP was detected on the blot, thus 
confirming the coupling of antibodies to the protein G beads. The possibility that the 
antibody failed to recognize the FLAG epitope was ruled out by successful IP in 
precipitating other FLAG-tagged proteins. A more probable explanation would therefore 
be that the FLAG tag on the aptamer was inaccessible or hidden from the surrounding 
environment. Nevertheless, the failure to immunoprecipitate CI2 could also be due to 
insufficient amount of antibody coupled to the protein G beads. On hindsight, the flow-
through of the IP assay should have been checked for the amount of antibody that did 
not bind to the beads.   





Figure 17. Western blots of immunoprecipitation experiments with protein G sepharose 
beads and monoclonal primary antibodies to check for interaction between CI2 and 
eIF4E. (I) Membrane stained with anti-FLAG HRP conjugated antibody to detect CI2, 
the interacting protein. (II) Membrane stained with anti-eIF4E antibody to detect eIF4E 
(as indicated by arrow). (III) Membrane stained with secondary anti-mouse antibody to 
check for monoclonal antibody bound to beads. The heavy and light chains of the 
antibody are located at approximately 50 kDa and 25kDa respectively.    
Lane:  
1) Anti-FLAG antibody + FL-CI2-eIF4G  
 2) Anti-FLAG antibody + FL-CI2-eIF4G (denatured) 
 3) Anti-FLAG antibody + eIF4E 
 4) Anti-FLAG antibody + FL-CI2-eIF4G + eIF4E 
 5) Anti-eIF4E + FL-CI2-eIF4G 
 6) Anti-eIF4E + FL-CI2-eIF4G (denatured) 
 7) Anti-eIF4E + eIF4E  
 8) Anti-eIF4E + FL-CI2-eIF4G + eIF4E 
 9) Anti-FLAG + --- 
10) --- + FL-CI2-eIF4G 
11) --- + FL-CI2-eIF4G (denatured) 
12) --- + eIF4E  
13) eIF4E (western blot control) 
14) FL-CI2-eIF4G (western blot control) 





















Diagram 17. Crystal structure of Chymotrypsin inhibitor 2. (Picture provided by Dr 
Chandra Verma, BII, A*STAR) 
4.3.2. Additional attempts at evaluating interaction.  
4.3.2.1. Chemical cross-linking  
As many protein interactions are dynamic, it may be difficult to capture the interactions 
using pulldown assays. These transient interactions could be captured or frozen by using 
chemical cross-linking reagents which enable the formation of covalent bonds between 
the activated reactive groups of two interacting molecules. 
As previous attempts at IP were unsuccessful due to the unsuitability of antibodies (both 
anti-eIF4E and anti-FLAG) for precipitating their target proteins, it was decided to try 
cross-linking the proteins themselves with chemical reagents. The cross-linking agents 








thereby overcoming the obstacle of not capturing binding due to hidden epitopes. The 
experiment is based primary on the principles of protein separation on a gel according to 
molecular weight and the covalent binding of cross-linked proteins which allow two 
proteins to migrate as one larger entity. Therefore, if there were interactions between 
eIF4E and CI2, an additional band corresponding to the combined molecular weight of 
the two proteins would be observed. The expected results of the cross-linking 
experiment were illustrated as shown below in Diagram 18. 
 
Diagram 18. Expected results of the cross-linking experiment between CI2 and eIF4E on 
a coomassie stained gel. Bands double the sizes of either eIF4E or CI2 were expected for 
each respective protein as the possibility of the proteins cross-linking with themselves 
exist. The pink band indicates the position of the new expected band if the eIF4E and 
CI2 were cross-linked. The green bands for lane 3 should be considerably reduced in 
intensity if eIF4E and CI2 were interacting as the proteins would be cross-linked and 
would be detected at the size of the pink band.   
Lane:  
1) eIF4E only 
2) FL-CI2-eIF4G only 













The cross linking experiment was performed as described and the cross-linked protein 
samples were run on a gel and stained with coomassie blue. As shown in Figure 18, 
eIF4E alone and CI2 alone appeared at positions on the gel approximately corresponding 
to their molecular weight (25kDa and 14kDa respectively). For the eIF4E and CI2 
protein mixture, there were only bands corresponding to the molecular weights of eIF4E 
and CI2 protein; no additional band was detected at the position of the gel where 
proteins of the combined molecular weight of eIF4E and CI2 (i.e.: cross-linked 
interacting proteins) would be expected (pink band in Diagram 18). No bands were 
observed for cross-linking of the proteins to themselves as well.  
 
Figure 18. Coomassie staining showing the results of the cross-linking experiment 
between CI2 and eIF4E. 10uM of each protein and 4mM of the chemical crosslinkers 
were used for the crosslinking experiment as described in materials and methods. 
Precision plus ladder was used.  
Lane:  
1) eIF4E only 
2) FL-CI2-eIF4G only 










4.3.2.2. Gel filtration assay 
At the same time, gel filtration experiments were conducted to investigate the binding 
between eIF4E and the CI2 aptamer. Protein preps of eIF4E alone, CI2 alone, and eIF4E 
with CI2 mixture were applied to a size exclusion column as described in material and 
methods. Since eIF4E is of a higher molecular weight, it was expected that the elution 
peak for eIF4E should occur before that of CI2. By extrapolation, if there is interaction 
between eIF4E and CI2, the complex should elute before eIF4E alone, due to the 
increase in bulk.  
The size exclusion chromatography for eIF4E protein alone however detected 
aggregation of the purified protein as revealed by the appearance of a sharp spike right at 
the beginning of the run. The spike was also detected for the run of eIF4E and CI2 
mixture (Figure 19, fractions 1 and 2). Two interesting peaks that were not found in both 
eIF4E alone and CI2 alone elution profiles appeared in the elution profile for the mixture 
of both proteins (indicated by the arrows in Figure 19). The fractions of interest to us 
were analyzed by western blot as shown in Figure 20.  
The western blot confirmed the first spike to be eIF4E, which verified that the purified 
eIF4E had aggregated. Lane 3, which came from fraction 5 where the first unique peak 
was observed, was found to contain both eIF4E and CI2. The amount of CI2 detected 
was however very low as indicated by the faint band. There was only CI2 and no eIF4E 
detected in lane 4 which was from the fraction corresponding to the second unique peak. 
Nevertheless, it was noteworthy that the peaks obtained (except for aggregated eIF4E) in 
the elution profiles were quite small compared to the background UV readings. As the 




UV readings could be affected at times by the buffer as well, it was difficult to 
differentiate actual peaks from just background differences. Likewise, peaks due to 
protein interaction could also be masked by fluctuations in the background UV readings. 
Nevertheless, as there were problems purifying large amounts of soluble eIF4E, it was 
not feasible to repeat the experiment with more purified protein.  
The gel filtration experiment did however reveal that the purified eIF4E was aggregating. 
As the protein conformations of the both eIF4E and aptamer are crucial in the 
investigation of a molecular interaction, it is important to ensure that the proteins used 
are correctly folded and functional.  





Figure 19. Gel filtration experiment showing the specific elution of the proteins from the 
size exclusion column detected by changes in UV absorbance at 280nm when a mixture 
of eIF4E and CI2 was applied. The elution profiles of eIF4E and CI2 when applied to 
the column individually are not shown. The arrows indicate absorbance peaks that were 
not observed in the individual elution profiles of eIF4E and CI2 and unique to the 
elution profile of eIF4E and CI2 protein mixture. The fractions circled in green were 
isolated and analyzed by western blot (Figure 20) to determine the proteins that were 
eluted. (The absorbance of eIF4E and CI2 is 2.11 and 0.758 units respectively for 
1mg/ml of protein at 280nM)  
 
Figure 20. Western blot analysis of the fractions from the gel filtration experiment. (I) 
Membrane stained with anti-FLAG to detect CI2. (II) Membrane stained with anti-eIF4E. 
Western blot controls for FL-CI2-eIF4G and eIF4E were loaded in the last 2 lanes 
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4.3.3. m7GTP pulldown assays 
As eIF4E was purified from the insoluble fraction of the bacterial induction pellet and 
refolded after purification, it was possible that the purified eIF4E was incorrectly folded. 
In addition, the purified and dialyzed eIF4E started precipitating out of solution after 
some time. It was highly probable that the purified and refolded eIF4E contained some 
incorrectly folded protein which could have further aggregated and caused the pulldown 
of correctly folded eIF4E. The gel filtration experiment provided additional evidence 
that suggested that the eIF4E purified was aggregating. CI2 on the other hand, was 
purified in its soluble form from the soluble fraction of the bacteria lysate, had lower 
chances of being misfolded. 
In an attempt to confirm and rectify what went wrong with the previous attempts to 
study the interaction between CI2 and eIF4E, the functionality of the eIF4E purified was 
examined. A simple binding assay was performed to compare the ability of the purified 
eIF4E (by batch purification and FPLC) refolded by different methods, and the eIF4E in 
crude bacteria lysate (induced to express eIF4E) to bind the m7GTP beads. The eluted 
proteins were analyzed on a coomassie gel. Western blot analysis was not performed as 
having functional eIF4E detectable only at the level of western blots was insufficient for 
our use.   





Figure 21. Validation of the ability of different eIF4E protein preparations to bind 
m7GTP as a measure of the functionality of the protein. The m7GTP beads were 
incubated with either FPLC purified eIF4E (refolded while bound to column), batch 
purified eIF4E (refolded by dialysis) or bacterial lysate containing eIF4E (soluble 
fraction). The effects of 2 different types of buffer: m7GTP and Hepes buffer, on the 
binding of eIF4E to m7GTP beads were also investigated. The bound proteins were 
eluted with 1mM of m7GTP diluted in the respective buffers and ran on a gel for 
analysis by western blot.  
Lane:  
1) Input 
2) Elutant (binding in m7GTP buffer) 
3) FT ((binding in m7GTP buffer) 
4) Elutant (binding in Hepes buffer) 
5) FT ((binding in Hepes buffer) 
 
As evident from Figure 21, the binding of batch purified eIF4E to m7GTP beads (if any) 
was undetectable on a coomassie-stained gel (lane 2 and 4). In comparison, the FPLC 
purified eIF4E was able to bind to the beads (faint negative staining band in lane 2 and 5 
as indicated by arrow). Nevertheless, eIF4E from crude bacterial lysate exhibited the 
greatest binding ability to the m7GTP beads. The proteins eluted from m7GTP beads 














incubated with bacterial lysate were surprisingly clean and free of other non-specific 
proteins. Therefore, until the yield of functional eIF4E purified could be improved,  
m7GTP beads and eIF4E from crude bacterial lysate (induced to express eIF4E) were 
used for the subsequent pulldown experiments. As the m7GTP beads were used to pull 
out functional eIF4E directly from crude bacterial lysate, the possibility of not detecting 
any interaction due to misfolded eIF4E was finally ruled out. For subsequent assays that 
absolutely required purified eIF4E, FPLC purification was used to isolate the protein.   
The binding assay between eIF4E and CI2 aptamer was repeated with m7GTP beads. 
The m7GTP beads were incubated with either purified eIF4E or bacterial cell lysate to 
bind functional eIF4E. The beads were then incubated with FL-CI2-eIF4G aptamer and 
the bound proteins were analyzed by western blot.  





Figure 22. Western blots of m7GTP beads pulldown to check for interaction of eIF4E 
(1uM) with CI2 aptamer.  
Lane:  
1) m7GTP beads + eIF4E 
2) m7GTP beads + FL-CI2-eIF4G 
3) m7GTP beads + bacterial lysate 
4) m7GTP beads only 
5) m7GTP beads + eIF4E + FL-CI2-eIF4G 
6) m7GTP beads + bacterial lysate + FL-CI2-eIF4G 
7) eIF4E (western blot control) 
8) FL-CI2-eIF4G (western blot control) 
 
In contrast to previous IP experiments, the amount of eIF4E pulled down with m7GTP 
beads was noticeably greater compared to that pulled down by anti-eIF4E antibody and 
protein G beads. Also, the amount of eIF4E pulled down from purified eIF4E is similar 
to that from bacterial lysate. This result appeared to contradict that of Figure 21, but it 
should be noted that different batches of purified eIF4E were used for the experiments. 
This observation further strengthens our theory that a small amount of misfolded eIF4E 
could cause further aggregation and precipitation of the protein. The amount of 
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functional eIF4E in the purified protein preparation was shown to decrease with time 
(results not shown).       
Some binding of FL-CI2-eIF4G to eIF4E was detected as shown in Lane 5 of Figure 2D, 
and the binding was specific as no CI2 was pulled down without addition of eIF4E 
(Lane 2). An interesting observation was made that when the aptamer was incubated 
with eIF4E pulled out from bacterial lysate by m7GTP beads, the binding of eIF4E to 
the m7GTP cap was greatly reduced (Lane 6). The same did not happen for eIF4E pulled 
out from purified eIF4E with m7GTP beads. The different effect of the aptamer on the 
cap-binding affinity of eIF4E from different sources could be due to the presence of 
cofactors or other binding partners that would be present in the bacterial lysate but not 
the purified protein. This is however pure postulation, more extensive studies would 
have to be performed to verify the hypothesis if one is interested to persue the 
differences in cap-binding affinity. There has been reports of the cap binding affinity of 
eIF4E being affected by eIF4G binding 195,196.   
This m7GTP pulldown experiment demonstrated successfully specific binding of the 
aptamer to eIF4E. Nevertheless, the weak binding of the aptamer makes it unsuitable for 
further experiments to study the effect of inhibition of eIF4E activity. To resolve this 
inadequacy, rational redesign of the aptamer was carried out based on the structural 
requirements of the peptide conformation for binding to eIF4E and the inherent 
structural characteristics of CI2 itself.  




4.4. Rational design to improve binding  
4.4.1. Removal of extra residues and re-positioning of tag 
 
Diagram 19. The crystal structure of eIF4E bound to m7GTP cap, demonstrating the 
binding site for eIF4G and 4E-BP1. The eIF4E-binding peptides exhibit the ability to 
form helices.   
As pointed out previously, the C-terminal FLAG tag of the aptamer is located between 
the body of the scaffold protein and its peptide presentation loop thus possibly obscuring 
the epitope for IP. In addition, the amino acids making up the FLAG tag (DYKDDDDK) 
are mainly negatively charged (D: aspartic acid), and may therefore interact with the 
positively charged residues of the binding peptide. As such, there was a probability that 









required for binding to eIF4E as shown in Diagram 19. Therefore, the FLAG tag was 
shifted from the C terminus of FL-CI2-eIF4G to the N terminus using PCR. Furthermore, 
19 amino acids which were found to be unstructured and have no effects on stability 197 
were removed from the N terminus of the scaffold protein.  A new shorter aptamer (CI2-
eIF4G) as illustrated in Diagram 20 with N terminal FLAG tag and His tag was cloned. 
The successful removal of the 19 amino acid extra residues from FL-CI2-eIF4G is 
shown in Figure 23.   
 
Diagram 20. Removal of the extra N-terminal amino acids and shifting of the FLAG tag 
from C-terminal to N-terminal from FL-CI2-eIF4G (I). A shorter version of CI2: CI2-
eIF4G resulted (II).  
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Figure 23. PCR screening with CI2 specific primers for successful removal of the extra 
19 amino acid residues from full length CI2.  
Lane:  
1) FL-CI2-eIF4G (300 bp) 
2) CI2-eIF4G (243 bp) clone 1 
3) CI2-eIF4G clone 2 
4) CI2-eIF4G clone 3 
 
4.4.2. Site-directed mutagenesis in scaffold and peptide 
The binding of eIF4G or 4E-BP1 to eIF4E requires the folding of the binding amino 
acids into a helix before they can fit into the binding cleft 198. Therefore, in an attempt to 
improve binding, the second lysine residue of the binding peptide was mutated to 
alanine to increase the helicity of the stretch of amino acids. This new aptamer (CI2-
eIF4G-K2A), shown in Diagram 21, was constructed by site directed mutagenesis as 
described in material and methods. CI2-eIF4G-K2A would be referred to as the lysine 
mutant subsequently for simplicity. 
Lastly, a third aptamer was constructed based on rational design to reduce the interaction 
of the main body of the protein with the peptide presentation loop. The published 
structure of CI2 identified several residues critical for binding of CI2 to its target protein 
1        2        3         4 
300 bp 




and its resistance to hydrolysis 199. There were 2 arginine residues that were found to be 
close to the peptide presentation loop. As evident in Diagram 22, the 65th and 67th 
arginine residues (positively charged, blue) of the CI2 scaffold protrudes into the space 
between the loop and the body of the protein and interacts with the negatively charged 
(red) loop. This interaction stabilizes but also restricts the flexibility of the loop. 
Therefore it was hypothesized that mutation of the charged arginines to uncharged 
alanines would introduce flexibility into the peptide loop, facilitating the helical 
conformation that is required for the aptamer to bind to eIF4E. This new aptamer was 
named CI2-R(65,67)A-eIF4G, but would be referred to as the arginine mutant or Arg+ve 
in subsequent discussions.  





Diagram 21. Rational redesign of Chymotrypsin inhibitor 2 (CI2) aptamers. (I) Removal 
of unstructured amino acids from N terminus and shifting of C terminal FLAG tag to the 
N terminus: CI2-eIF4G. (II) Mutation of lysine in binding peptide sequence to alanine: 
CI2-eIF4G-K2A (the lysine mutant). (III) Mutation of arginines 65 and 67 to alanines: 
CI2-R(65,67)A-eIF4G (the arginine mutant). 
 
 
Legend:  : His tag 
 
: FLAG tag 
 
  : Chymotrypsin inhibitor 2 
 
   : Inhibitor/ eIF4E binding peptide 
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Diagram 22. (I) Diagram of the modeled structure of Chymotrypsin inhibitor aptamer 
with the two arginine residues protruding and interacting with the peptide inserted into 
the presentation loop. (II) Diagram of the electrostatic interactions between the arginie 
residues and the peptide presentation loop of CI2 (Blue colour indicates positive charges; 
red colour indicates negative charges; picture provided by Chris Brown, IMCB) (III) 
Diagram of the modeled structure of modified CI2 aptamer (CI2-R(65,67)A-eIF4G) 
after site directed mutagenesis to remove the arginines interfering with peptide 
presentation. (Diagrams provided by Chandra Verma, BII)  
Control aptamers for the respective new CI2 constructs were obtained by site directed 
mutagenesis of the critical binding residues (as described in Diagram 16) to alanines. 
The new aptamers and their respective controls were cloned into pET19b vector, 
expressed and purified in the same manner as previously practiced for the full length CI2 















Figure 24. Batch purification of modified His-tagged CI2 aptamers (I) CI2-eIF4G (II) 
CI2-eIF4G-K2A /lysine mutant (III) CI2-R(65,67)A-eIF4G /arginine mutant. The bound 
proteins were eluted in 1ml fractions of wash buffer with either 100mM or 500mM 
imidazole.  
Lane: 
1) 100mM imidazole – fraction 1 
2) 100mM imidazole – fraction 2 
3) 100mM imidazole – fraction 3 
4) 500mM imidazole – fraction 1 
5) 500mM imidazole – fraction 2 
6) 500mM imidazole – fraction 3 
7) 500mM imidazole – fraction 4 
8) 500mM imidazole – fraction 5 
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4.5. In vitro binding assays: m7GTP and Ni-NTA beads pulldown 
The new CI2 constructs were assessed for their ability to bind to eIF4E using the 
m7GTP beads pulldown assays. The proteins pulled down by the eIF4E bound m7GTP 
beads were analyzed by coomassie staining and western. Binding of aptamer was 
detected by both coomassie staining and western blot as shown in Figure 25, lane 4.  
There was apecific binding of both CI2-eIF4G and arginine mutant to eIF4E as detected 
by western blot. The amount of CI2-eIF4G bound was however too little to be visible on 
a coomassie stained gel. This indicates that the removal of the arginine residues from 
CI2-eIF4G has successfully enhanced the binding affinity of the aptamer. The lysine 
mutant on the otherhand failed to bind, indicating a possible role for the amino acid role 
in binding to eIF4E.    
 
 




             
  
 
             
 
 
             
 
Figure 25. m7GTP pulldown of the improved CI2 aptamers (with FLAG tag) via 
interaction with eIF4E. Results were analyzed by (I) coomassie staining and western blot 
with (II) monoclonal anti-FLAG antibody and (III) monoclonal anti-eIF4E.  
Lane:  
1) m7GTP beads + lysate + CI2-eIF4G 
2) m7GTP beads + lysate + CI2-eIF4G-ala 
3) m7GTP beads + lysate + WT CI2 
4) m7GTP beads + lysate + CI2-R(65,67)A-eIF4G (arginine mutant /Arg+ve)  
5) m7GTP beads + lysate + CI2-R(65,67)A-eIF4G-ala (arginine mutant control /Arg-ve)                           
6) m7GTP beads + lysate + CI2-eIF4G-K2A (lysine mutant /Lys+ve) 
7) m7GTP beads + lysate + --- 
8) m7GTP beads + --- + CI2-eIF4G 
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Subsequent repeats of the experiment resulted in similar outcomes where strong binding 
was always observed for the Arg+ve aptamer and weaker or no binding was detected for 
CI2-eIF4G. This simple pulldown assay demonstrates the success of our rational design 
attempts to derive a better binding aptamer based on knowledge of known binding 
sequences, protein structures and protein binding conformations. 
In the m7GTP pulldowns using eIF4E from crude bacteria lysate, the exact amount of 
eIF4E that bound was hard to estimate due to leaching of the m7GTP analog from the 
beads over time. As a result, the molar ratio of the aptamer added to the amount of 
eIF4E bound could not be determined. As such, calculation of the aptamers affinity to 
eIF4E proved difficult. Only the affinity of one aptamer relative to another can be 
determined.  
In an attempt to better characterize the binding affinity of the Arg+ve mutant, the 
m7GTP pulldown assay was conducted with purified eIF4E instead of the bacteria lysate. 
The amount of eIF4E added was measured and varying molar ratios (0.5X to 2X) of 
interacting aptamer was used. Only the maximum amount was used for the control 
aptamers to minimize the amount of samples to handle. The results of the pulldown were 
analyzed directly by western blot.  
The amount of arginine mutant pulled down by eIF4E coupled to m7GTP beads 
increases as the amount of aptamer added increased from 1X to 2X; no binding was 
detected for CI2-eIF4G at all. Once again, the results demonstrated the differences in 
using purified eIF4E and unpurified eIF4E for pulldown assays. Nevertheless, the 




evidence supporting the improvement in binding affinity of the arginine mutant by 
rational design was confirmed.   





Figure 26. Titration of m7GTP pulldown of CI2, in increasing amounts, with eIF4E. 
Results were analyzed by western blot and detected by (I) monoclonal anti-FLAG 
antibody and (II) monoclonal anti-eIF4E. 
Lane:  
1) 0.5X of Arg+ve CI2 + 1X of eIF4E. 
2) 1X of Arg+ve CI2 + 1X of eIF4E. 
3) 2X of Arg+ve CI2 + 1X of eIF4E. 
4) 2X of Arg-ve CI2 + 1X of eIF4E. 
5) 2X of WT CI2 + 1X of eIF4E. 
6) 0.5X of CI2-eIF4G + 1X of eIF4E. 
7) 1X of CI2-eIF4G + 1X of eIF4E. 
8) 2X of CI2-eIF4G + 1X of eIF4E. 
9) 2X of CI2-eIF4G + 1X of eIF4E. 
 
An attempt to repeat the pulldown in the reverse order of binding the CI2 aptamer first 
was carried out by using Ni-NTA beads. eIF4E containing bacterial lysate was then 
added. The proteins pulled down were analyzed by western blot. The Ni-NTA beads 
bound the aptamers successfully as shown in Figure 27(I).  The bound aptamers 
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of the weak binding affinity of the aptamer as it failed to bind eIF4E in the presence of 
other non-specific cellular proteins, unlike in the m7GTP pulldowns which involved 
only eIF4E and aptamers. 
 
Figure 27.  Ni-NTA beads pulldown of His-tagged CI2 and interacting eIF4E from 
bacterial lysate. Results were analysed by western blot and detected with (I) anti-FLAG 
for CI2 and (II) anti-eIF4E antibodies. 
Lane:  
1) beads + CI2-eIF4G + bacterial lysate 
2) beads + CI2-eIF4G-ala + bacterial lysate 
3) beads + Arg+ve CI2 + bacterial lysate 
4) beads + Arg-ve CI2 + bacterial lysate 
5) FT after Arg+ve CI2 binding  
6) FT after Arg-ve CI2 binding 
7) FT after eIF4E binding 
8) bacterial lysate 
 
The weak eIF4E binding affinity of the CI2 aptamers however may not necessarily be a 
disadvantage. As eIF4E is essential for cap dependent translation, it would be unwise to 
block and inhibit the protein completely. A strong binding synthetic aptamer that is not 
subjected to regulation in vivo may just do that. As the long term effects of completely 
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blocking eIF4E are unknown and may be detrimental, the potential of the weak binding 
CI2 as an inhibiting aptamer in vivo seemed worth exploring. The aptamers were 
subsequently transfected into mammalian cells for an assessment of their effects in vivo, 
before a decision on whether more efforts should be further invested on characterizing 
the aptamers was made.   
4.6.  In vivo assay: mammalian cell transfection 
The aptamers, with their C-terminal FLAG tag but without their His-tag, were cloned 
into a mammalian expression vector pcDNA3 under the control of a CMV promoter. 
MCF7 cells were chosen primarily as the cell line to use for testing as it has been shown 
to be sensitive to rapamycin inhibition 200 and has reasonably high levels of eIF4E as 
previously shown in Figure 2. In addition, high transfection efficiencies using 
electroporation (Amaxa) could be obtained, which was an advantage. 
The construction of CI2 without an inhibitor peptide and wild type CI2 was carried out 
as shown in Diagram 23. The availability of these 2 constructs would enable us to 
determine if the insertion of eIF4G peptide into the loop of CI2 had affected protein 
stability or the ability of CI2 to fold correctly in mammalian cells. The eIF4G peptide 
sequence was removed by site directed mutagenesis to obtain CI2 (without insert) and 
the original CI2 peptide sequence removed by the insertion of eIF4G peptide sequence 
was re-inserted into its original position by site-directed mutagenesis to obtain wild type 
CI2 (WT CI2). These constructs were cloned into pcDNA3 as well.  





Diagram 23. Re-construction of Chymotrypsin inhibitor 2 by site-directed mutagenesis. 
(I) Removal of eIF4G peptide sequence: CI2 (without insert). (II) Insertion of original 
CI2 sequence that was replaced by eIF4G peptide sequence: wild type CI2 (WT CI2) 
 
4.6.1.  Low expression levels 
Transfections of MCF7 cells were carried out with the stronger binding aptamer 
(Arg+ve) and the relevant controls. The cells were harvested 24 hours after transfection 
to check for aptamer expression by western blot analysis (Figure 28). There was no CI2 
expression detected. The lack of protein expression was not a problem specific to the 
MCF7 cell line as H1299 cells failed to express CI2 as well. There was however a faint 
spot for H1299 cells transfected with Arg-ve after prolonged exposure of the film 
(Figure 28 (I), lane 2). Both H1299 and MCF7 cells transfected with 4E-BP1, which was 
also in pcDNA3, expressed the protein as shown in Figure 28 (II), lanes 4 and 9. The 
membranes were also probed for GFP to check for transfection efficiency. The amount 
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of GFP detected by western blot was approximately similar, indicating that 
approximately equal amounts of transfected cell lysates were loaded. In addition, the 
amount of transfected cells were estimated by GFP fluorescence under UV and found to 
be roughly equal. Therefore, the discrepancy in the expression levels of CI2 aptamer 
compared to 4EBP1 was most probably not due to differences in transfection 
efficiencies.      
The transfections were repeated and the cells were allowed to grow for an additional 24 
hours before harvesting. A proteosome inhibitor (MG132) was added to the cells for 4 
hours prior to harvesting. Nevertheless, prolonging the duration of transfection (Figure 
29) and adding MG132 did not result in the detection of aptamer expression. This 
suggests that the failure to detect the aptamer protein was not due to insufficient time 
allowed for protein synthesis, or protein degradation.  
The kozak sequences of the constructs were optimized and the expression of CI2 
aptamers was improved as shown in Figure 30 (I) lanes 2 to 5. However, the expression 
of the CI2 aptamers went down after 48 hours of transfection.  
The expression level of the aptamers that bind eIF4E (CI2-eIF4G and Arg+ve) were 
observed to be lower (lanes 2 and 4) compared to their respective controls (lanes 3 and 5 
respectively) as shown in Figure 30 (I). This observation was promising as it may be an 
indication of an inhibitory effect of the binding aptamers in vivo on protein translation. 
Alternatively, it could also mean that the binding CI2 aptamers were more prone to 
degradation.   




Since the expression of CI2 aptamers was not sustainable, it was evident that using 
Chymotrypsin inhibitor 2 as the scaffold for construction of an eIF4E binding aptamer 
was not favourable.  There might be some stability issues with expression of the plant 
protein in mammalian cells or the rational designs that were made had an adverse effect 
on the protein folding. Nevertheless, at this point a decision was made not to continue 
the process of optimizing the CI2 aptamers as CI2 was after all a less commonly used 
and studied scaffold.  
We were however still optimistic about using the aptamer approach to study the in vivo 
effects of inhibiting eIF4E. It was a matter of finding an appropriate aptamer. To this 
end, other aptamers have been explored and will be addressed in the upcoming chapters.   
 





Figure 28. Analysis of aptamer expression in H1299 and MCF7 cells transfected by 
electroporation with aptamer encoding plasmid DNA. Transfected cells were grown for 
24 hours and harvested for western blot analysis of recombinant protein expression. 
Membranes were individually probed with I) Anti-FLAG against CI2 aptamer II) anti-
4E-BP1 and III) Anti-GFP to check for the efficiency of transfection.  
Lanes:  
1) H1299 + Arg+ve   
2) H1299 + Arg-ve 
3) H1299 + WT CI2 
4) H1299 + 4E-BP1 
5) Untransfected MCF7 
6) MCF7 + Arg+ve 
7) MCF7 + Arg-ve 
8) MCF7 + WT CI2  
9) MCF7 + 4E-BP1 
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Figure 29. Analysis of protein expression in MCF7 cells transfected by electroporation. 
Transfected cells were grown for 48 hours, treated with MG132 for 4 hours and 
harvested. Cell lysates were analysed by western blot for protein expression using (A) 
anti-FLAG antibody against CI2 (B) anti-4E-BP1 and (C) anti-GFP to check for 
transfection efficiency.  
Lanes:  
1) Untransfected MCF7 
2) MCF7 + Arg+ve 
3) MCF7 + Arg-ve 
4) MCF7 + WT CI2  
5) MCF7 + 4E-BP1 
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Figure 30. Transfection of MCF7 cells with kozak optimized CI2 aptamers for 24hrs and 
48hrs respectively. Membranes are probed with I) Anti-FLAG against CI2 II) Anti-actin 
to check for equal loading and III) Anti-GFP to check for transfection efficiency.  
Lane:  
1) Untransfected 




6) CI2 (without insert) 
7) WT CI2 
48 hrs transfection 


















5. Reconstruction of protein aptamers using Thioredoxin A as an alternative 
scaffold 
5.1.  Introduction and aims 
The alternative scaffold that was selected is thioredoxin A (trxA) from Escherichia coli. 
TrxA is a small ubiquitous cytosolic protein that plays an important role in maintaining 
the intracellular environment in a reducing state for the proper functioning of enzymes in 
E.coli. 
TrxA is a well characterized, highly soluble and structurally rigid protein which makes it 
a good candidate for a scaffold protein. In addition it has an active site sequence (-C-G-
P-C-) which forms “a tight disulphide constrained and solvent accessible loop” 27. This 
makes TrxA an even better scaffold as peptides that are inserted into the active site 
would be accessible instead of being buried within the protein. The active site loop is 
able to tolerate insertions of diverse peptide sequences 42. The peptides upon insertion, 
inactivates the enzymatic activity of TrxA, thus eliminating the possibility of its 
biological function interfering with experimental observations. Lastly, trxA is easily 
expressed in both prokaryotes and eukaryotes, which should facilitate both in vitro and 
in vivo experiments. 
Much prior work has been done on trxA as an aptamer. Peptides libraries of 20 amino 
acids in length have been inserted in the active site loop and screened successfully for 
binders to Cdk2 26 and E2F 56. The insertion of an Mdm2 binding peptide, isolated from 
phage display, into the active site loop of trxA has shown the aptamer to be able to bind 
to Mdm2 and inhibit the degradation of p53 59. TrxA has also been used as a scaffold in 




a screen for BCL-6 binding aptamers 201. More recently, a study using randomized 
peptide libraries inserted into TrxA, isolated aptamers that bound mutant p53 and were 
able to induce apoptosis in cells expressing mutant p53 60. Given the existence of a 
larger body of work done using trxA as a scaffold, trxA would be a good choice as a 
scaffold for the presentation of the eIF4E-binding peptide. 
5.2.  Construction of aptamer protein for interaction studies 
5.2.1. Cloning of Trx aptamers  
Thioredoxin A gene (pET32a, Novagen) was cleaved with RsrII at its active site loop 
and was inserted with 4 different peptides as shown in Diagram 25. The first two 
peptides were the original eIF4G peptides used both in the peptide pulldown assay and 
in the construction of the CI2 aptamers: eIF4G, eIF4G-ala.  
To pre-empt some possible structural problems that could occur by insertion of eIF4G 
peptide into thioredoxin, the structure of the peptide in the binding groove of eIF4E was 
studied. As illustrated in Diagram 24, the binding of eIF4G to eIF4E groove requires an 
extended strand in addition to the α-helix conformation. The presence of the extended 
wave-like structure was hypothesized to be essential as one of the most critical binding 
residues (tyrosine) was located on it. As constraining the eIF4G peptide onto a scaffold 
limits its flexibility and possibly the formation of the wave-like extended strand 189, it 
was hypothesized that by adding two additional residues in front of the peptide, there 
will be extra room for the peptide to form the right conformation for binding. Glycine 
and serine were selected for insertion as they are small amino acids without bulky side 




chains and are commonly used as linker residues. Therefore, the third peptide was 
modified to have an extra serine and glycine residue in front of the eIF4G peptide 
sequence: SG-eIF4G. The fourth peptide was obtained by mutating the critical binding 
residues in the third aptamer to act as a non-binding control: SG-eIF4G-ala.  
 
 
Diagram 24. Co-crystal structure of eIF4GI peptide in the binding grove of eIF4E (PDB 
code: 1EJH). The peptide forms an extended wave-like strand followed by α-helix for 
binding to eIF4E. The 3 conserved critical binding residues: tyrosine, and the 2 leucines 
are located on the extended strand (Y624) and α-helix (L629 and L630) respectively. 











Diagram 25. Peptide sequences inserted into the active site loop of thioredoxin A (TrxA) 
as indicated by arrow. Four aptamers (two binding and two controls) were constructed.  
The aptamers were cloned in pET32a with a C-terminal His-tag to simplify purification. 
The aptamers were also cloned into pcDNA3 for expression within mammalian cells for 
conducting cellular based experiments further on into the study.  
5.2.2.  Expression of Trx aptamers 
A protein expression trial was conducted and the bacteria lysates were run on a gel to 
check for the expression of Trx. The expression of the trxA aptamer at 37 °C increased 
steadily after induction with IPTG (Figure 31). The optimal duration for expression at 37 
°C was found to be 3 hours as a further increase in incubation time did not result in any 
significant increase protein yield. The protein expressed just as well after 5 hours at 
room temperature (lane 8). The uninduced bacteria kept at 37 °C however, showed some 
leaky expression of the protein (lane 1) as compared to the uninduced bacteria at room 
temperature (lane 7). In addition, despite similar conditions, the yields of the binding 
aptamers (Trx-eIF4G and Trx-SG-eIF4G) were observed to be significantly lower when 
compared to that of the non-binding aptamers (Trx-eIF4G-ala and Trx-SG-eIF4G-ala) 
(data not shown). 
Aptamers :  
 
 WT TrxA     --- WAEWCGPCKMIAP 
 
 Trx-eIF4G     --- WAEWCGPP KKRYDREFLLGFQFEN GPCKMIAP   
 Trx-eIF4E-ala --- WAEWCGPP KKRADREFAAGFQFEN GPCKMIAP   
 
 Trx-SG-eIF4G     --- WAEWCGPP SG KKRYDREFLLGFQFEN GPCKMIAP   
 Trx-SG-eIF4E-ala --- WAEWCGPP SG KKRADREFAAGFQFEN GPCKMIAP 





Figure 31. Protein expression trial of thioredoxin aptamers at 37 °C and room 
temperature for 1 to 5 hours. Samples of the bacterial lysate were run on a 12% gel and 
stained with coomassie blue to visualize the expressed proteins. 
Lane: 
1) Uninduced BL21 (after 5 hours at 37 °C)  
2) 1 hour induction with 1mM IPTG 
3) 2 hours induction with 1mM IPTG 
4) 3 hours induction with 1mM IPTG 
5) 4 hours induction with 1mM IPTG 
6) 5 hours induction with 1mM IPTG 
7) Uninduced BL21 (after 5 hours at room temperature) 
8) 5 hours induction with 1mM IPTG 
  
5.2.3. Purification of Trx aptamers 
The aptamers were batch purified in a similar manner as previously described for CI2.  
Ni-NTA sepharose beads and protein columns were used. The bound aptamers were 
eluted in fractions with imidazole and dialyzed into PBS. The elution fractions were run 
on a gel to check which fraction the aptamers eluted in and purity of the aptamers 
37 °C  
Room 
temperature  
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obtained. The thioredoxin aptamers eluted at 100nm of imidazole, which was much 
lower than that of CI2. Also, there were more non-specific proteins that co-eluted with 
the Trx aptamer, presumably due to the lower concentration of imidazole required to 
dissociate Trx from the Ni-NTA beads. Nevertheless, the amount of protein obtained 
was sufficient for subsequent experiments. The fractions containing the Trx aptamers 
were pooled and dialyzed into PBS to remove the imidazole. As a note, there was 
variation in the amount of aptamer protein purified.  The binding aptamers were less 
well expressed than the non-binding control aptamers. The difference was less 
significant for the modified Trx-SG-eIF4G aptamer and its control. This confirmed the 
previous observation during the induction trial that there was more protein expressed for 
the non-binding aptamer as compared to the binding aptamer.     





Figure 32. Analysis of thioredoxin aptamer purification. The elution fractions (with 
100mM and 500mM imidazole) obtained from batch purification of the thioredoxin 
aptamers were run on a 4-12% gel and stained with coomassie blue. A representative 
picture for one aptamer is shown here. (For details of purification procedure, please refer 
to materials and methods) 
 
The dialyzed proteins were concentrated and checked on a gel by coomassie staining 
(Figure 33 (I)). There was no degradation of the aptamers detected. The identity of the 
purified protein aptamers were confirmed by western blotting with an antibody against 
thioredoxin (Figure 33 (II)).  
 









Figure 33. Verification of purified thioredoxin aptamers. (I) The dialyzed fractions of 
the purified Trx aptamers were run on a gel and checked for protein integrity by 
coomassie staining. (II) The identity of the aptamer was further verified by western blot, 
using an antibody against thioredoxin.  
Lane: 
1) Trx-eIF4G (eluted with 100nm imidazole) 
2) Trx-eIF4G (eluted with 500nm imidazole) 
3) Trx-eIF4G-ala (eluted with 100nm imidazole) 
4) Trx-eIF4G-ala (eluted with 500nm imidazole) 
5) Trx-SG-eIF4G (eluted with 100nm imidazole) 
6) Trx-SG-eIF4G (eluted with 500nm imidazole) 
7) Trx-SG-eIF4G-ala (eluted with 100nm imidazole) 
8) Trx-SG-eIF4G-ala (eluted with 500nm imidazole) 
 









5.3. In vitro assays for validation of the interaction between Trx aptamers and 
eIF4E and the stability of the aptamers 
5.3.1.  Pulldown assays using m7GTP beads and Ni-NTA beads 
Having obtained purified aptamers, in vitro pulldown assays were conducted to assess 
aptamer binding. Pull downs using m7GTP beads were first conducted, as described 
previously: FPLC purified eIF4E was first bound to the m7GTP beads before the 
aptamers were added.  
eIF4E bound to m7GTP beads, pulled down Trx-eIF4G and Trx-SG-eIF4G (Figure 
34(II), lane 1 and 3) but not their respective alanine controls (lane 2 and 4). Incubation 
of m7GTP beads with the trx aptamers alone without eIF4E did not bind any aptamers, 
demonstrating the specificity of the pull down. The aptamer modified with the addition 
of two extra residues: serine and glycine (Trx-SG-eIF4G), bound eIF4E with a higher 
affinity compared to Trx-eIF4G as shown in Figure 34 (II) lane 1 and 3. The difference 
in binding would be more pronounced if the loading of eIF4E was normalized as it is 
evident that more elutant was loaded in lane 1 and 2 as compared to lane 3 and 4. The 
additional residues did seem to improve aptamer binding to eIF4E.  





Figure 34. m7GTP pulldown demonstrating the binding of eIF4E and thioredoxin 
aptamers.  Bound protein was analyzed by western blot and detected with (I) anti-eIF4E 
for eIF4E and (II) anti-trx for thioredoxin aptamers.  
Lane:  
1) m7GTP beads + eIF4E + Trx-eIF4G 
2) m7GTP beads + eIF4E + Trx-eIF4G-ala 
3) m7GTP beads + eIF4E + Trx-SG-eIF4G 
4) m7GTP beads + eIF4E + Trx-SG-eIF4G-ala 
5) m7GTP beads + - + Trx-eIF4G 
6) m7GTP beads + - + Trx-eIF4G-ala 
7) m7GTP beads + - + Trx-SG-eIF4G 
8) m7GTP beads + - + Trx-SG-eIF4G-ala 
 
To confirm the m7GTP pulldown results, the pulldown was repeated in the reverse order. 
His-tagged trx aptamers were first bound to Ni-NTA sepharose beads, washed and then 
incubated with eIF4E containing bacteria lysate. The reverse pull down also serves to 
check if the aptamers were able to bind eIF4E in the presence of numerous other non-
specific cellular proteins. This will help to verify the binding affinity of the aptamer: to 
examine whether the aptamer is able to isolate and precipitate eIF4E from a sea of non-
specific proteins. This reverse pull down was also performed for the CI2 aptamers and 












demonstrated that the CI2 aptamers were unable to precipitate eIF4E when there are 
non-specific proteins around, i.e.: the CI2 aptamers had low binding affinity for eIF4E.  
The pulldown results were ran on a gel and analyzed by western blot as shown in Figure 
35. Ni-NTA beads bound Trx-eIF4G and Trx-SG-eIF4G aptamers pulled down eIF4E 
from the sea of proteins (lane 1 and 3) while their respective controls did not bind any 
eIF4E. The binding is definitely specific as without the aptamer, eIF4E does not get 
pulled down (lane 5). The pulldown of eIF4E is dependent on the presence of an 
aptamer with the binding eIF4E sequence. The relative binding affinity of Trx-eIF4G 
and Trx-SG-eIF4G is apparent in Figure 35 (II) as the amount of trx aptamer loaded is 
relatively constant among the samples, while a lot more eIF4E was detected for lane 3 
(Trx-SG-eIF4G) compared to lane 1 (Trx-eIF4G). Trx-SG-eIF4G has stronger binding 
affinity for eIF4E as compared to Trx-eIF4G.  





Figure 35. Ni-NTA beads pulldown of His-tagged thioredoxin aptamers and eIF4E from 
bacterial cell lysates. Bound protein was analyzed by western blot and probed with (I) 
anti-trx and (II) anti-eIF4E.  
Lane:  
1) Ni beads + Trx-eIF4G + eIF4E   
2) Ni beads + Trx-eIF4G-ala + eIF4E 
3) Ni beads + Trx-SG-eIF4G + eIF4E 
4) Ni beads + Trx-SG-eIF4G-ala + eIF4E 
5) Ni beads + - + eIF4E 
6) Ni beads + Trx-eIF4G + --- 
 
5.3.2. Fluorescence polarization assay 
Fluorescence polarization is the phenomenon that fluorescent molecules when excited 
will emit fluorescence in a fixed plane (polarized fluorescence) if the molecules were 
fixed and not moving. Molecules in solution are however not fixed; they tumble around 
and rotate in all different directions. The speed at which this random rotation occurs is 
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In this assay to validate the specificity of aptamer binding using fluorescence 
polarization measurements, fluorescein conjugated eIF4E binding peptides were 
synthesized. The unbound fluorescent peptides emit scattered fluorescence that cannot 
be measured on a fixed plane. However, upon binding to eIF4E, the rotation of the 
peptide slows down due to an increase in bulk. This allows the fluorescence emitted by 
the peptide to be captured along a fixed plane. As the amount of binding increases, the 
amount of polarized fluorescence measured increases. Fluorescence polarization and 
anisotropy values are comparable quantities that differ in their normalizations. 
Anisotropy readings were used for all plotting of graphs and mathematical calculations.    
5.3.2.1. Validation of the fluorescein-conjugated peptide 
Previous attempts to synthesized a fluorescein amidite (FAM) labeled eIF4G peptide 
were unsuccessful as the labeled peptide was either insoluble or did not show activity. A 
study by Moerke N et al, 2007 161, was subsequently published. In the study, they 
successfully optimized a sequence, which contained the conserved eIF4E binding 
sequence: YXXXXL∅ (where ∅ is a hydrophobic residue), for the ability to bind eIF4E 
and remain soluble after conjugation to fluorescein isothiocyanate (FITC). Therefore, we 
decided to adopt their approach. The C-terminal FITC-labeled peptide was synthesized 
according to the sequence published: KYTYDELFQLK.  
As the sequence that was published differs from that of eIF4G and 4EBP1, it was 
necessary to verify that the labeled peptide binds to eIF4E specifically. Therefore, a 
titration of eIF4E against a fixed concentration of labeled peptide was performed and the 
changes in anisotropy was measured. If there was binding of the labeled peptide to 




eIF4E, the amount of anisotropy measured should increase with increasing amounts of 
eIF4E as there are more peptide-eIF4E complexes formed. Figure 36 demonstrated 
exactly what was previously described: the amount of anisotropy measured increased 
with increased concentration of eIF4E. This indicated that as the availability of eIF4E 
increased, there was more stabilization of labeled peptide, presumably by binding to 
eIF4E. Nevertheless, the binding of the labeled peptide to eIF4E has to be verified to be 
specific and not due to random associations.  
 
Figure 36. FP assay with eIF4E and 60nM of FITC-labeled peptide. The concentration 
of the labeled peptide was kept constant while eIF4E was added in increasing amounts. 
The change in fluorescence polarization or anisotropy was measured and plotted against 
the increase in eIF4E concentration. (Diagram by Chris Brown.) 
To verify that the binding of the labeled to eIF4E was specific, a competition assay 
using 4EBP1, a known eIF4E binding protein, was performed. The amounts of peptide 
and eIF4E added were kept constant, while 4EBP1 protein was added in increasing 
concentrations. As the amount of 4EBP1 protein added increased, the amount of 
anisotropy measured decreased (Figure 37). The decrease in anisotropy indicated a 




decrease in stabilized, slower-rotating peptides. This implies that the number peptide-
eIF4E complexes were decreasing with addition of increasing amounts of 4EBP1. In 
other words, 4EBP1 was displacing the labeled peptide from eIF4E.  
The competition assay was repeated with 4EBP1, DMSO, the solvent used to dissolve 
the peptide, and FAM-labeled p53 peptide, which should not bind eIF4E. Similarly, 
4EBP1 successfully competed for binding to eIF4E, resulting in a decrease in anisotropy 
measured (Figure 38). Contrastingly, there was no significant change in anisotropy for 
competition with increasing concentrations of DMSO and FAM-labeled p53 peptide. 
This further confirmed that the binding of the labeled peptide to eIF4E was specific and 
the FITC-labeled peptide could be used for validation of the aptamers in FP assays.  
 
Figure 37. Competition assay of 4EBP1 against FITC-labeled peptide for binding to 
eIF4E. Different amounts of 4EBP1 protein was added to fixed concentrations of peptide 
(60nM) and eIF4E (6.5uM). The change in anisotropy was measured and plotted against 
the increase in 4EBP1 concentration. (Diagram by Chris Brown.) 





Figure 38. Competition assay of 4EBP1, DMSO and FAM-labeled p53 peptide against 
FITC-labeled peptide for binding to eIF4E. Different concentrations of the competitors 
were added to fixed amounts of  peptide (60nM) and eIF4E (6.5uM). The change in 
anisotropy was measured and plotted against the increase in competitor concentration. 
(Diagram by Chris Brown.) 
 
5.3.2.2.  Aptamer competition assays 
Having set up a system that allowed us to measure the affinity of eIF4E binding 
molecules, the binding properties of the thioredoxin aptamers observed using pulldown 
assays were further validated.  
Trx-eIF4G or Trx-SG-eIF4G aptamers were added in increasing concentrations to a 
mixture of eIF4E with fluorescein peptides, and the changes in polarized fluorescence 
were measured. The amount of eIF4E and fluorescein peptide added was kept constant 
throughout. The experiment was also performed at the same time with free unlabelled 
peptides as a positive control.   




At the beginning of the experiment, maximum polarized fluorescence or anisotropy was 
measured when there were only eIF4E and fluorescein peptide in the reaction mixture 
(Figure 39). As the concentration of binding aptamer added increased, the amount of 
anisotropy measured decreased. This indicated a corresponding displacement of bound 
fluorescein peptides from eIF4E with increasing aptamer concentrations. The gradients 
of the displacement curves for the FP assay is an approximate guage of the binding 
affinity of the aptamers. The greater the gradient, the higher the binding affinity. The 
gradients of the curves for Trx-SG-eIF4G aptamer (blue) resembles that of the 
unlabelled peptide (purple), indicating that similar binding affinities. On the other hand, 
the gradient of the curve for Trx-eIF4G (pink) is less steep as compared to that for Trx-
SG-eIF4G (blue). This further confirmed the observations from the pulldown assays that 
the binding affinity of Trx-SG-eIF4G to eIF4E is greater than Trx-eIF4G.  





Figure 39. Fluorescence polarization competition assay between Trx aptamer and 
fluorescein coupled eIF4G peptides for binding to eIF4E. Different amounts of Trx-
eIF4G aptamer, Trx-SG-eIF4G aptamer, and unlabelled eIF4G peptide were added 
individually to separate mixtures of eIF4E (6.5uM) with fluorescein coupled eIF4G 
peptides (60nM). The amount of polarized fluorescence was measured and the 
calculated anisotropy was plotted (in arbituary units) against the increase in 
concentration of competing aptamer added.  
 
The apparent dissociation constants (KD) of the aptamers were then calculated by Chris 
Brown using the anisotropy readings obtained from subsequent FP assays. The KD value 
of a ligand refers to the concentration of the ligand that is required to occupy half the 
number of the receptor targets or binding sites. Hence, if a ligand binds its target tightly, 
the concentration of ligand needed to occupy half the number of binding sites would be 
lower: a smaller KD. Therefore a smaller KD means a higher the affinity between the 
ligand and its target protein. The KD value of Trx-SG-eIF4E was similar to that of the 




unlabeled eIF4GI peptide, indicating that the aptamer had a binding affinity as strong as 
the unconstrained peptide. Alternatively, the KD of Trx-eIF4G was more than 10 times 
greater, indicating a much lower binding affinity compared to the modified aptamer 
(Trx-SG-eIF4E) and the unlabeled peptide. 
Ligand KD (µM) R2 value 
eIF4GI peptide 1.15±0.30 0.99 
eIF4G aptamer 14.20±4.0 0.96 
SG-eIF4G aptamer 1.05±0.41 0.98 
Figure 40. The determined apparent KD values for the linear eIF4GI peptide and 
thioredoxin aptamers against eIF4E derived by competitive fluorescence anisotropy 
experiments. (Calculations performed by Chris Brown) 
 
5.3.3. Investigation of protein stability using thermal unfolding  
The FP assay presented preliminary results that added support to our hypothesis that the 
addition of extra residues before the peptide allowed increased flexibility for the 
constrained peptide to form the right conformation desirable for binding to eIF4E.  
A thermal shift assay was designed to further investigate our theory of an increased 
binding affinity due to the increased flexibility of the aptamer. The thermal shift assay is 
a fluorescence based assay which uses a fluorescent dye that binds to the hydrophobic 
regions of a protein, which are usually concealed within the interior of a protein. When 
the protein is folded, there will be minimal binding of the dye and thus low fluorescence 
detected. However, when the protein is unfolded, the amount of dye binding increases 




and the fluorescence increases correspondingly. Therefore, the changes in emitted 
fluorescence could be used as a record of the unfolding dynamics of a protein when 
subjected to heating.  
The thermal shift or unfolding assay was performed by Dr Chris Brown in the lab. Wild 
type thioredoxin was included as a control to obtain the melting temperature of the 
original protein scaffold without any inserts. An aptamer with an Mdm2-binding peptide 
insert (SuperTIP) was also used as a control to check for effects of the peptide sequence 
on the stability of the protein itself. The melting temperatures of the aptamer proteins 






Tm /°C Tm (reducing) /°C  
Difference in Tm 
and Tm 
(reducing) 
Trx 0 80.99 ±  .13 72.19 ± 0.07 8.8 ± 0.2 
SuperTIP 
aptamer 19 53.76 ± 0.18 51.92 ± 0.21 1.84 ± 0.39 
eIF4G aptamer 19 53.91 ± 0.16 50.40 ± 0.01 3.51 ± 0.17 
SG-eIF4G 
aptamer 21 51.02 ± 0.20 48.52 ± 0.28 2.5 ± 0.48 
Figure 41. The melting temperatures (Tm) for thioredoxin protein and aptamers obtained 
from thermal denaturation. Tm (reducing) was obtained by performing the denaturation 
in the presence of 1mM DTT.  
The melting temperature of the aptamer reflects the thermal stability of the protein. Our 
hypothesis that Trx-SG-eIF4G has more flexibility to form the required structural 
conformations for binding would therefore mean that the modified aptamer would have 
a lower melting temperature as compared to the unmodified Trx-eIF4G. Indeed, Trx-SG-




eIF4G was found to have a lower melting point as compared to Trx-eIF4G and the 
SuperTIP aptamers. The additional residues added to the modified Trx-SG-aptamer have 
resulted in a protein that was less stable compared to the unmodified aptamer (Trx-
eIF4G). This supported our theory that the additional residues would allow for increased 
flexibility of the protein aptamer to adopt the preferred conformation for binding to 
eIF4E.   
Nonetheless, the insertion of peptides into wild type thioredoxin was found to destabilize 
the scaffold protein with an approximate reduction in Tm by 25 degrees, whereas the Tm 
obtained for Trx in a reducing environment (1mM DTT) was reduced by approximately 
9 degrees. Contrary to the idea of a scaffold being able to tolerate inserts, the insertion of 
peptides into thioredoxin had additional destabilizing effects on the protein besides 
disrupting the disulphide bond present in wild type thioredoxin. This suggests that 
besides the absence of disulphide bonds formation in mammalian expressed Trx, the 
protein might be further destabilized by the insertion of peptides. Nonetheless, in vitro 
binding experiments were not affected despite the aptamers having a much lower Tm 
compared to the wild type thioredoxin. However, the reduced stability of the aptamers 
may be an issue when used for in vivo expression.  
5.4.  Validation of aptamer activity in cellular based assays 
Having verified that the Trx aptamers bind to eIF4E specifically in vitro, with Trx-SG-
eIF4G having a higher affinity than Trx-eIF4G, further validation of the effects of these 
aptamers in vivo was carried out. 




Since tumourigenicity is characterized by uncontrollable growth, lack of contact 
inhibition, anchorage independent growth and ability to metastasize, the effects of the 
aptamers which bind to eIF4E, with known transforming properties, on the anchorage 
independent growth characteristic of tumour cells was examined. The characteristic 
experiment to verify changes in anchorage independence growth would be the soft agar 
assay. The assay ideally involves seeding single cells into agar and allowing the cells to 
grow for 2 to 3 weeks depending on the cell line. The layer of cells is overlaid on top of 
a base layer of agar to ensure that the cells are not attached to the plastic surface of the 
wells. In order to make sure that the cell line selected for use is relevant to the 
examination of the effects of eIF4E inhibition on tumourigenicity, a literature search for 
the appropriate cell line was conducted. 
Rapamycin, isolated from Streptomyces hygroscopicus, is a compound with anti-fungal, 
immunosuppressive and anti-tumour properties. Rapamycin indirectly binds to and 
inhibits the activation of mTOR, thus preventing the phosphorylation and activation of 
p70S6K and 4EBP1 202. This results in a reduction in the translation of cap-dependent 
mRNAs, such as those encoding growth factors, transcription factors and cycle-cycle 
regulators. Rapamycin was found to be effective at the nanomolar concentrations in 
inhibiting growth in small cell lung, breast (e.g.: BT474, SKBR3, MCF7) and prostate 
cancer cell lines 203,204. Cells that have upregulated phospholipase D and increased 
phosphatidic acid levels were found to be insensitive to rapamycin at nanomolar 
concentrations 200,205. 




Since we wanted a cell line best suited to the purpose of testing the effects of inhibiting 
eIF4E on tumourigenesis, a rapamycin-sensitive cell line (at nanomolar concentrations) 
would be the most suitable for testing our aptamers which should mimic the effects of 
4EBP1 not dissociating from eIF4E as in the case of treatment with rapamycin. In 
addition, it has also been well documented that eIF4E has been found to be upregulated 
in breast, prostate, and head and neck squamous cell cancers. MCF7 cells have been 
shown to be sensitive to rapamycin 200 and have reasonably high levels of eIF4E as 
previously shown. Therefore, the breast cancer cell line MCF7 which was available in 
the lab was selected for use in the soft agar assays to examine the efficacy of the 
aptamers in vivo.  
5.4.1. Mammalian cell transfections and optimization of protein expression levels 
MCF7 cells were transfected using Lipofectamine 2000 and the transfection conditions 
were optimized. The expression of the Trx aptamers were found to be optimal when 
transfecting 0.5 million MCF7 cells with 4ug of plasmid DNA, using a DNA to 
lipofectamine ratio of 1:2.5. Figure 42 shows part of the optimization process.  





Figure 42. Western blot showing the expression levels of thioredoxin aptamers in 
transfected cells. Different numbers of MCF7 cells were transfected with 4ug of 
thioredoxin aptamers to check for optimal transfection efficiency and expression. 
Transfection efficiency was equally good (approximately 90% based on visual 
inspection of GFP fluorescence) for all 3 different cell numbers used for transfection. 
Blot (I) was probed with anti-actin to check for equal loading while blot (II) was probed 
with anti-thioredoxin to check for aptamer expression.  
Lane:  
1) Trx-eIF4G  
2) Trx-eIF4G-ala  
3) Untransfected 
 
5.4.2.  Contact inhibition test: soft agar assay 
MCF7 cells were transfected with varying amounts (1 to 4ug) of plasmid encoding for 
the aptamers. The transfected cells were grown for 2 days and seeded into soft agar as 
described. The ability of the transfected cells to exhibit anchorage independent growth 
was assessed in this assay without applying selection pressure. The colonies obtained 
were stained and counted.  
1          2          3         1         2        3         1         2          3 
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Figure 43. Representative pictures of colony formation using soft agar assay as a 
measure of the ability of the aptamers to inhibit anchorage independent growth. MCF7 
cells were transfected with different aptamers. 4E-BP1 and a non-phosphorylable mutant 
form of 4E-BP1 were included as positive controls for eIF4E inhibition. The cells were 
then counted and different numbers of cells were seeded into 0.3% agar (Pictures above 
are of agar dishes seeded with 25K of cells). The cells were then incubated at 37C and 
fresh media was added every 3-4 days for 12 days. The colonies formed by the cells 
were then stained with 0.005% crystal violet solution and pictures were taken under 4X 
magnification. (The seeded cells were not selected for expression of the aptamers.)   
(I) 1ug Trx-eIF4G  
(II) 1ug Trx-eIF4G-ala  
(III) 2ug 4E-BP1  
(IV) 2ug non-p 4E-BP1  
(V) mock transfected   











Figure 44. Graph comparing the number of colonies obtained for soft agar assay 
between the aptamers and their respective alanine controls. The colonies formed were 
counted under the microscope at 4X magnification. Three different fields of each dish 
were counted and the average number of colonies formed was calculated. (The seeded 
cells were not selected for expression of the aptamers.)  
*: data for MCF7 transfected with 4ug of Trx-SG-eIF4G-ala encoding plasmid DNA is 
not available to contamination of agar plate with fungus.  
 
 Figure 43 shows some pictures representative of the staining of colonies obtained from 
the soft agar assays. Figure 44 compares the number of colonies counted for the seeded 
cells transfected with different types and amounts of DNA encoding the aptamers.  
There were significantly less colonies formed by MCF7 cells transfected with 1ug of the 
aptamer Trx-eIF4G as compared to those transfected with its alanine control Trx-eIF4G-

































ala (Figure 44, blue and purple bars respectively). Similarly, there were fewer colonies 
formed for cells transfected with 1ug of the modified aptamer Trx-SG-eIF4E (beige) as 
compared to its control Trx-SG-eIF4G-ala (green); the difference however, was not as 
significant.  
Initially, the growth inhibition effect of the aptamers in cells looked encouraging. 
However, the trend was not repeated in a dose dependent manner. As the amount of 
DNA transfected increased, the subsequent difference between the number of colonies 
formed for cells transfected with the binding aptamers and the non-binding controls was 
not amplified. In the case of Trx-eIF4G, the cells transfected with 2ug and 4ug of the 
binding aptamer actually had more colonies than that transfected with the non-binding 
construct. The difference between binding and non-binding construct for 2ug of 
transfected modified aptamer remains but was still not significant. The inhibitory effect 
for 4ug of transfected Trx-SG-eIF4G cannot be determined due to the contamination of 
the agar plate by fungus growth.  
In addition to the apparent lack of dose dependent effects, the number of colonies 
formed in general by cells transfected with the control aptamers was also greatly reduced 
compared to the mock transfected and untransfected MCF7 cells (compare Figure 43 (II) 
with (V) and (VI)). To examine whether the growth inhibitory effects were partly due to 
overexpression of the foreign bacterial scaffold itself, a downward titration of the 
amount of plasmid DNA transfected starting from 1ug was performed. In addition, the 
original thioredoxin scaffold without any peptide insertion was included as a control to 




examine the effects of the bacterial protein if any, on the formation of cell colonies 
within the soft agar.  
However, this time a decision was made to focus on the aptamer Trx-eIF4G which 
demonstrated significant colony formation inhibition compared to its control aptamer 
(Figure 44 at 1ug of plasmid transfected). Similarly, MCF7 cells were transfected with 
varying amounts of plasmid DNA (0.2-1.0ug) and seeded into soft agar at different cell 
densities. Colony formation occurred faster and the assay was terminated after 9 days 
and the cells stained. This time, the colonies were counted using a colony counter 
(GelCountTM from Oxford Optronix) to eliminate the bias in manual counting and to 
minimize error due to uneven seeding as the whole well is counted instead of selective 
microscopic fields. The colonies of cells were stained using MTT as recommended by 
the manufacturer instead of crystal violet to ensure a clear background and also that only 
live cells were stained.  
The growth inhibitory effects of Trx-eIF4G at 1ug of transfected DNA was reproduced 
and found to be significant compared to its control Trx-eIF4G-ala (Figure 46 (I)). 
However, the transfection of the original thioredoxin scaffold (Trx-WT) alone had 
similar growth inhibitory effects. The number of colonies formed by cells transfected 
with the control aptamer was still significantly lower compared to the untransfected 
control.  
When the amount of DNA transfected was reduced to 0.5ug, the number of colonies 
formed by cells transfected with Trx-eIF4G-ala and Trx-WT started to resemble more 
closely that of the untransfected control (Figure 46 (II)). The number of colonies 




obtained for Trx-WT was not significantly different from that for the untransfected 
control. Additionally, there was still significant inhibition of colony formation for cells 
transfected with Trx-eIF4G compared to its non-binding control.   
However, the growth inhibitory effects of the aptamers observed for 0.5ug of transfected 
DNA was absent for 0.2ug of transfected DNA. A reversal of the effects for the binding 
and non-binding aptamer was observed instead (Figure 46 (III)). The number of colonies 
formed for cells transfected with Trx-WT was once again significantly different from 
that of the untransfected MCF7 cells.  
To verify the results obtained, the soft agar assay was repeated. The significant 
inhibitory effects of the binding aptamer at 1.0ug and 0.5ug were not reproducible. The 
reversal of effects observed for 0.2ug of aptamer previously was however, once again 
observed.  
Subsequent attempts at repeating the soft agar assay yielded inconsistent and sometimes 
conflicting results.  





Figure 45. Sample picture of soft agar assay colony counting using GelCountTM. Each 
red dot indicates a colony that is counted. (Only stained colonies with a diameter >50µm 
are counted; cell clusters <50µm in diameter are not counted.)  





Figure 46. Graphs demonstrating the number of colonies counted by GelCountTM for 
cells transfected with the respective aptamers and seeded in triplicate wells. The number 
of colonies in the entire well was counted and the average number of colonies for 3 
wells was tabulated and plotted in the graphs shown: MCF7 cells transfected with (I) 
1ug, (II) 0.5ug, and (III) 0.2ug of aptamer encoding plasmid DNA. (The seeded cells 
were not selected for expression of the aptamers but allowed to grow without selection 
pressure.)   
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6. Aptamer testing: tumourigenesis inhibition 
6.1. Introduction and aims 
Although the previous soft agar assay was conducted using MCF7, a cell line sensitive 
to mTOR inhibition, it is noteworthy that MCF7 is derived from a metastatic site of a 
breast cancer patient. Metastatic tumours would usually have accumulated various 
mutations or gene deletions in different signaling pathways to acquire their invasive 
abilities.  
Therefore, to validate the aptamers in an experimental setting that minimizes extraneous 
influencing factors, the aptamers were tested in NIH3T3 cells instead. Although NIH3T3 
cells are similarly immortalized cells, they are derived from primary cells after many 
generations in culture. These cells are highly contact inhibited and are therefore useful 
for testing the transforming potential of genes or compounds. As the aim of these 
cellular based experiments is to evaluate the ability of the aptamers at inhibiting the 
tumourigenic activity of eIF4E, NIH3T3 seemed a good choice of cell line for our 
purposes.  
Overexpression of eIF4E in these highly contact inhibited mouse embryonic fibroblast 
cells (NIH3T3), has been shown to result in the transformation of these cells, which then 
lose contact inhibition, leading to foci formation 144. It was also shown subsequently in 
primary rat embryo fibroblasts (REF) that eIF4E could transform the cells when co-
expressed with oncogenes such as E1A and v-myc 145.  




6.2.  Generation of transformed NIH3T3 cells 
6.2.1. Transformation of NIH3T3 cells with eIF4E and Ras  
In order to investigate the ability of the aptamers at inhibiting the tumourigenic effects 
of eIF4E, eIF4E transformed NIH3T3 cells were generated. NIH3T3 cells were 
transfected with 1-4 ug of either eIF4E or Ras, and grown for approximately 3 weeks. 
The formation of cell foci indicates the transformation of NIH3T3 cells which are 
usually contact inhibited. Each individual foci was then isolated for further 
characterization.  
Foci formation occurred much earlier and was more obvious for cells transfected with 
Ras as compared to cells transfected with eIF4E (Figure 47). The cells transformed by 
Ras appeared spindle-like and were growing in all directions, overlapping. The cells 
transformed by eIF4E had a less drastic change in morphology. This was not unexpected 
as Ras is known to be a potent oncogene and plays a major role upstream in many 
signaling pathways. Since Ras plays a major role in activating the mTOR pathway, a 
stable Ras overexpressing cell line might be useful for validating the aptamers as well. 
In addition, eIF4E and Ras stably transfected cell lines were also isolated by antibiotic 
selection. 





Figure 47. Transformation of NIH3T3 cells with either eIF4E or Ras gene. NIH3T3 cells 
were transfected with 1-4ug of either eIF4E or Ras encoding plasmid DNA and allowed 
to grow until foci formation occurs (approximately 3 weeks). Fresh media was 
replenished every 3-4 days. Each individual visible focus was isolated as a single clone 
of stably transformed cells for further validation. NIH3T3 cells (I) were transfected with 











6.2.2. Screening for genomic integration of transfected gene 
The genomic DNA of the clones were examined for integration of the transfected eIF4E 
or Ras gene using PCR with vector and gene specific primers. The PCR products of 
clones with positive results for both rounds of PCR were subsequently purified and sent 
for sequencing.  
 
Figure 48. Sample picture of PCR amplification to check for gene integration using 
genomic DNA isolated from eIF4E and Ras transformed stable cell lines. PCR was 
performed using primers specific for CMV promoter and poly-A tail regions found in 
the vector containing eIF4E and Ras, to check for integration of the transfected plamid 
into genomic DNA. The PCR product of clones with only one band on the gel was 
purified and subjected to an additional round of PCR with gene specific primers for 
verification. (The mRNA sequence coding for eIF4E used for transformation is 654bp.) 
6.2.3. Screening for protein over-expression 
Stably transfected clones for Ras and eIF4E were selected based on the results of the 
PCR screening performed on their genomic DNA, and tested for protein overexpression 
using western blots. As evident from Figure 49(II), the Ras stably integrated clone 
expressed extremely high levels of Ras as compared to the undetectable levels of Ras in 
the untransfected and eIF4E stably integrated NIH3T3 cells. eIF4E levels however were 
only slightly elevated in the eIF4E stably integrated clone as compared to untransfected 
NIH3T3 and Ras stable clone (Figure 49 (V)).  
650bp 





Figure 49. Western blot to check for protein overexpression in eIF4E and Ras 
transformed stable cell lines. Cell lysates from 1) eIF4E transformed NIH3T3, 2) Ras 
transformed NIH3T3, and 3) untransformed NIH3T3. Blot I was detected with anti-actin 
to check for equal loading while blots II and IV were detected with anti-Ras and anti-
eIF4E respectively. Pictures II and IV were exposures of the blots for 1 min while 
pictures III and V were overexposures.   
As the overexpression of eIF4E was not obvious by western blot analysis, cell staining 
on the selected eIF4E stably transfected cell line was carried out. The NIH3T3 cells 
stably transfected with eIF4E were stained uniformly by the anti-eIF4E antibody (Figure 
50 (I)). Untransfected NIH3T3 cells were stained to varying degrees by the antibody: 
some cells were stained as dark as the stable clone, while some were markedly lighter. 
The spontaneous over-expression of eIF4E in untransformed NIH3T3 cells may account 
for the low difference in eIF4E overexpression when analyzed by western blot (Figure 
49 (V)). The unsubstantial eIF4E overexpression in eIF4E stably transfected cells as 























Figure 50. Pictures of (I) eIF4E transformed NIH3T3 cells and (II) untransfected 
NIH3T3 stained with anti-eIF4E antibodies. The cells were fixed with 3% PFA and 
0.1% of Triton X and stained for eIF4E using mouse monoclonal eIF4E (P-2) antibody. 
I 
II 




6.3. Transfection of transformed NIH3T3 cells with aptamers 
6.3.1. Soft agar assay as an anchorage independence test for tumourigenicity  
Having obtained stably transfected cell lines, the soft agar assay for validating the 
effects of the aptamer on anchorage independent growth or colony formation, was 
repeated using the Ras and eIF4E stable cell lines. Unfortunately, the eIF4E stably 
transfected cells failed to form colonies in soft agar. The Ras stably transfected cells 
however, grew well and formed colonies. Therefore, the effects of the aptamers were 
subsequently examined in the Ras stable cell line.  
Ras transformed NIH3T3 cells were transfected with plasmid DNA encoding the 
aptamers and used for seeding into soft agar. It was noted that the transfection efficiency 
of the Ras stable cells was considerably lower than that of the untransformed NIH3T3 
cells. As there was no selection pressure applied, the untransfected cells would overgrow 
the cells transfected with the growth inhibitory aptamers. In addition, the Ras stable cells 
tended to clump after trypsinization, making it difficult to obtain a single cell suspension 
for seeding into soft agar. These factors may mask the growth inhibitory effects of the 
aptamers if there are any. 
There was no significant difference between the number of colonies formed for Trx-
eIF4G and Trx-eIF4G-ala for the various concentration of aptamer DNA transfected. 
The Ras stable cells exhibited higher ability at forming colonies in soft agar compared to 
the eIF4E stable cells and untransformed NIH3T3 cells (Figure 51). Surprisingly, Ras 




stable cells transfected with 0.5ug of aptamer encoding plasmid DNA appear to form 
colonies even more efficiently than untransfected Ras stable cells.  
 
Figure 51. Graph showing the number of colonies obtained in a soft agar assay using 
Ras stably expressing cells for transfection with aptamers. Varying concentrations of 
aptamer from 0.2 to 1 ug were used. The cells were trypsinized 2 days after transfection 
and seeded into soft agar for colony formation. The cells were fed with fresh media 
every 3-4 days and grown for approximately 2 weeks, before staining with MTT and 
counting the number of colonies using the automated GelCount machine. Non-
phosphorylable 4EBP1 was used as a positive control for eIF4E inhibition. The 
experiment was performed in triplicates. (The seeded cells were not selected for 
expression of the aptamers but allowed to grow without selection pressure.)   
 
There were several issues with the accuracy of the soft agar assays. Most importantly, 
the lack of selection pressure would result in untransfected cells overgrowing cells 
transfected with the aptamers. In addition, the protocol itself was susceptible to 
substantial inconsistency due to differential seeding, sensitivity of transfected cells to 
heat and fungal contamination of the nutrient rich agar. Foci formation assays where the 
Soft agar assay of Ras transformed NIH3T3 






































cells were tested for contact inhibition on flat petri dishes were subsequently used 
instead of the soft agar assays.  
6.3.2. Foci formation assay as a contact inhibition test for tumourigenicity 
NIH3T3 cells are known to be highly contact inhibited, a characteristic absent in cancer 
cells. It has been previously demonstrated that transfection with Ras abrogates this 
contact inhibition and transforms the NIH3T3 cells, resulting in the cells growing in 
layers on top of one another forming a focus, when space is limiting. Therefore, we 
decided to test the ability of the aptamer to reactivate this capacity to be contact 
inhibited in the Ras transformed cells.  
NIH3T3 cells were transfected concurrently with 0.5ug of Ras and 5ug of Trx-eIF4G or 
Trx-eIF4G-ala encoding plasmid DNA and allowed to grow for 2 to 3 weeks without 
selection. Pictures of cells stained for their DNA were taken.  
Figure 52 (I) shows the staining of cells transfected with Ras and Trx-eIF4G: there were 
significantly fewer stained foci as compared to that transfected with Ras and Trx-eIF4G-
ala or Ras alone. However, there were also visibly more foci formed for cells transfected 
with Ras and Trx-eIF4G-ala (II) as compared to Ras (III) alone. Untransfected NIH3T3 
cells did not form any foci as expected.      





Figure 52. Pictures of foci formation assay with aptamers and Ras encoding plasmid 
DNA. NIH3T3 transfected in 10 cm dish with (I) 0.5ug of Ras and 5ug of Trx-eIF4G (II) 
0.5ug of Ras and 5ug of Trx-eIF4G-ala (III) 0.5ug Ras only and (IV) untransfected 
NIH3T3. Cells were grown for 19 days without selection, then fixed and stained with 
Hoechst stain. Picures were then taken under UV light.  
6.4.  Generation of the aptamers with new tags and in new vectors using Gateway 
technology  
One of the common problems with both the soft agar and foci formation assays would be 








up to 3 weeks. A drop in expression levels due to loss of plasmid during cell 
proliferation or negative selection would lead to a false negative result for an aptamer 
with anti-proliferative effects in a proliferation assay without any selection pressure.  
To eliminate the possibility of losing the exogenous plasmid transfected as the cell 
proliferates, the aptamers were cloned into a vector (pCMV-HBGI-N-FLAG-FRT) for  
stable integration into special cell lines with designated integration sites. A human beta 
globin intron (HBGI) was cloned into the vector prior to the attR site for insertion of the 
aptamer gene to increase the expression of the aptamer. Having an intron before a gene 
has been found to enhance the translation and expression of the particular gene via 
splicing mechanisms 206.  
The Trx aptamers were cloned into pCMV-HBGI-N-FLAG-FRT and pcDNA6.2- N-
SBP gateway destination vectors as shown in Diagram 26. The protocol for cloning the 
aptamers using the gateway system was described in material and methods.  
 
Diagram 26. A simplified illustration of the GW destination vectors used for cloning of 
the thioredoxin aptamers. (I) pcDNA6.2- N-SBP-Trx-eIF4G has an N-terminal 
streptavidin-binding peptide (SBP) tag for pulldowns and detection. (II) pCMV-HBGI-
N-FLAG-FRT-Trx-eIF4G has an human beta globin intron to enhance protein 
expression and an N-terminal FLAG tag for detection. The vector also has a FLP 
recombinase target (FRT) site for integration of the entire vector into a similar FRT site 
cloned into the genome of a cell line, and a hygromycin resistance gene (not shown) for 
selection. 
SBP Trx-eIF4G Poly-A tail 
CMV 
promoter 











After the LR reaction, the GW destination clones were screened by restriction enzyme 
digestion followed by PCR with thioredoxin-specific primers to confirm that the 
recombination has taken place successfully.  
The restriction enzyme digestion profiles obtained for the Trx aptamer in various 
destination vectors differed from that of the empty destination vectors and the presence 
of the aptamer gene was subsequently confirmed by PCR with thioredoxin specific 
primers (not shown).  
 
Figure 53. Representative picture of the restriction enzyme analysis performed on the 
GW clones. (I) pcDNA6.2-N-SBP-Trx aptamar plasmids were digested with NcoI and 
run on a 1% agarose gel, using 1kb plus DNA ladder. The last lane contained 
pcDNA6.2-N-SBP empty destination vector digested with NcoI as a comparison. (II) 
pCMV-HBGI-N-FLAG-Trx aptamer plasmids were digested with RsrII and run on a 1% 
agarose gel, using 1kb DNA ladder. No empty vector was run for comparison as there 


















6.4.1. Antibiotic selection for integrated aptamers to investigate the effect of 
aptamer expression on cell growth 
To counter the natural phenomenon of decreasing expression of transfected gene over 
time, the aptamer genes were stably integrated into the genomic DNA of the cell line. In 
addition, to eliminate expression variability that may arise as a result of chromatin 
modifications due to integration of the gene at different parts of the genome, it was 
optimal to integrate the aptamer gene in a specific position. To do so, a strain of H1299 
cells with a FRT site integrated into their genome (H1299 LZ4) was used. The FRT 
integration site allows for integration of the aptamer genes at a specific and consistent 
location. The aptamers were transfected into H1299 LZ4 cells and selected for 
integration with antibiotics. Cells that contained the integrated gene and are still viable 
grow and form colonies.  
The colonies of cells obtained were fixed and stained using Hoechst stain, which binds 
to DNA and accurately reflects the amount of DNA, and therefore the number of cells, 
present. From Figure 54, it can be observed that there were significantly more surviving 
cells growing in (II) than in (I). Alternatively, the difference in amount of surviving cells 
was not as significant for the modified aptamers Trx-SG-eIF4G and Trx-SG-eIF4G-ala. 
Untransfected cells which did not have the antibiotic resistance gene were completely 
killed. In other words, cells with integrated Trx-eIF4G-ala survived and grew better 
compared to cells with integrated Trx-eIF4G, implying possibly an inhibitory effect of 
the binding Trx-eIF4G aptamer on growth. The modified aptamer Trx-SG-eIF4G did not 
seem to exhibit similar inhibitory effects on cell growth when compared to its non-




binding control. These deductions were made based on the reasonable assumption (since 
all were transfected at the same time and under the same conditions) that the transfection 
efficiency was equal for all the wells transfected with the different aptamers. It was 
noteworthy that the similar lack of significant growth inhibition for the modified Trx-
SG-eIF4G aptamer was observed as well for the soft agar assays.   
This experiment allowed us to conclude that the forced expression of the binding Trx-
eIF4G aptamer had some growth inhibitory if not toxic effects of the cells. This was the 
first clear indication of growth inhibitory effects by the aptamer within cells. However, 
the effects of modified Trx-SG-eIF4G aptamer were not as expected based on in vitro 
data.   
 





Figure 54. Antibiotic selection of H1299 LZ4 cells (with FRT site for incorporation of 
target gene into genome) transfected with: (I) Trx-eIF4G, (II) Trx-eIF4G-ala, (III) Trx-
SG-eIF4G, (IV) Trx-SG-eIF4G-ala, and (V) untransfected cells. The transfected cells are 
kept at 32 degrees for 2 days for incorporation of the transfected gene into genomic 
DNA and transferred to 37 degrees and selected with 500ug/ml of Hygromycin for 2-3 








6.4.2. Streptavidin binding peptide (SBP) tag pulldowns for validation of protein 
interaction 
Streptavidin binding peptide (SBP) tag is a 38 amino acid long peptide sequence (~ 4.4 
kDa) which has the ability to bind with high affinity to streptavidin. It has been shown 
that purification of recombinant proteins with SBP tag is much cleaner compared to His 
or maltose binding protein (MBP) tags 207. In addition, SBP tag is also smaller compared 
to MBP (~42 kDa) and glutathione S-transferase (GST; ~26kDa) tags, thus minimizing 
the possibility of the tag interfering with the structure or function of the protein. Last but 
not least, the ability to bind large amounts of SBP tag proteins using immobilized 
streptavidin is also a huge advantage as compared to smaller tags, such as FLAG or myc 
tags, which require antibodies for binding.  
Transfections of SBP-tagged Trx aptamers were carried out in 293FT cells. 293FT cells 
are derived from human embryonic kidney cells (HEK293) immortalized with the large 
T antigen from simian virus 40 (SV40). These cells are able to produce a lot of protein 
and are therefore suited for the purpose of producing enough SBP-tagged proteins for 
pulldowns.  
293FT cells were transfected with 4ug of Trx aptamers and grown for 48hrs before 
harvesting. The expression of the SBP tagged aptamers were first checked by western 
blot (Figure 55). A great difference in the expression levels of the aptamers was 
observed as shown in Figure 55 (II). The binding aptamers Trx-eIF4G and Trx-SG-
eIF4G were very poorly expressed (detectable by streptavidin peroxidase conjugates; not 
shown) compared to their non-binding alanine control aptamers. The same membrane 




was probed with antibodies against actin and found that the loading of the gel was 
approximately equal. The difference in aptamer expression was not due to unequal 
loading of the gel.    
To check if the difference in expression levels was due to degradation of the protein, the 
transfected 293FT cells were treated with proteosome inhibitor MG132 for 4 hours prior 
to harvesting. The expression levels of the aptamers were now approximately equal. The 
membrane was probed for actin levels to check for equal loading of the gel (blot not 
shown). It seemed that the binding aptamers were prone to degradation, which was 
inhibited by the addition of MG132.    
  
Figure 55. Analysis of aptamer protein expression in 293FT cells transfected with SBP 
tagged thioredoxin aptamers for approximately 40 hours before harvesting. The cell 
lysates were run on a gel for analysis by western blot. The membrane was probed with (I) 






















Figure 56. Analysis of aptamer protein expression in 293FT cells transfected with Trx 
aptamers and treated with 20uM of MG132 for 4 hours prior to harvesting. The cells 
were lyzed with 2X LDS loading dye and run on a 12% gel for analysis by western blot. 
The blot was probed with a streptavidin peroxidase conjugate. Membrane was probed 







6) untransfected 293FT cells 
 
These results may suggest that the binding of the aptamers to eIF4E increased its 
instability. Alternatively, it may also be possible that the presence of the critical contact 
residues in the binding aptamer destabilizes the protein in comparison to its alanine 
control.  
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7. Validation of nature’s own aptamer: 4EBP1 as an aptamer 
7.1.  Introduction and aims 
Cap dependent translation requires the presence and activity of translation initiation 
factor eIF4E. The activity of eIF4E is regulated mainly by its in vivo binding partners: 
translation activator eIF4G and inhibitor 4EBP1. The binding of 4EBP1 is determined 
by the phosphorylation status of the protein: hypophosphorylated 4EBP1 binds to eIF4E 
whereas hyperphosphorylated 4EBP1 dissociates from eIF4E. In the presence of external 
stimuli, such as nutrients, insulin and growth factors, a signaling cascade is triggered 
leading to the downstream effect of 4EBP1 phosphorylation by mTOR. 
4EBP1 is a small protein of 117 amino acids (~12.5 kDa) with 6 known phosphorylation 
sites. 4 of the identified phosphorylation sites are well documented to be important in 
regulating binding to eIF4E and are phosphorylated in a sequential manner upon growth 
factor signaling. Although there are some conflicting reports, the general consensus of 
the phosphorylation hierarchy for 4EBP1 is that threonine 37 and 46 are first 
phosphorylated followed by threonine 70 and serine 65 178,208, and subsequently, leading 
to dissociation of 4EBP1 from eIF4E.  
In the previous attempts to synthesize an artificial aptamer, the in vitro studies worked 
well and demonstrated binding to eIF4E. The rational designs made improved in vitro 
binding substantially in comparison to the unmodified aptamers. Nonetheless, various 
problems arose when the effects of the aptamer were validated in cells. Issues such as 
low expression levels, protein instability, and intracellular effects due to the aptamer 




protein scaffold itself were encountered. Therefore, to counter these effects, an 
alternative approach was designed. 
An important prerequisite of an aptamer is the size of the protein, followed by its ability 
to withstand peptide insertions without major structural changes. Chymotrypsin inhibitor 
2 is 74 amino acids long (~8.5kDa) and thioredoxin A is 109 amino acids long 
(~11.8kDa); 4EBP1 is similarly small in size (117 amino acids; ~12.5kDa). Since 
4EBP1 is naturally occurring in mammalian cells, low protein levels due to expression 
in a heterologous organism would not be a problem. However, since 4EBP1 activity is 
tightly regulated by mTOR phosphorylation, steps were taken to remove this level of 
regulation.  
7.2.  Construction of eIF4E binding aptamer using 4EBP1: modification of 4EBP1 
to remove known regulation sites 
The cDNAof 4EBP1 was amplified and cloned into a mammalian expression vector 
(pcDNA3) for transfection purposes. As the binding of 4EBP1 to eIF4E in vitro has 
already been well characterized and studied 209,210, the proposed modified 4EBP1 
aptamer was tested directly in cells.  
Since 4EBP1 binding to eIF4E is regulated by the phosphorylation status of 4EBP1, a 
way to prevent the dissociation of 4EBP1 from eIF4E is to prevent phosphorylation of 
4EBP1 by mTOR. Studies conducted have shown that the mTOR inhibitor rapamycin 
has an effect on the phosphorylation status and thus activity of 4EBP1. Rapamycin 
inhibits the function of mTOR and prevents the phosphorylation of 4EBP1, resulting in 




the persistent binding of 4EBP1 to eIF4E 211. Nevertheless, rapamycin acts upstream at 
the level of mTOR inhibition and affects all mTOR targets, not just 4EBP1 
phosphorylation.  
Therefore, to construct a persistent eIF4E binding aptamer, 4EBP1 was modified by 
removing all the mTOR phosphorylation sites that are known to regulate binding to 
eIF4E: Thr 37/46, Ser65 and Thr 70.  
7.2.1. Non-phosphorylable 4EBP1 aptamer 
The 4 amino acids known to be phosphorylated by mTOR, leading to the dissociation of 
4EBP1 from eIF4E, were mutated to alanines (Diagram 27). The modified 4EBP1 now 
resembles hypophosphorylated 4EBP1 and therefore functions as an eIF4E binding 
aptamer. The modified non-phosphorylable 4EBP1 aptamer was similarly cloned into 
pcDNA3, a mammalian expression vector. 
 
Diagram 27. Site directed mutagenesis of the phosphorylation sites on wild type 4EBP1 
(WT 4EBP1) that leads to the dissociation of 4EBP1 from eIF4E. The 4 amino acids that 












7.2.2.  Non-eIF4E binding 4EBP1 aptamer controls 
To effectively evaluate the effects of aptamer binding to eIF4E, it is important to include 
non-eIF4E binding controls for means of comparison. The following controls as shown 
in Diagram 28 were made using site directed mutageneis. Critical amino acids residues 
known to be essential for binding to eIF4E were mutated to alanine (Diagram 28). In 
addition, 9 amino acids from the eIF4E binding sequence of 4EBP1 were removed as an 
additional non-binding control for comparison purposes. The removal of the 9 amino 
acids from 4EBP1 has been shown to abrogate binding to eIF4E 212. These control 
aptamers were cloned into pcDNA3 as well.  
 
 
Diagram 28. Construction of modified 4EBP1 aptamers and its non-binding controls. (I) 
non-phosphorylable 4EBP1, (II) non-phosphorylable 4EBP1-ala control, (III) non-
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7.3.  Transfection of mammalian cells with aptamers and observations of effects on 
GFP translation  
MCF 7 cells were transfected using electroporation (Amaxa), with wild type 4EBP1 and 
non-phosphorylable 4EBP1. Green fluorescent protein (GFP) DNA was included at the 
same time to check for transfection efficiency. The transfected cells were checked for 
fluorescence 24 hours after transfection. Interestingly, it was observed that the GFP 
fluorescence for cells transfected with non-phosphorylable 4EBP1 (Figure 57 (III)) was 
a lot dimmer compared to cells transfected with either GFP alone (I) or WT 4EBP1 with 
GFP (II). The difference in fluorescence intensity between the transfected cells remained 
evident even after 48 hours. As the MCF7 cells were transfected at the same time and 
under the same conditions with equal amounts of aptamer and GFP DNA, it is unlikely 
that the difference on GFP expression is due to actual differences in transfection 
efficiency. Although not obvious from the photographs, it was evident under microscope 
that the number of cells fluorescing green were similar, it was the intensity of their 
fluorescence that was different.  
The transfected cells were harvested and lysed for western blots. The blots were probed 
with anti-phosphorylated 4EBP1, to detect phosphorylated 4EBP1 levels, anti-4EBP1, to 
detect total 4EBP1 levels, anti-GFP and anti-actin, to check for equal loading.  
As shown in the second lane of Figure 58 (I), no phosphorylated 4EBP1 was detected 
for cells transfected with the non-phosphorylable form of 4EBP1, as expected. In the 
first lane for cells transfected with wild type 4EBP1, there was a faint band. This was 
most probably due to phosphorylation of the transfected wild type 4EBP1, which was 




the usual regulation that takes place intracellularly. The intracellular levels of 
phosphorylated 4EBP1 could not be detected (third lane). 
 
Figure 57. Photographs of MCF7 cells transfected with (I) GFP only (II) wild type 4E-
BP1 and GFP (III) non-phosphorylable 4E-BP1 and GFP. Pictures of the same 
microscopic view were taken under both light and fluorescent microscope at 10X 









   
Figure 58. Western blot analysis of cell lysates of MCF7 cells co-transfected with wild 
type 4E-BP1/ non-phosphorylable 4E-BP1 and GFP. Cells were harvested after 72 hours 
and analyzed by western blot for protein expression with (I) anti-phosphorylated 4E-BP1 
(II) anti-4E-BP1 (i.e.: total 4E-BP1) (III) anti-GFP and (IV) anti-actin.  
The expression level of the non-phosphorylable 4EBP1 was very high compared to that 
of the transfected wild type as shown by the western blot with anti-4EBP1 for the total 
amount of 4EBP1 (Figure 58 (II)). This could be explained by the insusceptibility of the 
non-phosphorylable aptamer to degradation. It has been documented that 4EBP1 
undergoes phosphorylation followed by ubiquitination and degradation 213. Therefore, 
the overexpression levels of transfected wild type 4EBP1 would be expected to be lower 
due to degradation, as compared to the non-phosphorylable form. The level of 
























Congruent with prior observations of differences in fluorescence, there was less GFP 
detected on the blot for cells transfected with the non-phosphorylable 4EBP1 as 
compared to the wild type 4EBP1 (Figure 58 (III)). Analysis of the membrane with anti-
actin antibody showed approximately equal loading of the cell lysates for all 3 lanes 
(Figure 58 (IV)).  
7.4.  In vivo cellular-based assays  
Having ascertained the expression of the expression of the modified non-phosphorylable 
4EBP1, further validation of the aptamer effects within cells were carried out.  
7.4.1.  Flow cytometry analysis of the cell cycle profile of aptamer transfected cells 
Growth and proliferation involves the synthesis of many proteins, such as cyclins and 
kinases. The expression of these proteins is tightly regulated at mRNA translation level 
by eIF4E, the rate limiting cap-dependent translation initiation factor. As inhibition of 
cap-dependent translation would have an anti-proliferative effect, it was of interest to 
check for perturbations of the cell cycle profile of cells transfected with wild type and 
non-phosphorylable 4EBP1.  
MCF 7 cells were transfected with 4EBP1 and GFP, non-phosphorylable 4EBP1 and 
GFP, and GFP alone. The transfected cells were harvested after 48 hours, fixed and 
stained with propidium iodide. The cells were then analyzed and sorted by fluorescence-
activated cell sorting (FACS) for the cell cycle profile of fluorescent cells (i.e.: 
transfected cells). The cells transfected with only GFP were used as a control for the 
comparison of the DNA profile for 4EBP1 aptamer transfected cells. 





Figure 59. Fluorescence-activated cell sorting (FACS) analysis of MCF7 cells 
transfected with 4E-BP1 constructs. The histogram shows the percentage differences 
between the G1 populations of cells transfected with 4E-BP1 and GFP; and non-
phosphorylable 4E-BP1 and GFP, respectively. Experiment was repeated 3 times.  
There was a slight but consistence difference (> 5%) in the percentage G1 population of 
cells transfected with non-phosphorylable 4EBP1 and GFP control (Figure 59), 
indicating a possible G1 arrest effect of the non-phosphorylable aptamer on the cell 
cycle profile of transfected cells. The effects of over expressing wild type 4EBP1 were 
less consistent and notable, suggesting that the activity of the protein may be tightly 
regulated in vivo.   
7.4.2. Soft agar assay as an anchorage independence test for tumourigenicity 
Soft agar assays were also performed as previously described, for the 4EBP1 aptamers 
(WT and non-phosphorylable). The results were tabulated as shown in Figure 60. For 
MCF7 cells transfected with 1 to 4ug of DNA encoding non-phosphorylable 4EBP1, 
there was a consistent and significant inhibition of colony formation recorded. MCF7 












































cells transfected with WT 4EBP1 exhibited significant inhibition of colony formation as 
well, compared to untransfected MCF7 cells. The inhibitory effect on colony formation 
by WT 4EBP1 was however less potent as compared to non-phosphorylable 4EBP1.  
Strangely, the inhibitory effect of WT 4EBP1 did not increase or remain unchanged with 
increasing amount of DNA transfected. Instead, it was reversely proportional to the 
amount of DNA transfected. A probable explanation would be an upregulation of 
mechanisms regulating the levels of 4EBP1 in response to the increase in 4EBP1 levels 
with increasing amount of DNA transfected. The non-phosphorylable form would not be 
susceptible to the regulation mechanism and thus might explain why its inhibitory 
effects persisted. 
 
Figure 60. Graph comparing the number of colonies obtained for soft agar assay using 
MCF7 cells transfected with WT 4EBP1 and non-phosphorylable 4EBP1. The colonies 
formed were counted under the microscope at 4X magnification. Three different fields 
of each dish were counted and the average number of colonies formed was calculated. 
The number of colonies counted for the untransfected MCF7 cells was out of the scale of 
the graph (approximately 3 to 4X) and thus, not shown. (The seeded cells were not 
selected for expression of the aptamers but allowed to grow without selection pressure.)   































7.4.3. Foci formation assay as a contact inhibition test for tuourigenicity 
Similarly, besides the soft agar assay, WT 4EBP1 and the non-phosphorylable 4EBP1 
aptamer were evaluated for their foci formation inhibition ability in transformed 
NIH3T3 cells. NIH3T3 cells were transformed separately by Ras and eIF4E with E1A.  
7.4.3.1.  Foci formation assay with Ras transformed NIH3T3 cells  
NIH3T3 cells were successfully transformed by Ras as shown by the formation of foci 
observed in Figure 61 (III). The cells transfected with Ras and non-phosphorylable 
4EBP1 were found to have significantly less foci as compared to the cells transfected 
with both Ras and wild type 4EBP1, and Ras only. However, strangely, the cells 
transfected with both Ras and wild type 4EBP1 (I) formed more foci as compared to 
cells transfected with Ras only (III). The abnormality may be a result of compensatory 
regulatory mechanisms that arise to regulate the overexpression of WT 4EBP1, thereby 
leading to other unexpected effects. The same compensatory effects, if any, would also 
occur for cells transfected with non-phosphorylable 4EBP1, but the modifications made 
have granted the aptamer immunity to down-regulation.  Figure 61 (IV) shows the 
absence of spontaneous foci formation for untransfected NIH3T3 cells.   





Figure 61. Pictures of foci formation assay with 4EBP1 and Ras encoding plasmid DNA. 
NIH3T3 cells were transfected with (I) 1ug of Ras and 10ug WT 4EBP1, (II) 1ug of Ras 
and 10ug non-phosphorylable 4EBP1, (III) 1ug of Ras only, and (IV) untransfected 
NIH3T3 cells. The cells were then grown for 2-3 weeks without selection and observed 
for the formation of foci. The petri dishes was subsequently fixed and stained with 
Hoechst stain and pictures were taken under UV light.  
7.4.3.2.  Foci formation assay with eIF4E and E1A transformed NIH3T3 cells 
Ideally, to investigate the effect of a protein on inhibiting the tumourigenic effect of 
eIF4E, the ability of the protein to inhibit foci formation in eIF4E transformed NIH3T3 








 However, attempts to transform NIH3T3 cells with eIF4E alone were unsuccessful. Co-
transfection of eIF4E with E1A on the other hand, does transform NIH3T3 cells as 
shown in Figure 62 (I) and (II). Increasing the amount of E1A co-transfected with eIF4E 
seemed to increase the number of foci formed slightly as shown in Figure 62 (II). 
Transfection of NIH3T3 with E1A alone resulted in the formation of some foci, but the 
number of foci formed was greatly reduced (Figure 63 (I)) in comparison to NIH3T3 
cells transfected with both E1A and eIF4E. Similarly, increasing the amount of E1A 
used for transforming NIH3T3 cells increased the number of foci formed only slightly 
(Figure 63 (II)). eIF4E was required for the efficient transformation of NIH3T3 cells as 
observed in Figure 62. Notably, even though co-transfecting eIF4E with E1A 
transformed the NIH3T3 cells, the morphology of the foci formed was distinctly 
different from that of Ras transformed cells. The foci formed by transformation with 
eIF4E and E1A were considerably smaller and rounder, as compared to the larger and 
branching foci formed by cells transformed with Ras.   
WT 4EBP1 did not demonstrate significant effects on inhibiting the formation of foci 
formed by NIH3T3 cells transformed with E1A and eIF4E (Figure 62 (III)), whereas 
non-phosphorylable 4EBP1 exhibited inhibitory effects on foci formation by the 
transformed cells (Figure 62 (IV)). The little number of foci formed by E1A 
overexpression seemed also to be affected more by the overexpression of non-
phosphorylable 4EBP1 as compared to wild type 4EBP1. 





Figure 62. Pictures of foci formation assay with 4EBP1, E1A and eIF4E encoding 
plasmid DNA. NIH3T3 cells were transfected with: (I) 1ug E1A + 2ug eIF4E, (II) 1.5ug 
E1A + 2ug eIF4E, (III) 1ug E1A + 2ug eIF4E + 1ug WT 4EBP1, (IV) 1ug E1A + 2ug 
eIF4E + 1ug non-phosphorylable 4EBP1. The transfected cells were grown for 3 weeks 
without selection, then fixed and stained with Hoechst stain. Pictures were then taken 










Figure 63. Pictures of foci formation assay (without selection for aptamer expression) of 
NIH3T3 cells transfected with (I) 1ug E1A (II) 1.5ug E1A (III) 1ug E1A and 1ug WT 
4EBP (IV) 1ug E1A and 1ug non-phosphorylable 4EBP1. The cells were fixed and 
stained with Hoechst stain 2 to 3 weeks after transfection. The pictures were taken under 
UV light. 
 
7.5.  Generation of WT 4EBP1 and non-phosphorylable 4EBP1 aptamer with new 
tags and in new vectors using Gateway technology  
Likewise, to achieve sustained expression of the growth inhibitory 4EBP1 proteins, the 
gene sequences for the proteins were cloned, using gateway technology, into the pCMV-
I II 
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HBGI-N-FLAG-FRT for integration into cell line. In addition, as expression of a growth 
inhibitory protein is unfavourable and may be toxic, it would be advantageous to have an 
inducible system whereby the expression of the protein can be switched on and off when 
required. Therefore, WT 4EBP1 and non-phosphorylable 4EBP1 were cloned into 
another gateway vector: pGALT–HBGI–N–FLAG-4EBP1, which puts the expression of 
the gene under a promoter that is inducible by the addition of a chemical compound. 
Lastly, the 4EBP1 constructs were also put into the vector: pcDNA 6.2–N-SBP to tag 
the aptamers for pulldown assays and western blot detection (Diagram 29).  
 
Diagram 29. Cloning of the 4EBP1 constructs into gateway destination vectors. (I) 
pcDNA 6.2–N-SBP–4EBP1: contains an N-terminal streptavidin-binding peptide (SBP) 
tag for pulldowns and detection. (II) pGAL4–HBGI–N–FLAG-4EBP1 for inducible 
expression: contains an intron to enhance protein expression, an N-terminal FLAG tag 
for detection and an FRT site for integration into cell lines with a similar FRT. (III) 
pCMV–HBGI–N–FLAG–FRT-4EBP1 for constitutive expression: contains an intron to 
enhance protein expression, an N-terminal FLAG tag for detection and an FRT site for 
integration into cell lines with a similar FRT. 
The successful cloning of the 4EBP1 constructs into pDONR221 were verified by 
sequencing and the successful cloning of the constructs into the various destination 
FRT site
FRT site
SBP tag 4EBP1 Poly-A tail 
CMV 
promoter 
N-FLAG 4EBP1 Poly-A tail HBGI 
CMV 
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vectors were confirmed by restriction enzyme digestion and PCR screening with 4EBP1 
specific primers.  
 
Figure 64. Representative pictures of the restriction enzyme analysis performed on the 
GW clones. (I) pcDNA6.2-N-SBP-4EBP1 aptamar plasmids were digested with NcoI 
and run on a 1% agarose gel. The pcDNA6.2-N-SBP empty destination vector digested 
with NcoI was run on a separate gel for comparison and not shown. (II) pGAL4-HBGI-
N-FLAG-4EBP1 aptamer plasmids were digested with NcoI and run on a 1% gel. The 
last lane contained pGAL4-HBGI-N_FLAG empty destination vector digested with 
NcoI. (III) pCMV-HBGI-N-FLAG-Trx aptamer plasmids were digested with NcoI and 
run on a 1% agarose gel. The last lane contained empty vector digested with NcoI. All 
gels were run using 1kb plus DNA ladder as the marker. 
Figure 64 shows several representative pictures of the actual fragments generated after 
the RE digestion with NcoI for both 4EBP1 containing and empty vectors. 3 clones were 
picked and the presence of the aptamer gene sequence was further confirmed by PCR. 
The gateway destination vectors containing WT 4EBP1, non-phosphorylable 4EBP1, 
non-phosphorylable 4EBP1 alanine control and non-phosphorylable 4EBP1 deletion 

















7.5.1.  Antibiotic selection for integrated aptamer to investigate the effect of 
aptamer expression on cell growth 
The genes encoding for the 4EBP1 constructs were transfected and integrated into the 
genome of H1299 LZ4 cells which contained the FRT site required. The cells with 
integrated 4EBP1 genes were selected for by treating with antibiotics as previously 
described for the thioredoxin aptamers. The remaining cells were subsequently stained 
with Hoechst stain which not only allows the cells to be visualized and photographed 
under UV light, but also allows an approximate quantification of the number of 
surviving cells as the stain binds to DNA and therefore reflects approximately the 
amount of DNA present. Untransfected cells which do not carry the antibiotic resistance 
gene were killed off as shown in Figure 65 (VI). There were also no colonies stained for 
cells transfected with non-phosphorylable 4EBP1 (Figure 65 (II)). In contrast, there were 
quite a number of cells that survived the antibiotic selection for cells transfected with 
WT 4EBP1 and non-phosphorylable 4EBP1 deletion control, judging by the intensity of 
fluorescence detected. There were comparatively less cells surviving for the non-
phosphorylable 4EBP1 alanine control and GFP transfected cells, but still there were 
more surviving cells or colonies present when compared to the cells transfected with 
non-phosphorylable 4EBP1.  
Once again, these observations reflect that the cells with integrated WT 4EBP1, non-
phosphorylable 4EBP1 alanine control, non-phosphorylable 4EBP1 deletion control and 
GFP grew or survived better as compared to the cells transfected with non-
phosphorylable 4EBP1. The lack of colonies implies that the gene integrated may be 




toxic or simply growth inhibitory. The possibility of no surviving cells due to low 
transfection efficiencies can be safely eliminated as the cells were transfected under 
similar conditions and subsequent repeats of the experiment obtained similar results. The 
phenomena of cells with non-phosphorylable 4EBP1 integrated failing to grow under 
antibiotic selection pressure was also previously observed and described for the binding 
Trx-eIF4G aptamer.    





Figure 65. Antibiotic selection of H1299 LZ4 cells (with FRT sites for incorporation of 
target gene into genome) transfected with: (I) WT 4EBP1, (II) non-phosphorylable 
4EBP1, (III) non-phosphorylable 4EBP1-ala control, (IV) non-phosphorylable 4EBP1-
del control, (V) GFP, and (VI) untransfected cells. The transfected cells are kept at 32 
degrees for 2 days for incorporation of the transfected gene into genomic DNA and 
transferred to 37 degrees and selected with 500ug/ml of Hygromycin for 2-3 weeks (18 








7.5.2.  Generation of inducible cell lines with aptamer genes stably integrated 
As the over expression of WT 4EBP1 and non-phosphorylable 4EBP would presumably 
affect the translation machinery in cells and would therefore be selected against, an 
inducible system whereby the expression of the aptamers could be regulated is most 
advantageous.  
The aptamers were put under the regulation of five tandem repeats of the GAL4 
response element. The transcription receptor and activator: an insect ecdysone receptor 
(EcR) receptor fused to the yeast GAL4 DNA binding domain and a mammalian 
retinoid-X-receptor (RXR) fused to the viral activation domain VP16 were pre-integrated 
into H1299 LZ4 cells (H1299 LZ4 pNEBR). The aptamers were transfected into H1299 
LZ4 pNEBR cells and cells with integrated aptamer genes were selected for using 
antibiotic.    
The EcR is an insect nuclear receptor that heterodimerizes with ultraspiracle (USP), the 
insect homologue of the mammalian RXR, and upon binding to ecdysone steroid 
hormones, leads to the transcription of ecdysone responsive genes. The ecdysone steroid 
hormones regulate growth, molting, and development in insects. In the absence of the 
steroid, the inactive transcription receptor EcR fused to GAL4 DNA binding domain 
binds to the GAL4 response elements and represses transcription. Upon the addition of a 
ecdysone steroid, the EcR receptor changes conformation and dimerizes with RXR, 
resulting in an activated transcription factor complex, leading to transcription of the 
aptamer gene downstream of the GAL4 response elements.   




A stable cell line for each 4EBP1 construct was obtained and the expression of the 
aptamers was induced with tebufenozide, a non-steroidal compound with ecdysone 
receptor agonist activity. The expression of the 4EBP1 proteins was very low, nearly 
undetectable for both anti-FLAG (Figure 66) and anti-4EBP1 antibodies. There was also 
leaky expression of the protein in the uninduced cells (Figure 66, lane 2). This was also 
observed by other colleagues in the lab using the same cell line and system. As western 
blot analysis could not confirm that inducible system was working properly for the 
4EBP1 aptamer stable cell lines, the effects of inducing the construct on cell growth by 
plotting a growth curve for each of the cell lines over a span of 72 hours was 
determined. 
 
Figure 66. Western blot analysis of the cell lysates of uninduced and induced H1299 
LZ4 pNEBR cells stably transfected with (1) WT 4EBP1 (2) non-phosporylable 4EBP1 
and (3) non-phosporylable 4EBP1 alanine control aptamer. The membrane was probed 
with anti-FLAG to detect the FLAG-tagged aptamers.  
Equal numbers of cells were seeded in duplicates each for treatment with and without 
tebufenozide. The cells were harvested at different time points for up to 72 hours and the 
total numbers of cells were quantitated using  a dye that fluoresces upon binding to 
double stranded DNA. The amount of fluorescence measured for the various cell lines 
(induced and uninduced) at different time points were plotted against time (Figure 67).  
14kDa 
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For cell lines stably transfected with inducible WT 4EBP1 and non-phosphorylable 
4EBP1, there were decreased proliferation for the induced cells in comparison to the 
uninduced cells, using the amount of fluorescence as a measure. Cells stably transfected 
with non-phosphorylable 4EBP1 exhibited slightly more growth inhibition, whereas the 
growth of cells carrying the 4EBP1 control constructs were unaffected, upon induction 
of protein expression. However, it was puzzling that the cell lines stably transfected with 
WT 4EBP1 and non-phosphorylable 4EBP1 grew much faster compared to the control 
constructs under both induced and uninduced conditions.   
 
   





















































































































































































































































































































































































































































































































































































































































































































































The doubling time for each cell line was calculated using the equations obtained from 
the growth curve plotted (Figure 67) and listed in Figure 68. There was growth 
inhibition of WT 4EBP1 and non-phosphorylable 4EBP1 stable cell lines upon induction 
of aptamer expression, when compared to uninduced cells, as indicated by an increase in 
the time required for the cells to double. The doubling time for the non-phosphorylable 
4EBP1 alanine control stable line did not increase as much when induced to express the 
aptamers; the non-phosphorylable 4EBP1 deletion control line grew faster instead when 
induced. Nevertheless, as pointed out previously, the doubling time of cells stably 
transfected with the control constructs were longer compared the cells stably transfected 
with binding 4EBP1 constructs: the cells stably transfected with the binding constructs 
were growing faster than cells transfected with non-binding controls. The leaky 
expression of the constructs in the stable lines when uninduced (Figure 66) does not 
explain abnormality as the cells transfected with the binding constructs should grow 
slower instead. 
The major difference (up to 8 hours) in the doubling times or growth rates of the cells 
stably transfected with the constructs when uninduced makes it impossible to compare 
the effects of the protein on cells between binding and control constructs. In addition, 
the small difference in the growth rate of the cell line induced and uninduced might not 
be sufficient for detection of differences in soft agar or foci formation assays which are 
not as sensitive.  The small effect on the growth rate between induced and uninduced 
may be due to both leaky and low expression levels of the protein as previously noted in 
Figure 66. A stronger inducible system with cleaner background would be preferred. 




Even though the stable cell lines were not used for additional experiments subsequently, 
they did provide additional evidence that the 4EBP1 binding constructs have growth 
inhibitory effects intracellularly.     












Doubling time for 
un-induced /hr 23.03 21.26 28.29 29.75 
Doubling time for 
cell line induced 
with 5uM 
Tebufenozide /hr 





1.64 1.03 0.23 -0.99 
Figure 68. Doubling time of the stable cell lines (induced and uninduced) calculated 
from growth curves obtained. Positive values indicate an inhibition in growth, while 
negative values indicate an increase in growth.  
7.5.3.  Streptavidin binding peptide pulldown 
To demonstrate physical interaction of 4EBP1 with eIF4E intracellularly, plasmids 
encoding SBP-tagged 4EBP1 constructs were transfected into 293FT cells for pulldown 
experiments to be conducted. 
The expression levels of the 4EBP1 constructs were checked by western blot analysis 
and found to be satisfactory (Figure 69). It was also noted that the expression of non-
phosphorylable 4EBP1 (lane 2) was significantly reduced compared to WT 4EBP1 and 
the alanine control aptamer (lanes 1 and 3).    





Figure 69. Analysis of expression of SBP-tagged 4EBP1 aptamers in transfected 293FT 
cells (48 hours). The cell lysates were run on a gel and analyzed by western blot. 
Membrane was probed with (I) anti-actin AC-15 to check for equal loading of the gel 
and with (II) streptavidin-peroxidase conjugate polymer to detect SBP-tagged 4EBP1.  
Lane: 
1) WT 4EBP1 
2) non-phosphorylable 4EBP1 
3) non-phosphorylable 4EBP1 alanine control 
4) non-phosphorylable 4EBP1 deletion control 
 
The pulldown of the SBP-tagged 4EBP1 constructs were carried out as previously 
described, with and without avidin, and the results were shown in Figure 70. Pre-
clearing the cell extracts used for pulldown with avidin removed most of the non-
specific band detected on western blot when using streptavidin-HRP conjugated 
polymers (Figure 70 (I)). The ability of avidin to bind to and prevent biotin and 
biotinylated proteins from binding to the streptavidin beads used in the pulldown not 
only reduces the background on western blots but also increases the amount of SBP-
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For both sets of pulldown shown in Figure 70 with and without pre-clearing, SBP-
tagged 4EBP1 constructs were successfully pulled down. As expected, eIF4E was pulled 
down at the same time by WT 4EBP1 and non-phosphorylable 4EBP1, but not by the 
control constructs. This result demonstrated clearly the interaction of eIF4E 
intracellularly with the WT 4EBP1 and the non-phosphorylable 4EBP1 aptamer. The 
interaction was specific and not due to the tag as the SBP-tagged controls without the 
correct binding residues failed to pull down any eIF4E.  
WT 4EBP1 and the non-phosphorylable 4EBP1 aptamer were shown to interact and 
bind specifically to eIF4E intracellularly: the modifications did not render the 4EBP1 
protein unstable or inactive. Since the modified non-phosphorylable 4EBP1 aptamer 
exhibited better ability at inhibiting transformation (shown in the soft agar and foci 
formation assays) as compared to the WT 4EBP1, was not subjected to regulation 
(phosphorylation sites removed), and did not have any major issues with expression and 
stability (encountered for the previous aptamers), it is the ideal aptamer to use for further 
development into a potential tumour suppressor protein.    





Figure 70. SBP pulldown of SBP-tagged 4E-BP1 aptamers with and without pre-
clearing with avidin. 293FT cells were transfected with SBP-tagged 4EBP1 aptamers for 
2 days and harvested for pulldowns, using magnetic strepavidin dynabeads. Lanes 1-5 
are IP samples  without pre-clearing, whereas lanes 6-10 are loaded with IP samples that 
had been pre-cleared with avidin prior to the pulldown. SBP tagged aptamers bound to 
the beads were detected with streptavidin-HRP conjugates in blot I. Blot II was probed 
with anti-eIF4E to detect for aptamer interacting protein. Cell lysates (input) were run 
and transferred onto blot III and probed with streptavidin-HRP conjugate to check for 
expression.   
Lane: 1) WT 4EBP1 
          2) Non-phosphorylable 4EBP1 
          3) Non-phosphorylable 4EBP1 alanine control 
          4) Non-phosphorylable 4EBP1 deletion control 
          5) untransfected 293FT cells 
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8. Discussion  
Peptide aptamers are small proteins molecules that present binding peptides to a target 
protein from a scaffold. Target validation using peptide aptamers is a relatively new and 
less explored field. There are several advantages of using protein aptamers for inhibition 
of a target protein. The key advantage of protein aptamers is the ability of the aptamers 
to selectively inhibit a specific function of the target protein or block the interaction with 
a binding partner. The targeted disruption of protein function enables an accurate 
assessment of the downstream effects of the particular function and a specific inhibition 
of the function without other side effects which may be toxic to cells. Knockdown 
techniques (siRNA and ASOs) on the other hand work by inducing degradation of the 
target mRNA resulting in a general reduction of target protein expression level. The 
decrease in the levels of the target protein as a whole may result in diverse effects, 
especially if the protein is involved in many cellular processes. This hinders the 
validation of a specific function of the target protein. Genetic knockout and knock-in 
models can be inaccurate models for validation of target protein function as the total 
removal or overexpression of the target protein may result in the induction of 
compensatory mechanisms which are absent normally and will complicate experimental 
observations. The effects of small molecule inhibitors however resemble that of protein 
aptamers. They disrupt a specific interaction of the target protein and enable precise 
inhibition of a particular activity of the protein without affecting other functions of the 
protein. Nonetheless, large scale screenings have to be carried out to isolate a small 
molecule inhibitor and the binding is dependent on the presence of a small binding 
pocket at the protein domain whereby the disruption of interaction is to be carried out.  




Protein aptamers are much more stable in comparison to free unbound peptide and 
allows for proper presentation of the binding peptide to the environment. In addition, 
peptides constrained within a scaffold usually exhibit higher binding affinity as 
compared to the unconstrained peptides 32. However, the binding affinity of the Trx-SG-
eIF4G aptamer in vitro was found to be similar to that of the unbound peptide and not 
better as would be expected. Nevertheless, it is important to note that the affinity of the 
aptamer is dependent of the scaffold that is used to constrain the binding peptide 55. 
Same CDK2 binding peptides exhibited different binding affinities when constrained in 
different scaffolds (thioredoxin A or stefin A), demonstrating the dependence of aptamer 
binding affinity not only on binding peptide sequence but choice of scaffold as well 61. 
The differential binding affinities observed for the CI2 and Trx aptamers further 
demonstrates the dependence of aptamer binding affinity on scaffold. Therefore, it may 
be advantageous to screen for aptamers with enhanced binding affinities using a mixture 
of libraries that consist of random or bias peptides constrained in different scaffolds.  
One of the important observations made over the duration of this project is that although 
the rational redesigned aptamers may demonstrate great potential in vitro, the effects in 
vivo can differ. Rational design of the Trx aptamers resulted in an improved aptamer 
(Trx-SG-eIF4G) with higher binding affinity in vitro, but the higher binding affinity did 
not translate into observable differences in cellular based assays. In addition, the 
expression levels of the binding aptamers constructed using CI2 and Trx were found to 
be always lower in comparison to their respective controls. However, whether the lack 
of an observable effect for Trx-SG-eIF4G is due to selective degradation of the binding 
aptamer or inherent instability remains to be determined. In short, affinity maturation by 




rational design has proved to be inefficient and may not necessary yield the best binding 
aptamer in vivo. Directed evolution may be a better way to improve the binding affinity 
of an aptamer 214. 
The potential of using a scaffold from human origin is extremely attractive but just 
slightly explored. Recently, there was a study on using human thioredoxin as a scaffold 
for construction of Stat3 binding aptamers. The aptamers inhibited Stat3 signaling in 
cellular based assays when transduced across cell membranes and resulted in growth 
arrest and apoptosis in glioblastoma cells 23. The Stat3 aptamers are currently being 
evaluated in animal models according to the author. Using scaffold proteins of human 
origin for the construction of scaffolds is extremely intuitive as the possibility of 
immunogenicity is greatly reduced. In addition to being a useful tool for target 
validation, humanized aptamers have the additional potential for use in therapeutics. 
Most importantly, using a human protein, with a suitable half life, for the construction of 
aptamers eliminates potential issues with protein expression and stability in vivo. A 
human intracellular protease inhibitor stefin A has been successfully modified (STM) for 
use as a scaffold for presentation of peptides in mammalian cells. STM is a small, single 
domain protein (~ 11 kDa) that is extremely stable, thereby satisfying the basic 
requirements for a scaffold protein; the tailored scaffold has been patented 61.  
Similarly, 4EBP1 is a small (~12.5 kDa), heat and acid stable protein that has the 
favourable features of an aptamer, at least in the context of eIF4E. 4EBP1 is extremely 
stable and insensitive to degradation after the removal of several phosphorylation sites. 
However, there has been no success in crystallizing 4EBP1 yet and the protein is found 




to be relatively unstructured and flexible 215,216. The lack of compact structure greatly 
undermines the potential of using 4EBP1 as a scaffold according to the current paradigm 
of requirements for a good scaffold. Nonetheless, there is a possibility that unstructured 
4EBP1 may be suitable for use in presenting peptides which require the adoption of 
certain conformations for bioactivity. The lack of a rigid structure in this case may allow 
for increased flexibility for the constrained peptide to form the correct conformation for 
binding. As previously discussed, different peptides may require different scaffolds for 
the construction of bioactive protein aptamers. Therefore, the suitability of 4EBP1 as a 
scaffold has to be further evaluated in terms of its ability to present other bioactive 
peptides for binding to their target protein in the context of the conformational 
requirements for binding. Nevertheless, it is important to keep in mind that when using 
human proteins as the scaffold for aptamer construction, the interaction sites of the 
scaffold protein with its native binding partners have to be removed to abrogate non-
specific interactions. The chances of a false positive binding aptamer due to biological 
activity of the scaffold protein itself is higher if human origin proteins are to be used for 
the construction of aptamers.  
Besides target validation, aptamers can also be used directly as drugs, models for 
development of small molecule drugs or an antibody-like affinity reagent. The aptamers 
can be conjugated to protein transduction domains (e.g.: HIV TAT transduction domain 
and 9 arginine residues) to make them cell permeable 217,218. In addition the aptamers can 
be encapsulated within polymers or lipids for delivery into cells, protection from 
degradation and controlled release of the therapeutic aptamers 219. The aptamers can also 
be modified chemically to improve protein stability in vivo for a longer half life. 




The co-crystallization of the target protein together with its binding aptamer will provide 
3-dimensional information of the structural requirements for docking onto the binding 
site of the target protein. The knowledge of these structural requirements will enable and 
facilitate the design of small molecules that have pharmacological activity against the 
target protein. The recent development of HIV protease inhibitors was based similarly 
on protein structure information 220.  
Lastly, a strong and specific binding aptamer can also be used as a detection reagent for 
its target protein for diagnostic purposes or as an antibody-like reagent in western blot 
analysis. The potential of using aptamers as an antibody-like reagent for detection of a 
target protein is extremely attractive considering the ease of developing and obtaining 
large amounts of binding aptamers as compared to the difficulties of raising monoclonal 
antibodies.  
Despite the attractiveness of developing aptamers against target proteins, it is evident 
from this project that there are many complications that can arise and delay significantly 
the process of obtaining bioactive aptamers that are effective in vitro and in vivo. A 
simple knockdown with ASO or siRNA might have yielded results much faster. 
Nonetheless, the application and advantages of protein aptamers are vast. Protein 
aptamer technology though new, demonstrates potential for development. Protein 
aptamers will no doubt be an extremely powerful tool for target validation and 
therapeutic purposes in the future. 
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10. Appendix  
     E         P     X                                            
     C         A     H                                            
     R         C     O                                            
     1         1     1                                            
                                                                  
     GAATTCTTAATTAAGACTCGAGATGAGCAGCGTGGAAAAGAAGCCGGAGGGTGTGAACAC 
 1   ----.----|----.----|----.----|----.----|----.----|----.----| 60 
     CTTAAGAATTAATTCTGAGCTCTACTCGTCGCACCTTTTCTTCGGCCTCCCACACTTGTG 
 
 
                                       M                          
                                       S                          
                                       C                          
                                       1                          
                                                                  
     CGGAGCGGGGGATCGCCATAACTTGAAAACGGAGTGGCCAGAACTCGTTGGTAAAAGCGT 
 61  ----.----|----.----|----.----|----.----|----.----|----.----| 120 
     GCCTCGCCCCCTAGCGGTATTGAACTTTTGCCTCACCGGTCTTGAGCAACCATTTTCGCA 
 
 
     GGAAGAAGCAAAAAAGGTTATTTTACAGGATAAACCGGAAGCTCAGATTATCGTTCTGCC 
 121 ----.----|----.----|----.----|----.----|----.----|----.----| 180 
     CCTTCTTCGTTTTTTCCAATAAAATGTCCTATTTGGCCTTCGAGTCTAATAGCAAGACGG 
 
 
                             N                   B                
                             R                   S                
                             U                   P                
                             1                   E                
                                                                  
     GGTGGGCACTAAAAAACGCTATGATCGCGAATTTCTGCTGGGCTTCCGGATTGACCGTGT 
 181 ----.----|----.----|----.----|----.----|----.----|----.----| 240 
     CCACCCGTGATTTTTTGCGATACTAGCGCTTAAAGACGACCCGAAGGCCTAACTGGCACA 
 
 
                                              B                   
                                              S                   
                                              S                   
                                              S                   
                                                                  
     ACGTCTGTTTGTAGATAAACTTGACAATATCGCCCAAGTCCCTCGTGTCGGCGACTACAA 
 241 ----.----|----.----|----.----|----.----|----.----|----.----| 300 
     TGCAGACAAACATCTATTTGAACTGTTATAGCGGGTTCAGGGAGCACAGCCGCTGATGTT 
 
 
                           B B       P   H      
                           A S       A   I      
                           M P       C   N      
                           1 L       1   3      
                                                
     AGATGATGATGACAAATAGTAAGGATCCTTAATTAAAAGCTT 
 301 ----.----|----.----|----.----|----.----|-- 342 
     TCTACTACTACTGTTTATCATTCCTAGGAATTAATTTTCGAA 
  
 
Appendix 1.Gene sequence of codon optimized CI2 synthesized.  




MS-Fit Search Results 
 
Sample ID (comment): \\Maldi1\Voyager D\Voyager\Yong Chiang spectrum\2005\05June21\eif4e 
1_19_0001.dat 
Database searched: nr050405 
Molecular weight search (1000 - 100000 Da) selects 2292213 entries. 
Full pI range: 2408643 entries. 
Species search ( HUMAN RODENT ) selects 218019 entries. 
Combined molecular weight, pI and species searches select 198844 entries. 
MS-Fit search selects 5763 entries (results displayed for top 20 matches).  


















































Protein Name  
              
1  1.06e+005 9/50 (18%) 25096.4 / 6.00 HOMO SAPIENS  61363416 
Eukaryotic translation initiation 
factor 4E  
2  4.31e+003 8/50 (16%) 25037.3 / 5.79 MUS MUSCULUS  31982407 unnamed protein product  
3  4.31e+003 8/50 (16%) 25053.3 / 5.79 RAT  16758870 
Eukaryotic translation initiation 
factor 4E (eIF4E) (eIF-4E) (mRNA 
cap-binding protein) (eIF-4F 25 
kDa 
subunit)gi|293334|gb|AAA37545.1| 
translation initiation factor eIF-4E  
4  681  6/50 (12%) 68070.0 / 8.75 MUS MUSCULUS  29477040 RIKEN cDNA 4933405K07  
5  680  6/50 (12%) 68097.0 / 8.75 MUS MUSCULUS  21312718 unnamed protein product  
6  521  6/50 (12%) 83111.1 / 8.12 RATTUS NORVEGICUS 34855773 
similar to hypothetical protein 
FLJ36991  
7  212  5/50 (10%) 59198.0 / 9.04 MUS MUSCULUS  12853462 unnamed protein product  
8  203  4/50 (8%)  23589.1 / 8.46 MUS MUSCULUS  26338129 unnamed protein product  
9  198  6/50 (12%) 91452.1 / 8.03 HOMO SAPIENS  5102733 
hypothetical protein, similar to 
(AC007017) putative RNA 
helicase A  
10  192  6/50 (12%) 93977.0 / 7.87 HOMO SAPIENS  21740289 hypothetical protein  





11  189  5/50 (10%) 64959.4 / 8.13 MUS MUSCULUS  14250235 Zinc finger protein 69  
11  189  5/50 (10%) 64989.4 / 8.04 MUS MUSCULUS  29789231 unnamed protein product  
12  186  7/50 (14%) 73035.7 / 9.22 HOMO SAPIENS  34191049 zinc finger protein 555  
13  177  7/50 (14%) 78463.0 / 9.22 HOMO SAPIENS  40788368 KIAA0798 protein  
14  166  4/50 (8%)  93867.4 / 6.99 HOMO SAPIENS  1136428 KIAA0184  
15  162  5/50 (10%) 12954.6 / 5.34 MUS MUSCULUS  51772083 
similar to Eukaryotic translation 
initiation factor 4E (eIF4E) (eIF-
4E) (mRNA cap-binding protein) 
(eIF-4F 25 kDa subunit)  
16  156  5/50 (10%) 68314.1 / 8.93 RAT  25742783 
Serine/threonine-protein kinase 
PLK1 (Polo-like kinase 1) (PLK-
1)gi|497994|gb|AAA18885.1| polo 
like kinase  
 
Detailed Results 
1. 9/50 matches (18%). 25096.4 Da, pI = 6.00. Acc. # 61363416. HOMO SAPIENS. Eukaryotic 




matched Delta ppm start end 
Peptide Sequence  
(Click for Fragment Ions) 
764.4406 764.4167 31.2109 37  42  (K) HPLQNR(W)  
882.5036 882.4797 27.0207 174  181  (R) EAVTHIGR(V)  
887.5457 887.5355 11.5413 113  119  (R) WLITLNK(Q)  
888.4911 888.4692 24.6903 55  61  (K) TWQANLR(L)  
997.5446 997.5300 14.6442 43  49  (R) WALWFFK(N)  
1348.6136 1348.5731 30.0065 96  106  (K) DGIEPMWEDEK(N)  
1503.7914 1503.7807 7.0985 193  206  (K) IVIGYQSHADTATK(S)  
1758.8350 1758.8299 2.9100 22  36  (K) TESNQEVANPEHYIK(H)  
2299.0797 2299.0651 6.3081 1  21  (-) MATVEPETTPTPNPPTTEEEK(T)  
 
41 unmatched masses: 720.4439 730.8823 747.0692 748.0296 761.4002 764.5510 764.6452 764.8908 
765.2895 765.4394 765.5646 766.4380 786.4274 861.1188 877.0871 882.7286 883.5053 889.4914 
904.4850 920.4823 1173.6925 1334.6421 1335.6451 1364.5970 1367.6297 1390.6562 1391.6305 
1392.6690 1394.6718 1406.6793 1408.6684 1424.6396 1446.6415 1453.6600 1483.7508 1544.6653 
1780.8289 2216.9636 2330.0193 2606.1724 2807.2405  
The matched peptides cover 44% (96/217 AA's) of the protein.  
Coverage Map for This Hit (MS-Digest index #): 1137568  
Appendix 2. Mass spectrometry results for eIF4E.  
